
<html lang="en"     class="pb-page"  data-request-id="646b71ef-ae76-4fdd-8ab3-ea4697326f08"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-10;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b01814;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer" /></meta><meta name="dc.Creator" content="Zilma  Escobar" /></meta><meta name="dc.Creator" content="Anders  Bjartell" /></meta><meta name="dc.Creator" content="Giacomo  Canesin" /></meta><meta name="dc.Creator" content="Susan  Evans-Axelsson" /></meta><meta name="dc.Creator" content="Olov  Sterner" /></meta><meta name="dc.Creator" content="Rebecka  Hellsten" /></meta><meta name="dc.Creator" content="Martin H  Johansson" /></meta><meta name="dc.Description" content="The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3..." /></meta><meta name="Description" content="The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 3, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01814" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01814" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01814" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01814" /></link>
        
    
    

<title>Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01814" /></meta><meta property="og:title" content="Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0009.jpeg" /></meta><meta property="og:description" content="The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes. In this study we characterized 6 (GPA512, Johansson, M.; Sterner, O. Patent WO 2015/132396 A1, 2015), a prodrug of 1. In vitro studies showed that 6 is rapidly converted to 1 in plasma and is stable in a buffer solution. The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbed and converted to 1 with a tmax of 15 min. Oral administration of 6 in mice increased the plasma exposure of the active parent compound 20-fold compared to when 1 was dosed orally. 6 treated mice bearing DU145 xenograft tumors had significantly reduced tumor growth compared to untreated mice. The favorable druglike properties and safety profile of 6 warrant further studies of 6 for the treatment of castration-resistant prostate cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01814"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01814">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01814&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01814&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01814&amp;href=/doi/10.1021/acs.jmedchem.5b01814" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4551-4562</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01806" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01863" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Preclinical Characterization of 3β-(<i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zilma++Escobar">Zilma Escobar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Bjartell">Anders Bjartell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giacomo++Canesin">Giacomo Canesin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Evans-Axelsson">Susan Evans-Axelsson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Olov++Sterner">Olov Sterner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rebecka++Hellsten">Rebecka Hellsten</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+H++Johansson">Martin H Johansson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Center for Analysis and Synthesis, Lund University, SE-221 00 Lund, Sweden</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Division of Urological Cancers, Department of Translational Medicine, Lund University, SE-205 02 Malmo, Sweden</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Glactone Pharma Development AB, SE-252 20 Helsingborg, Sweden</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#761b1704021f18581c191e17180505191836111a1715021918135815191b"><span class="__cf_email__" data-cfemail="adc0ccdfd9c4c383c7c2c5ccc3dedec2c3edcac1ccced9c2c3c883cec2c0">[email protected]</span></a>. Telephone: +1 7057680603.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01814&amp;href=/doi/10.1021%2Facs.jmedchem.5b01814" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4551–4562</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 25, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2015</li><li><span class="item_label"><b>Published</b> online</span>3 May 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 May 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01814" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01814</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4551%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZilma%2BEscobar%252C%2BAnders%2BBjartell%252C%2BGiacomo%2BCanesin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D10%26contentID%3Dacs.jmedchem.5b01814%26title%3DPreclinical%2BCharacterization%2Bof%2B3%25CE%25B2-%2528N-Acetyl%2Bl-cysteine%2Bmethyl%2Bester%2529-2a%25CE%25B2%252C3-dihydrogaliellalactone%2B%2528GPA512%2529%252C%2Ba%2BProdrug%2Bof%2Ba%2BDirect%2BSTAT3%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BProstate%2BCancer%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4562%26publicationDate%3DMay%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01814"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1485</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01814" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zilma&quot;,&quot;last_name&quot;:&quot;Escobar&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Bjartell&quot;},{&quot;first_name&quot;:&quot;Giacomo&quot;,&quot;last_name&quot;:&quot;Canesin&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Evans-Axelsson&quot;},{&quot;first_name&quot;:&quot;Olov&quot;,&quot;last_name&quot;:&quot;Sterner&quot;},{&quot;first_name&quot;:&quot;Rebecka&quot;,&quot;last_name&quot;:&quot;Hellsten&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;H Johansson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;4551-4562&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01814&quot;},&quot;abstract&quot;:&quot;The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes. In this study we characterized 6 (GPA512, Johansson, M.; Sterner, O. Patent WO 2015/132396 A1, 2015 ), a prodrug of 1. In vitro studies showed that 6 is rapidly converted to 1 in plasma and is stable in a buffer solution. The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbed and converted to 1 with a tmax of 15 min. Oral administration of 6 in mice increased the plasma exposure of the active parent compound 20-fold compared to when 1 was dosed orally. 6 treated mice bearing DU145 xenograft tumors had significantly reduced tumor growth compared to untreated mice. The favorable druglike properties and safety profile of 6 warrant further studies of 6 for the treatment of castration-resistant prostate cancer.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01814&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01814" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01814&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01814" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01814&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01814" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01814&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01814&amp;href=/doi/10.1021/acs.jmedchem.5b01814" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01814" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01814" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01814%26sid%3Dliteratum%253Aachs%26pmid%3D27111731%26genre%3Darticle%26aulast%3DEscobar%26date%3D2016%26atitle%3DPreclinical%2BCharacterization%2Bof%2B3%25CE%25B2-%2528N-Acetyl%2Bl-cysteine%2Bmethyl%2Bester%2529-2a%25CE%25B2%252C3-dihydrogaliellalactone%2B%2528GPA512%2529%252C%2Ba%2BProdrug%2Bof%2Ba%2BDirect%2BSTAT3%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BProstate%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D10%26spage%3D4551%26epage%3D4562%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292225" title="Thiols">Thiols</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292547" title="Adducts">Adducts</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/jmcmar.2016.59.issue-10/20160526/jmcmar.2016.59.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (<b>1</b>), a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes. In this study we characterized <b>6</b> (GPA512, <contrib-group>Johansson, M.; Sterner, O.</contrib-group> Patent WO 2015/132396 A1, 2015), a prodrug of <b>1</b>. In vitro studies showed that <b>6</b> is rapidly converted to <b>1</b> in plasma and is stable in a buffer solution. The pharmacokinetics of <b>6</b> following a single oral dose indicated that the prodrug was rapidly absorbed and converted to <b>1</b> with a <i>t</i><sub>max</sub> of 15 min. Oral administration of <b>6</b> in mice increased the plasma exposure of the active parent compound 20-fold compared to when <b>1</b> was dosed orally. <b>6</b> treated mice bearing DU145 xenograft tumors had significantly reduced tumor growth compared to untreated mice. The favorable druglike properties and safety profile of <b>6</b> warrant further studies of <b>6</b> for the treatment of castration-resistant prostate cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The transcription factor signal transducer and activator of transcription 3 (STAT3) is classified as an oncogene and is implicated in drug resistance, progression of androgen independent growth, metastatic spread, tumor growth, and immune avoidance.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> STAT3 is thus a promising target for the treatment of castration-resistant prostate cancer as well as other cancers expressing active STAT3.</div><div class="NLM_p">Eventually most prostate cancers advance to become metastatic and resistant to anti-androgen therapies, making it important to develop novel treatment strategies for this patient group. Targeted therapy toward STAT3 may reverse or overcome this resistance, and STAT3 inhibitors may be used alone or in combination with other prostate cancer treatments such as chemotherapy and anti-androgens. Furthermore, STAT3 is involved in the tumor microenvironment, suggesting a role for STAT3 inhibitors in immunotherapy.</div><div class="NLM_p">STAT3 may be activated by numerous extracellular factors, with one main factor being interleukin-6 (IL-6). Constitutive activation of STAT3 may be caused by aberrant cytokine signaling, increased tyrosine kinase activation, and loss of suppressor proteins.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In liver cancer, mutations in upstream activators of STAT3 as well as somatic STAT3 mutations have been found, all promoting constitutive activation of STAT3.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Furthermore, activating mutations have also been found in large granular lymphocyte leukemia and autoimmune disorders.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Due to the numerous activating pathways converging on STAT3,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> a direct inhibitor of STAT3 would likely be effective against STAT3 related pathologies regardless of activating process.</div><div class="NLM_p">Direct STAT3 inhibitors have been difficult to find due to the lack of enzymatic activity of STAT3.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> The most investigated strategy for inhibiting STAT3 signaling has been targeting the SH2 domain, thereby blocking the STAT3 dimerization process.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Galiellalactone (<b>1</b>) is a fungal metabolite that was discovered to inhibit the IL-6/STAT3 pathway<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and later shown to directly bind to STAT3 thereby preventing the binding to DNA.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Like many naturally occurring transcription factor inhibitors, <b>1</b> is a cysteine reactive Michael acceptor and <b>1</b> has been shown to react with cysteine-468 in the DNA binding domain of STAT3.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Binding to this residue has previously been shown to block STAT3 signaling.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Due to the promise of STAT3 inhibition as a new modality of targeting cancer growth and resistance, new chemical starting points are highly desired.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Over the past 10 years there has been a renewed interest in covalent inhibitors. Several covalent inhibitors have been approved, and covalent inhibitors might prove to be highly suitable for targeting difficult targets, including blocking protein–protein and protein–DNA interactions and achieving selectivity.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a></div><div class="NLM_p">When studying the ability of <b>1</b> to act as a Michael acceptor and its reactivity toward nucleophiles, we observed that cysteine adds rapidly to <b>1</b> but that the addition of cysteine is reversible (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). We have previously discovered that secondary amines add to <b>1</b> and that this addition is also reversible which led us to investigate if these amine adducts could be used as prodrugs of <b>1</b> (unpublished results). This prodrug strategy, utilizing the reversibility of the Michael addition reaction, has previously been used for preparing orally bioavailable prodrugs of cysteine reactive sesquiterpene lactones.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20-23)</a> As the chemical stability of the amine adducts of <b>1</b> was less than optimal under physiological conditions and oral administration of an amine adduct of <b>1</b> did not increase the exposure of the active compound, we investigated the possibility to instead use thiol adducts of <b>1</b> as prodrugs.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reaction of <b>1</b> with Cysteine in PBS and MeOH</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> In Vitro and in Vivo ADME Characterization of Galiellalactone (<b>1</b>)</h3><div class="NLM_p">Initial preclinical ADME studies revealed that <b>1</b> had a solubility of 143 μM in phosphate buffered saline (PBS; pH 7.4). Furthermore, <b>1</b> showed good chemical stability in 0.1 M PBS, with a half-life of more than 9.8 h but only moderate stability when incubated at 37 °C in mouse plasma (a half-life value of 74 min).</div><div class="NLM_p">The cellular permeability of <b>1</b> was evaluated using Caco-2 cell monolayers. The absorptive (apical to basal) and secretory (basal to apical) permeability was studied in the absence of chemical inhibitors, and cellular uptake followed by efflux to buffers was measured in the presence and absence of 50 μM MK-571, an inhibitor of multidrug-resistance-associated protein efflux transporters. The apparent absorptive permeability of <b>1</b> over Caco-2 cell monolayers was high (mean A to B <i>P</i><sub>app</sub> of 65.9 × 10<sup>–6</sup> cm/s ) and approximately 2 fold higher in the absorptive direction than to secretory direction, suggesting a potential involvement of apical uptake or basolateral efflux of this compound in Caco-2 cells. A glutathione adduct of <b>1</b> was observed in both apical and basolateral compartments in all incubations. Rapid glutathione conjugation of <b>1</b> was also observed in intestinal S9 fractions. The in vitro metabolic stability of <b>1</b> was studied using mouse hepatocytes. <b>1</b> disappeared to about 45% in a 2 h incubation with mouse, and no disappearance was observed without cells.</div><div class="NLM_p">As a next step evaluating the druglike properties of <b>1</b>, the plasma exposure in mice following single oral, intravenous, and intraperitoneal administrations at 10, 1.25, and 5 mg/kg, respectively was determined (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Following oral administration, circulating concentrations of <b>1</b> were low, with an average <i>C</i><sub>max</sub> of 52 ng/mL. The drug was measurable in plasma out to 4 h postdose from all animals. However, absorption appeared to be quite rapid, <i>T</i><sub>max</sub> being at 30 min after dosing and concentrations declining with a modest apparent elimination half-life of around 90 min. Following intravenous administration, quantifiable concentrations of <b>1</b> were detected up to the last time-point taken at 8 h postdose (63 ng/mL). A moderate half-life was obtained (2.2 h) due to a low clearance (7.3 mL min<sup>–1</sup> kg<sup>–1</sup>) and a moderate volume of distribution (1.4 L/kg). Following intraperitoneal dosing, <b>1</b> could also be detected at 8 h postdose (98 ng/mL). A similar moderate half-life was obtained (2.4 h) following intraperitoneal dosing.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmacokinetic Parameters for <b>1</b><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">route of administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center">oral (10 mg/kg)</th><th class="colsep0 rowsep0" align="center">intravenous (1.25 mg/kg)</th><th class="colsep0 rowsep0" align="center">intraperitoneal (5 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">2965</td><td class="colsep0 rowsep0" align="left">5517</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apparent half-life (min)</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">130</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd (L/kg)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">159</td><td class="colsep0 rowsep0" align="left">351</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">171</td><td class="colsep0 rowsep0" align="left">372</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Mean pharmacokinetic parameters for <b>1</b> in mouse following oral, intravenous, and intraperitoneal dosing, derived from analysis of plasma.</p></div></div></div><div class="NLM_p last">Although <b>1</b> displays good solubility and permeability and moderate plasma and hepatocyte stability, oral administration in mice provided very low plasma exposure levels which severely limits its usefulness as an oral STAT3 inhibitor. The plasma levels following intraperitoneal administration supports the positive results obtained in the previously described DU145 xenograft studies.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> The lack of adequate exposure following oral administration illustrates the need for a prodrug approach to develop <b>1</b> into an oral STAT3 inhibitor.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemical Synthesis of Thiol Adducts</h3><div class="NLM_p"><b>1</b> was reacted with simple thiols and cysteine derivatives in MeOH containing catalytic amounts of triethyl amine (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). For most thiols the reaction proceeded smoothly and the adducts were obtained in good to high yields following flash chromatography. One notable exception was the addition of cystamine (2-aminoethanethiol), which gave a complex mixture of products. The chemical purity of the novel adducts produced was determined to be at least 98%, by <sup>1</sup>H NMR and integration of eventual peaks of impurities. The addition of thiols was completely stereoselective with thiols adding exclusively from the least hindered face to give just one stereoisomeric product (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: RCH<sub>2</sub>SH, triethylamine, MeOH, room temperature, overnight.</p></p></figure><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Galiellalactone adducts <b>2</b>–<b>17</b> prepared according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Efficacy of <b>1</b> and Thiol Adducts</h3><div class="NLM_p">The inhibitory effect of <b>1</b> on prostate cancer cell lines with varying levels of STAT3 expression and activity was studied. As expected, <b>1</b> inhibited the proliferation and viability of the prostate cancer cell lines DU145 and LNCaP-IL6+, which express constitutively active STAT3 (pSTAT3), but had no effect on PC3 cells which lack STAT3 or LNCaP cells which do not express constitutively active STAT3 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A,B).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro efficacy of <b>1</b> and thiol adducts. (A) Effect of <b>1</b> on viability and proliferation of prostate cancer cells incubated with 3 μM <b>1</b> for 72 h. The proliferation was measured using the WST-1 proliferation assay and calculated as percent of untreated control (<i>n</i> = 6). (B) Western blot analysis of the expression of STAT3 and pSTAT3 in prostate cancer cell lines. (C) DU145 prostate cancer cells expressing active STAT3 were treated with compounds at various concentrations for 72 h (<i>n</i> = 3). The proliferation was measured using the WST-1 proliferation assay and calculated as percent of untreated control and presented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesized thiol adducts were tested for their ability to inhibit the proliferation of pSTAT3 expressing DU145 prostate cancer cells. We have previously shown that STAT3 inhibition by <b>1</b> inhibits proliferation and induces apoptosis in DU145 cells by downregulating STAT3 target genes and proteins.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C and <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> show that all of the thiol adducts tested could reduce the proliferation of STAT3 dependent DU145 prostate cancer cells. Since all these thiol adduct compounds lack a conjugated double bond that can act as Michael acceptor, which is an absolute requirement for <b>1</b> and galiellalactone analogues to inhibit STAT3,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> they must be undergoing a retro-Michael addition under the assay conditions. Furthermore, the ability to block DU145 cell proliferation follows the stability of the thiol adducts at pH 7.4 where more stable compounds (e.g., <b>5</b>) have reduced activity compared to the compounds displaying a lower stability at pH 7.4. Notable is that <b>17</b>, the glutathione adduct, displays activity. This indicates that even in the presence of glutathione, the active compound <b>1</b> will not be completely inactivated due to it being in equilibrium with added glutathione and free <b>1</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of Compounds on DU145 Cell Proliferation in Vitro<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">2.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">4.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">9.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">4.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">9.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">11.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">6.14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">DU145 cells were incubated with the compounds for 72 h followed by cell proliferation measurement using a WST-1 proliferation assay to determine IC<sub>50</sub> values.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Chemical Stability</h3><div class="NLM_p">Thiol adducts <b>2</b>–<b>6</b>, <b>8</b>–<b>10</b>, <b>14</b>, <b>15</b>, and <b>17</b> were assayed for their stability in PBS buffer, and the half-lives of the thiol adducts were monitored by LC/MS and determined by the formation of <b>1</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Notably, thiol adducts containing free −NH<sub>2</sub> or −COOH groups (<b>2</b>–<b>4</b> with the exception of <b>10</b> and <b>14</b>) showed poor stability at pH 7.4. However, these compounds showed increased stability in acidic buffer at pH 1.2 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). This is consistent with previous reports on the stability of Michael addition products where a pH dependency has been observed.<a onclick="showRef(event, 'ref20 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref20 ref27 ref28">(20, 27, 28)</a> Compounds <b>2</b>–<b>4</b> that contain ionizable functional groups (free amine (<b>4</b>), carboxylic acid (<b>3</b>), or both free amine and carboxylic acid (<b>2</b>)) showed decreased stability at pH 7.4 and are more rapidly converted to <b>1</b>. It is possible that these ionizable groups, −NH<sub>2</sub> or −COOH, could assist or catalyze a retro-Michael reaction, thus liberating the parent drug. The remaining compounds showed chemical stabilities at pH 7.4 that made them amendable to in vivo pharmacokinetic (PK) assessment (vide infra).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Stability of Prodrugs in Vitro<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">half-life (min)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">0.1 M PBS, pH 7.4</th><th class="colsep0 rowsep0" align="center">acidic buffer, pH 1.2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">>150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">>150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Stability of prodrugs was investigated in PBS and acidic buffer. The half-lives of the thiol adducts were monitored by LC/MS and determined by the formation of <b>1</b>. ND = not determined.</p></div></div></div><div class="NLM_p">On the basis of the PK assessment, thiol adduct <b>6</b> was chosen for a study of its stability in plasma and was found to be highly unstable in plasma of all tested species (see <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). This instability in plasma is in contrast to the chemical stability in PBS buffer, indicating that the prodrug <b>6</b> is metabolized to an instable intermediate, similar to compounds <b>2</b>–<b>4</b>, that is converted to the active parent (metabolic activation). In the plasma stability studies, <b>1</b> was present in all samples in all species, including early time-points, indicating a rapid conversion of prodrug <b>6</b> to the parent compound (data not shown). In mouse plasma <b>1</b> displays moderate stability with a half-life of 74 min.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Plasma Stability of <b>6</b><a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">plasma species</th><th class="colsep0 rowsep0" align="center">half-life (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left"><5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">The stability of <b>6</b> in different species plasma was determined by the formation of <b>1</b>.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Study in Mouse</h3><div class="NLM_p">To investigate if oral administration of thiol adducts could increase the plasma exposure of <b>1</b> compared to oral administration of <b>1</b> itself and thereby function as prodrugs of <b>1</b>, mice were given an oral gavage of 10 mg/kg of 10 thiol adducts (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The plasma levels of <b>1</b> were analyzed for up to 24 h after dosing (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). All compounds tested had rapid <i>T</i><sub>max</sub> values (15–30 min), and all thiol adducts in the PK study, except <b>8</b> and <b>16</b>, gave an increased total exposure of <b>1</b> as measured by AUC and greatly enhanced <i>C</i><sub>max</sub>. The PK results indicate that thiol adducts of <b>1</b> have increased uptake and absorption following oral dosing compared to <b>1</b> itself and that they are converted to <b>1</b> in vivo, thereby acting as prodrugs. Assuming that <i>C</i><sub>max</sub> is more important than AUC for covalently acting drugs for ensuring target inhibition, <b>6</b> was selected for a proof of concept efficacy study using a prostate cancer cell xenograft mouse model. Oral dosing of <b>6</b> significantly increased the plasma exposure of <b>1</b>; <i>C</i><sub>max</sub> and AUC of <b>1</b> was increased 36-fold and 20-fold, respectively, compared to when <b>1</b> was dosed orally. Dose escalation PK studies using 40 and 100 mg/kg <b>6</b> showed that the exposure of <b>1</b> was fairly linear across the dose levels tested, in terms of both area under the curve (AUC) and maximal concentrations (<i>C</i><sub>max</sub>) (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). The PK results show that an oral dose of 40 mg/kg <b>6</b> would give comparable plasma exposure levels of <b>1</b> as the previously used intraperitoneal dose of 3 mg/kg.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Pharmacokinetic analysis of <b>1</b> and <b>6</b> following a single oral dose (10 mg/kg po) in mice (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vivo PK Parameters<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>7</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>13</b></th><th class="colsep0 rowsep0" align="center"><b>14</b></th><th class="colsep0 rowsep0" align="center"><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>16</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">788</td><td class="colsep0 rowsep0" align="left">1893</td><td class="colsep0 rowsep0" align="left">263</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">478</td><td class="colsep0 rowsep0" align="left">1102</td><td class="colsep0 rowsep0" align="left">949</td><td class="colsep0 rowsep0" align="left">303</td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apparent half-life (min)</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">278</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">348</td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">129</td><td class="colsep0 rowsep0" align="left">254</td><td class="colsep0 rowsep0" align="left">189</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">102</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">101</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">Plasma levels of <b>1</b> in mice after a single oral dose of 10 mg/kg of thiol adduct.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Dose Escalation in Vivo PK Parameters<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">oral dose</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center">40 mg/kg</th><th class="colsep0 rowsep0" align="center">100 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">3733</td><td class="colsep0 rowsep0" align="left">7478</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apparent half-life (min)</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">213</td><td class="colsep0 rowsep0" align="left">676</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (μg mL<sup>–1</sup> min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">215</td><td class="colsep0 rowsep0" align="left">679</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">Plasma levels of <b>1</b> in mice after a single oral dose of 40 mg/kg and 100 mg/kg of <b>6</b>.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vitro ADME Characterization of Thiol Adduct <b>6</b></h3><div class="NLM_p">To study potential metabolites, <b>6</b> was incubated with cryopreserved mouse hepatocytes for 2 h with an initial concentration of 10 μM. Samples were analyzed using UPLC/Q-TOF-MS.</div><div class="NLM_p"><b>6</b> was completely metabolized in 2 h with mouse hepatocytes. The major metabolite was <b>3</b>, the result of ester hydrolysis of <b>6</b>. <b>1</b> was detected as the second most abundant metabolite. This suggests that the initial step in the conversion of the prodrug <b>6</b> to the active parent <b>1</b> is metabolic ester hydrolysis to the carboxylic acid <b>3</b>, an enzymatic step, followed by spontaneous conversion of <b>3</b> to <b>1</b>, as <b>3</b> was determined (vide supra) to be chemically unstable. The conversion of <b>3</b> to <b>1</b> most likely involves a retro-Michael addition.</div><div class="NLM_p last">In the Caco-2 assay <b>6</b> showed intermediate apparent permeability to both directions without difference between absorptive and secretory directions.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <b>6</b> Inhibits Prostate Cancer Xenograft Growth in Vivo</h3><div class="NLM_p">The in vivo effect of <b>6</b> was investigated in mice bearing DU145 prostate cancer cell xenograft tumors expressing pSTAT3 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The mice were orally treated with <b>6</b> (40 mg/kg) or vehicle daily five times a week for 4 weeks. The tumor growth rate was significantly reduced in <b>6</b> treated mice after 26 and 29 days compared to vehicle treated mice (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). <b>6</b> was well tolerated and no weight loss (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B), apparent behavioral alterations, or other side effects were observed. All mice survived the treatment.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Oral treatment with <b>6</b> inhibits prostate cancer xenograft growth. Mice with subcutaneous DU145 xenografts were treated orally with <b>6</b> (40 mg/kg) or vehicle (2% DMSO in citric buffer) for 4 weeks, daily 5 times per week. (A) Mice treated with <b>6</b> had significantly smaller tumors compared to vehicle treated mice at day 26 and day 29 ((∗) <i>p</i> < 0.05 and (∗∗) <i>p</i> < 0.01; <i>n</i> = 10). (B) There was no significant difference in body weights between vehicle and <b>6</b> treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular analysis of DU145 xenograft tumors showed decreased proliferation and increased apoptosis in <b>6</b> treated tumors compared to vehicle treated, as measured by decreased Ki67 ratio and increased amount of cleaved caspase-3 positive cells (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B). The mRNA expression of STAT3 regulated antiapoptotic genes MCL1 and BCL2 were reduced by <b>6</b> treatment, indicating an effect via STAT3 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). This is in line with previous findings showing that <b>1</b> induces apoptosis via caspase-3 cleavage, decreased MCL1 gene expression, and BCL2 protein downregulation.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> The pSTAT3 expression was not altered by <b>6</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D), which is in accordance with the fact that <b>1</b> is a direct inhibitor that does not effect the phosphorylation of STAT3 but prevents DNA binding and transcription of STAT3 regulated genes.<a onclick="showRef(event, 'ref13 ref25'); return false;" href="javascript:void(0);" class="ref ref13 ref25">(13, 25)</a> Taken together, these results show that oral administration of the prodrug <b>6</b> is well tolerated and shows similar antitumor effects via STAT3 inhibition as <b>1</b> given intraperitoneally,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> thus confirming that <b>6</b> functions as a prodrug.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>6</b> inhibits proliferation and induces apoptosis of tumor cells in vivo. (A) Proliferation measured as Ki67 ratio was significantly decreased by <b>6</b> treatment in DU145 xenografts (<i>p</i> = 0.0061; <i>n</i> = 9). (B) The amount of cleaved caspase-3 expressing cells, indicating apoptotic cells, was significantly increased by <b>6</b> treatment in xenograft tumors (<i>p</i> = 0.0005; <i>n</i> = 9). (C) The mRNA expression of the antiapoptotic genes MCL1 and BCL2 in <b>6</b> treated tumor xenografts (<i>p</i> = 0.015 and <i>p</i> = 0.18, respectively; <i>n</i> = 8). (D) pSTAT3 expression in DU145 xenografts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Toxicity</h3><div class="NLM_p">To assess the tolerability and eventual toxicity of <b>6</b>, the maximum tolerated dose (MTD) of <b>6</b> was determined in male CD1 mice following a single oral dose.</div><div class="NLM_p"><b>6</b> was administered as single dose orally (by gavage) at 40 mg/kg, 200 mg/kg, and 400 mg/kg with 5 male mice per group. One group received the vehicle alone (50 mM citrate buffer, pH 4.0, 5% DMSO) as a control. Under the experimental conditions of the study, when administered as a single dose orally to male CD1 mice, <b>6</b> showed no toxicologically relevant clinical signs, no changes in body weight (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), and no adverse events in clinical pathology and histopathology. Thus, the MTD was considered to be 400 mg/kg.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Toxicity Study: Mouse Weight after a Single Oral Dose of <b>6</b><a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">body weight (g)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">group</th><th class="colsep0 rowsep0" align="center">day 1</th><th class="colsep0 rowsep0" align="center">day 4</th><th class="colsep0 rowsep0" align="center">day 8</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="left">33.5 ± 4.34</td><td class="colsep0 rowsep0" align="left">34.68 ± 4.71</td><td class="colsep0 rowsep0" align="left">32.28 ± 4.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">40 mg/kg</td><td class="colsep0 rowsep0" align="left">32.52 ± 2.09</td><td class="colsep0 rowsep0" align="left">33.68 ± 2.06</td><td class="colsep0 rowsep0" align="left">31.12 ± 1.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">200 mg/kg</td><td class="colsep0 rowsep0" align="left">33.56 ± 1.17</td><td class="colsep0 rowsep0" align="left">35.3 ± 0.79</td><td class="colsep0 rowsep0" align="left">33.02 ± 1.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">400 mg/kg</td><td class="colsep0 rowsep0" align="left">33.16 ± 1.86</td><td class="colsep0 rowsep0" align="left">34.76 ± 1.76</td><td class="colsep0 rowsep0" align="left">32.1 ± 1.64</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Mean ± SD; <i>n</i> = 5.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">By exploitation of the reversible nature of the Michael addition of thiols to a reactive electrophilic double bond, an orally bioavailable prodrug of the STAT3 inhibitor <b>1</b> was discovered. <b>1</b> itself is not suitable for oral administration, having very low plasma exposure following oral administration, but by conjugation of <b>1</b> with a thiol, a stable adduct was obtained that functioned as an oral prodrug. Therefore, the prodrug <b>6</b> is an orally active STAT3 inhibitor whereas the parent compound only displays in vivo activity following intraperitoneal administration.</div><div class="NLM_p">The reason for the poor oral bioavailability of <b>1</b> could not be determined from these studies. The permeability per se does not seem to be limiting as observed from the quick <i>T</i><sub>max</sub>. However, the instability toward intestinal S9 fractions suggests extensive intestinal metabolism and it cannot be excluded that <b>1</b> is conjugated with glutathione in the intestinal membrane and then effluxed. Preconjugation of <b>1</b> with <i>N</i>-acetyl cysteine methyl ester, as in prodrug <b>6</b>, would protect the compound from this initial conjugation and allow it to pass over the intestinal membrane.</div><div class="NLM_p">The proposed two-step conversion of the prodrug <b>6</b> to the active parent is shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. The data suggest that the chemically stable <i>N</i>-acetyl cysteine methyl ester prodrug is metabolically hydrolyzed to the corresponding free carboxylic acid which is less stable under physiological conditions and undergoes a spontaneous reversible Michael addition reaction to liberate the active parent drug <b>1</b>.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed conversion of prodrug <b>6</b> to active parent <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">STAT3 as a drug target in cancer is supported by a vast number of in vitro and in vivo studies. However, the discovery and development of selective and orally bioavailable STAT3 inhibitors have been slow and only few small molecules have made it into the clinic.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a><b>1</b> is a promising lead for generating an efficacious STAT3 inhibitor. The direct inhibition of STAT3 through the alkylation of cysteine-468 in the DNA binding domain makes it possible for a small molecule to block the binding interactions between the protein and DNA. Furthermore, <b>1</b> targets a cysteine residue unique to the STAT3 sequence, and covalent inhibition offers the possibility of decoupling pharmacokinetics from pharmacodynamics thus giving sustained inhibition even when systemic exposure has decreased.</div><div class="NLM_p last">The favorable druglike properties and safety profile of the prodrug <b>6</b> and the direct inhibition of STAT3 by <b>1</b> warrant further studies of <b>6</b> (GPA512) as a drug candidate for treatment of patients with castration-resistant prostate cancer. Finally, it is clearly demonstrated that <b>1</b> reacts reversibly with thiols, thus making it a reversible covalent inhibitor, and therefore has less potential for toxic effects caused by irreversible binding to cysteine residues and thiols.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Information</h3><div class="NLM_p">Reagents was purchased from commercial suppliers and used without further purification unless otherwise noted. All reactions were carried out in standard dry glassware and atmospheric surroundings, unless otherwise stated.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz) and <sup>13</sup>C NMR (125 MHz) were recorded at room temperature with a Bruker DRX500 spectrometer with an inverse multinuclear 5 mm probehead equipped with a shielded gradient coil. The spectra were recorded in CD<sub>3</sub>OD, CDCl<sub>3</sub>, and CD<sub>2</sub>Cl<sub>2</sub>, and the solvent signals (3.31/49.15 ppm, 7.27/77.00 ppm, 5.34/54.00 ppm, respectively) were used as reference. The chemical shifts (δ) are given in ppm, and the coupling constants (<i>J</i>) are given in Hz. COSY, HMQC, and HMBC experiments were recorded with gradient enhancements using sine shaped gradient pulses. For the 2D heteronuclear correlation spectroscopy the refocusing delays were optimized for <sup>1</sup><i>J</i><sub>CH</sub> = 145 Hz and <sup><i>n</i></sup><i>J</i><sub>CH</sub> = 10 Hz. The raw data were transformed, and the spectra were evaluated with the standard Bruker XWIN-NMR software (revision 010101). Mass spectra (HREI, HRFAB) were recorded with a Jeol SX102 spectrometer, while HRESI spectra were recorded with a Micromass Q-TOF Micro. The chemical purity of the novel adducts was determined to be at least 95% by analytical HPLC. HPLC analyses were performed using an Agilent 1260 Infinity system with an Agilent C18 (3.5 μm, 4.6 mm × 100 mm column. A linear gradient was applied from 0 to 20 min using 0.1% of TFA in a H<sub>2</sub>O/MeCN gradient 5–95% and a flow rate of 1.6 mL/min. UV detection was performed at 220 and 254 nm.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry. 3β-(<span class="smallcaps smallerCapital">l</span>-Cysteine)-2aβ,3-dihydrogaliellalactone (<b>2</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (10 mg, 0.053 mmol) in methanol-<i>d</i><sub>4</sub> (0.5 mL) was added <span class="smallcaps smallerCapital">l</span>-cysteine (7 mg, 0.058 mmol) and triethylamine (1 μL, 0.007 mmol). The reaction was followed by NMR and was complete after 24 h. The excess of solvent and the triethylamine were removed in vacuum, and <b>2</b> was obtained in quantitative yield. δ <sup>1</sup>H (400 MHz, CD<sub>3</sub>OD) 4.58 (1 H, brs), 3.82 (1 H, dd, <i>J</i> 8.8, 3.8), 3.39 (2 H, s), 3.11 (2 H, m), 2.88 (1 H, d, <i>J</i> 10.4), 2.19 (2 H, m), 2.01 (3 H, m), 1.79 (1 H, m), 1.36 (1 H, m), 1.21 (3 H, d, <i>J</i> 6.6), 0.74 (1 H, m). δ <sup>13</sup>C (101 MHz, CD<sub>3</sub>OD) 178.3, 173.5, 91.2, 85.3, 55.9, 49.0, 48.5, 47.1, 38.2, 35.2, 34.6, 33.0, 30.6, 21.2. HRMS calcd for C<sub>14</sub>H<sub>22</sub>NO<sub>5</sub>S [M + H], 316.1219; found, 316.1225.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 3β-(<i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine)-2aβ,3-dihydrogaliellalactone (<b>3</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (10 mg, 0.053 mmol) in methanol-<i>d</i><sub>4</sub> (0.5 mL) were added <i>N</i>-acetyl <span class="smallcaps smallerCapital">l</span>-cysteine (10 mg, 0.058 mmol) and triethylamine (1 μL, 0.006 mmol). The reaction was followed by NMR and was complete after 24 h. The excess of solvent and the triethylamine were removed in vacuum, and <b>3</b> was obtained in quantitative yield. δ <sup>1</sup>H (400 MHz, CD<sub>3</sub>OD) 4.64 (1 H, dd, <i>J</i> 7.8, 4.6), 4.51 (1 H, brs), 3.21 (2 H, q, <i>J</i> 7.9), 3.03 (1 H, dd, <i>J</i> 13.6, 7.9), 2.88 (2 H, d, <i>J</i> 10.1), 2.18 (1 H, m), 2.10 (1 H, m), 1.96 (3 H, s), 1.94 (2 H, m), 1.90 (1 H, m), 1.65 (1 H, m), 1.14 (3 H, d, <i>J</i> 6.6), 0.63 (1 H, dt, <i>J</i> 13.7, 12.2). δ <sup>13</sup>C (101 MHz, CD<sub>3</sub>OD) 178.1, 174.3, 173.4, 91.0, 85.4, 54.7, 49.0, 48.5, 48.0, 38.6, 35.3, 34.6, 32.9, 30.2, 22.6, 21.6. HRMS calcd for C<sub>16</sub>H<sub>23</sub>DNO<sub>6</sub>S [M + H], 359.1387; found, 359.1388.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3β-(<span class="smallcaps smallerCapital">l</span>-Cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>4</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (10 mg, 0.051 mmol) in methanol-<i>d</i><sub>4</sub> (0.5 mL) were added <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester hydrochloride (10 mg, 0.057 mmol) and triethylamine (1 μL, 0.006 mmol). The reaction was followed by NMR and was complete after 24 h. The excess of solvent and the triethylamine were removed in vacuum, and <b>4</b> was obtained in quantitative yield. δ <sup>1</sup>H (400 MHz, CD<sub>3</sub>OD) 4.61 (1 H, s), 4.46 (1 H, t, <i>J</i> 5.8), 3.92 (3 H, s), 3.91 (1 H, s), 3.28 (2 H, dd, <i>J</i> 5.8, 2.3), 2.88 (1 H, d, <i>J</i> 10.3), 2.24 (1 H, ddd, <i>J</i> 9.2, 7.1, 3.0), 2.17 (2 H, m), 2.01 (3 H, m), 1.73 (1 H, m), 1.35 (1 H, m), 1.19 (3 H, d, <i>J</i> 6.6), 0.73 (1 H, dt, <i>J</i> 13.8, 12.1). δ <sup>13</sup>C (101 MHz, CD<sub>3</sub>OD) 178.1, 169.8, 91.3, 85.4, 54.1, 53.8, 51.8, 48.6, 47.1, 38.3, 35.1, 32.9, 32.7, 30.4, 21.4. HRMS calcd for C<sub>15</sub>H<sub>23</sub>DNO<sub>5</sub>S [M + H], 331.1438; found, 331.1439.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3β-(<i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine amide)-2aβ,3-dihydrogaliellalactone (<b>5</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (13 mg, 0.064 mmol) in methanol (0.5 mL) were added <i>N</i>-acetyl <span class="smallcaps smallerCapital">l</span>-cysteine amide (11 mg, 0.065 mmol) and triethylamine (1 μL, 0.006 mmol). The reaction was followed by NMR and was complete after 24 h. The excess of solvent and the triethylamine were removed in vacuum, and <b>5</b> was obtained in quantitative yield. δ <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) 7.21 (1 H, d, <i>J</i> 8.3), 4.82 (1 H, m), 4.61 (1 H, m), 3.43 (1 H, m), 3.18 (2 H, m), 2.19 (1 H, m), 2.09 (3 H, s), 2.05 (1 H, m), 2.01 (2 H, m), 1.88 (1 H, m), 1.64 (1 H, m), 1.42 (1 H, m), 1.38 (1 H, m), 1.11 (3 H, d, <i>J</i> 6.8), 0.70 (1 H, m). δ <sup>13</sup>C (101 MHz, CDCl<sub>3</sub>) 176.6, 173.7, 172.3, 89.8, 84.6, 53.1, 52.6, 47.4, 45.7, 36.7, 34.3, 33.5, 31.6, 29.3, 22.8, 21.1. HRMS calcd for C<sub>16</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>S [M + H], 357.0978; found, 357.0958.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3β-(<i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>6</b>)</h3><div class="NLM_p last">Galiellalactone (<b>1</b>) (1.2 g, 6.18 mmol) was dissolved in MeOH (30 mL), and <i>N</i>-acetyl-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester (1.2 g, 6.80 mmol) was added at room temperature, followed by triethylamine (86 μL, 0.62 mmol). The reaction mixture was stirred for 30 h under N<sub>2</sub>, whereafter the solvent and the triethylamine were removed under reduced pressure. The resulting orange oil was passed through a Sephadex LH-20 column eluted with methanol. The crude product was passed through a very short SiO<sub>2</sub> column, using EtOAc as eluent, affording 2.1 g (91%) of <b>6</b> as a pale yellow oil that crystallized in CH<sub>2</sub>Cl<sub>2</sub>. δ <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) 6.50 (1 H, d, <i>J</i> 7.2), 4.90 (1 H, dt, <i>J</i> 8.0, 5.8), 4.60 (1 H, t, <i>J</i> 2.8), 3.81 (3 H, s), 3.43 (1 H, dd, <i>J</i> 2.1, 1.3), 3.08 (2 H, dd, <i>J</i> 5.8, 0.6), 3.02 (1 H, dd, <i>J</i> 8.9, 2.1), 2.21 (1 H, m), 2.11 (1 H, m), 2.08 (3 H, s), 2.03 (2 H, m), 1.85 (1 H, ddd, <i>J</i> 14.3, 6.7, 3.2), 1.57 (1 H, ddd, <i>J</i> 8.7, 6.7, 3.3), 1.42 (1 H, ddd, <i>J</i> 17.5, 12.9, 8.0), 1.13 (3 H, d, <i>J</i> 6.7), 0.74 (1 H, dt, <i>J</i> 14.3, 12.3). δ <sup>13</sup>C (101 MHz, CDCl<sub>3</sub>) 175.4, 171.2, 170.7, 89.4, 84.4, 52.9, 52.7, 52.6, 47.3, 46.1, 36.3, 34.4, 34.3, 31.5, 29.3, 23.2, 21.2. HRMS calcd for C<sub>17</sub>H<sub>26</sub>NO<sub>6</sub>S [M + H], 372.1481; found, 372.1499.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3β-(<i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine ethyl ester)-2aβ,3-dihydrogaliellalactone (<b>7</b>)</h3><div class="NLM_p last"><i>N</i>-Acetyl <span class="smallcaps smallerCapital">l</span>-cysteine (30 mg, 0.184 mmol) was dissolved in EtOH (2 mL) at room temperature, and thionyl chloride (15 μL, 0.20 mmol) was added at 0 °C under N<sub>2</sub>. The reaction was stirred at room temperature, and the residual solvent was removed under reduced pressure to yield <i>N</i>-acetyl <span class="smallcaps smallerCapital">l</span>-cysteine ethyl ester that was used without further purification in the next step. To a solution of galiellalactone (25 mg, 0.129 mmol) in methanol (2 mL) were added the <i>N</i>-acetyl <span class="smallcaps smallerCapital">l</span>-cysteine ethyl ester and triethylamine (2 μL, 0.013 mmol). The reaction was stirred at room temperature for 24 h, and the excess of solvent was removed under vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using EtOAc as eluent to yield compound <b>7</b> (22 mg, 44%). δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 6.59 (1 H, dt, <i>J</i> 12.8, 8.0), 4.86 (1 H, dt, <i>J</i> 8.0, 5.6), 4.59 (1 H, t, <i>J</i> 2.9), 4.25 (2 H, qd, <i>J</i> 7.1, 1.7), 3.41 (1 H, dd, <i>J</i> 2.6, 1.8), 3.08 (2 H, dd, <i>J</i> 5.6, 1.7), 3.00 (1 H, dtd, <i>J</i> 7.7, 4.7, 2.6), 2.20 (1 H, dt, <i>J</i> 13.1, 5.2), 2.10 (1 H, dd, <i>J</i> 13.6, 5.2), 2.03 (2H, m), 2.02 (3 H, s), 1.85 (1 H, ddd, <i>J</i> 14.2, 6.8, 3.3), 1.64–1.54 (2 H, m), 1.32 (3 H, t, <i>J</i> 7.1), 1.12 (3 H, d, <i>J</i> 6.6), 0.73 (1 H, dt, <i>J</i> 14.2, 13.6). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 175.4, 170.7, 170.7, 89.4, 84.5, 62.2, 52.8, 52.7, 47.4, 46.1, 36.4, 34.4, 34.3, 31.5, 29.3, 23.2, 21.1, 14.1. HRMS calcd for C<sub>18</sub>H<sub>28</sub>NO<sub>6</sub>S [M + H], 386.1637; found, 386.1623.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3β-(<i>N</i>-(<i>tert</i>-Butylcarbonate)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>8</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (22 mg, 0.113 mmol) in methanol (2 mL) were added <i>N</i>-(<i>tert</i>-butylcarbonate)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester (30 μL, 0.147 mmol) and triethylamine (2 μL, 0.011 mmol). The reaction was stirred at room temperature for 24 h, and the excess of solvent was removed under vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (3:7) as eluent to yield compound <b>8</b> (34 mg,70%). δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 5.48 (1 H, d, <i>J</i> 7.3), 4.57 (1 H, dd, <i>J</i> 7.3, 2.5), 4.56 (1 H, d, <i>J</i> 1.7), 3.78 (3 H, s), 3.37 (1 H, m), 3.05 (2 H, d, <i>J</i> 5.8), 3.01 (1 H, dd, <i>J</i> 8.6, 1.9), 2.20 (1 H, m), 2.09 (1 H, m), 2.02 (2 H, m), 1.82 (1 H, ddd, <i>J</i> 14.2, 6.6, 3.4), 1.59 (1 H, m), 1.44 (9 H, s), 1.42 (1 H, m), 1.12 (3 H, d, <i>J</i> 6.7), 0.73 (1 H, dt, <i>J</i> 14.2, 12.3). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 175.2, 171.3, 155.6, 89.3, 84.6, 80.6, 53.7, 52.7, 52.5, 47.0, 46.0, 36.2, 34.4, 34.2, 31.4, 29.3, 28.3, 21.2. HRMS calcd for C<sub>20</sub>H<sub>31</sub>NO<sub>7</sub>SNa [M + Na]: 452.1719; found, 452.1736.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3β-(Benzylthio)-2aβ,3-dihydrogaliellalactone (<b>9</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (12 mg, 0.062 mmol) in methanol (0.5 mL) were added benzylthiol (8 μL, 0.068 mmol) and triethylamine (1 μL, 0.006 mmol). The reaction was stirred at room temperature for 24 h, and the excess of solvent and the triethylamine were removed in vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (15:85) as eluent to yield compound <b>9</b> (15 mg, 76%). δ <sup>1</sup>H (400 MHz, CD<sub>3</sub>OD) 7.42 (2 H, m), 7.33 (2 H, m), 7.25 (1 H, m), 4.54 (1 H, t, <i>J</i> 2.3), 3.86 (2 H, s), 3.45 (1 H, t, <i>J</i> 1.5), 2.84 (1 H, dd, <i>J</i> 10.1, 1.8), 2.22 (1 H, m), 2.12 (1 H, m), 2.00 (2 H, m), 1.89 (1 H, ddd, <i>J</i> 13.8, 7.0, 2.8), 1.64 (1 H, m), 1.33 (1 H, m), 1.00 (3 H, d, <i>J</i> 6.6), 0.61 (1 H, dt, <i>J</i> 13.8, 12.2). δ <sup>13</sup>C (101 MHz, CD<sub>3</sub>OD) 178.0, 140.1, 130.4, 129.5, 128.0, 90.9, 85.5, 54.9, 47.4, 47.2, 38.6, 36.8, 34.8, 32.9, 30.2, 21.4. HRMS calcd for C<sub>18</sub>H<sub>23</sub>O<sub>3</sub>S [M + H], 319.1368; found, 319.1365.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3β-(Ethyl sulfonate)-2aβ,3-dihydrogaliellalactone (<b>10</b>)</h3><div class="NLM_p last">To a solution of galielallactone (<b>1</b>) (12 mg, 0.062 mmol) in methanol-<i>d</i><sub>4</sub> (0.5 mL) were added sodium 2-sulfanylethanesulfonate (Mesna) (11 mg, 0.068 mmol) and triethylamine (1 μL, 0.006 mmol). The reaction was followed by NMR at room temperature for 24 h, and after the reaction had finished the solvent and the triethylamine were removed in vacuum. <b>10</b> was obtained in quantitative yield. δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 4.52 (1 H, dd, <i>J</i> 5.3, 2.0), 3.40 (1 H, m), 3.15 (2 H, m), 3.03 (1 H, d, <i>J</i> 7.3), 3.01 (2 H, m), 2.20 (1 H, m), 2.11 (1 H, m), 1.98 (2 H, m), 1.92 (1 H, ddd, <i>J</i> 14.2, 6.2, 3.9), 1.63 (1 H, m), 1.32 (1 H, m), 1.14 (3 H, d, <i>J</i> 6.8), 0.64 (1 H, ddd, <i>J</i> 14, 12, 12) δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 178.0, 90.9, 85.4, 53.0, 54.2, 47.9, 47.1, 38.6, 35.0, 32.9, 30.2, 27.2, 21.6. HRMS calcd for C<sub>13</sub>H<sub>20</sub>O<sub>6</sub>NaS<sub>2</sub> [M + H], 359.0599; found, 359.0594.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3β-(Butyllthio)-2aβ,3-dihydrogaliellalactone (<b>11</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (33 mg, 0.170 mmol) in methanol (2 mL) were added 1-butanethiol (20 μL, 0.187 mmol) and triethylamine (2 μL, 0.017 mmol). The reaction was stirred at room temperature for 24 h, and the excess of solvent was removed in vacuum. The crude product was purified by column chromatography using heptane/EtOAc (3:7) to yield compound <b>11</b> (35 mg, 72%). δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 4.59 (1 H, dd, <i>J</i> 4.9, 2.1), 3.20 (1 H, m), 3.06 (1 H, dd, <i>J</i> 7.1, 1.9), 2.64 (1 H, tdd, <i>J</i> 12.6, 8.4, 7.3), 2.58 (1H, ddd, <i>J</i> 12.6, 8.4, 7.3), 2.23 (1 H, dtd, <i>J</i> 12.8, 8.2, 4.5), 2.12 (1 H, m), 2.08 (2 H, m), 2.00 (1 H, m), 1.78 (1 H, ddd, <i>J</i> 14.3, 6.1, 4.5), 1.64 (1H, m), 1.63 (2 H, m), 1.51 (1 H, m), 1.43 (1 H, dtd, <i>J</i> 14.3, 7.3, 1.3), 1.15 (3 H, d, <i>J</i> 6.8), 0.93 (3 H, t, <i>J</i> 7.3), 0.78 (1 H, dt, <i>J</i> 14.3, 12.4). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 175.3, 88.9, 85.1, 51.7, 46.7, 44.8, 35.5, 34.8, 31.4, 31.4, 31.3, 29.5, 22.00, 21.7, 13.6. HRMS calcd for C<sub>15</sub>H<sub>25</sub>O<sub>3</sub>S [M + H], 285.1524; found, 285.1527.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3β-(Phenylthio)-2aβ,3-dihydrogaliellalactone (<b>12</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (22 mg, 0.113 mmol) in methanol (2 mL) were added thiophenol (13 μL, 0.125 mmol) and triethylamine (2 μL, 0.011 mmol). The reaction was stirred at room temperature for 24 h, and the excess of solvent was removed under vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (3:7) as eluent to yield compound <b>12</b> (25 mg, 73%). δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 7.45 (2 H, tt, <i>J</i> 8.5, 1.3), 7.34 (2 H, t, <i>J</i> 8.5), 7.25 (1 H, td, <i>J</i> 8.5, 1.3), 4.50 (1 H, dd, <i>J</i> 4.6, 1.9), 3.63 (1 H, dd, <i>J</i> 7.4, 1.6), 3.15 (1 H, m), 2.38 (1 H, m), 2.15 (1 H, m), 2.06 (1 H, dt, <i>J</i> 8.1, 4.6), 2.00 (1 H, m), 1.84 (1 H, ddd, <i>J</i> 14.3, 6.1, 3.8), 1.75 (1 H, m), 1.51 (1 H, m), 1.22 (3 H, d, <i>J</i> 6.7), 0.85 (1 H, dt, <i>J</i> 14.3, 12.4). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 175.0, 134.4, 130.8, 129.4, 127.2, 88.9, 85.0, 50.6, 47.1, 46.8, 35.7, 34.1, 31.3, 29.3, 21.7. HRMS calcd for C<sub>17</sub>H<sub>21</sub>O<sub>3</sub>S [M + H], 305.1211; found, 305.1219.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3β-(<i>N</i>-Acetyl-<span class="smallcaps smallerCapital">l</span>-homocysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>13</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (30 mg, 0.154 mmol) in methanol (2 mL) were added homocysteine (23 mg, 0.170 mmol) and triethylamine (2 μL, 0.015 mmol). The reaction was stirred at room temperature overnight, and the excess of solvent was removed under vacuum. The crude was dissolved in dry THF (3 mL), and triethylamine (27 μL, 0.289 mmol) was added at 0 °C followed by acetyl chloride (17 μL, 0.238 mmol). The reaction was stirred for 20 h at room temperature, and the residual solvent was removed under vacuum. The intermediate was dissolved in MeOH (1.5 mL), and SOCl<sub>2</sub> (28 μL, 0.385 mmol) was added at 0 °C, and the mixture was stirred overnight. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (3:7) as eluent to yield compound <b>13</b> (24 mg, 40%) after three steps. δ <sup>1</sup>H (500 MHz, CD<sub>2</sub>Cl<sub>2</sub>) 6.47 (1 H, d, <i>J</i> 7.9), 4.68 (1 H, td, <i>J</i> 7.9, 4.6), 4.55 (1 H, m), 3.73 (3 H, s), 3.42 (1 H, m), 2.20 (1 H, m), 2.17 (1 H, m), 2.10 (2 H, m), 2.01 (2 H, m), 2.00 (3 H, s), 1.98 (2 H, m), 1.87 (1 H, ddd, <i>J</i> 14.2, 7.0, 3.1), 1.67 (1 H, m), 1.36 (1 H, m), 1.12 (3 H, d, <i>J</i> 6.6), 0.69 (1 H, dt, <i>J</i> 14.2, 12.2). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 176.2, 172.9, 171.1, 90.2, 85.1, 53.6, 53.1, 52.1, 47.5, 46.8, 37.4, 32.9, 32.2, 32.2, 29.9, 28.3, 23.6, 21.4. HRMS calcd for C<sub>18</sub>H<sub>27</sub>NO<sub>6</sub>SNa [M + Na], 408.1457; found, 408.1454.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3β-(<i>N</i>-(<span class="smallcaps smallerCapital">l</span>-Valine)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>14</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-[(1,1-dimethylethoxy)carbonyl]-<span class="smallcaps smallerCapital">l</span>-valine (0.50 g, 2.30 mmol) in dry THF (10 mL) was added <i>N</i>-methylmorpholine (0.30 g, 2.76 mmol) at room temperature, followed by isobutyl chloroformate (0.36 mL, 2.76 mmol) at −15 °C. After the reaction mixture had turned to a homogeneous solution it was stirred for an additional 30 min before addition of <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester (0.43 g, 2.53 mmol) in dry THF (2 mL) under N<sub>2</sub>. The reaction was quenched by addition of NaHCO<sub>3</sub> (sat.) and extracted with EtOAc (3 × 7 mL) and the organic phase concentrated under vacuum to yield <i>N</i>-[(1,1-dimethylethoxy)carbonyl]-<span class="smallcaps smallerCapital">l</span>-valine-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester that was used in the next step without further purification. To a solution of galiellalactone (40 mg, 0.201 mmol) in methanol (2 mL) was added the <i>N</i>-[(1,1-dimethylethoxy)carbonyl]-<span class="smallcaps smallerCapital">l</span>-valine-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester, followed by triethylamine (3 μL, 0.020 mmol). The reaction was stirred at room temperature overnight, and the excess of solvent was removed under vacuum. The reaction mixture was dissolved in Et<sub>2</sub>O (3 mL), and HCl in Et<sub>2</sub>O (1 N, 4 mL) was added at 0 °C. The reaction was stirred for 8 h. The crude product was purified by SiO<sub>2</sub> chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:9) as eluent, to yield compound <b>14</b> (30 mg, 34%) after two steps. δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 8.00 (1 H, d, <i>J</i> 6.7), 4.89 (1 H, dd, <i>J</i> 12.4, 6.7), 4.73 (1 H, s), 4.14 (1 H, dd, <i>J</i> 7.5, 3.8), 3.79 (3 H, s), 3.72 (1 H, m), 3.18 (2 H, m), 2.93 (1 H, d, <i>J</i> 10.2), 2.33 (1 H, m), 2.17 (1 H, m), 2.10 (1 H, m), 1.99 (2 H, dd, <i>J</i> 7.3, 3.3), 1.85 (1 H, ddd, <i>J</i> 14.0, 6.6, 2.9), 1.63 (1 H, m), 1.36 (1 H, m), 1.14 (6 H, d, <i>J</i> 3.8), 1.13 (3 H, d, <i>J</i> 6.6), 0.69 (1 H, dd, <i>J</i> 14.2, 12.2). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 176.4, 170.6, 89.5, 84.4, 58.8, 52.8, 52.7, 52.2, 47.1, 45.4, 36.8, 34.1, 33.4, 31.5, 30.4, 29.2, 21.1, 18.2, 18.1. HRMS calcd for C<sub>20</sub>H<sub>33</sub>N<sub>2</sub>O<sub>6</sub>S [M + H], 429.2059; found, 429.2067.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3β-(<i>N</i>-Isobutyryl-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>15</b>)</h3><div class="NLM_p last">To a solution of <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester hydrochloride (0.2 g, 1.17 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added triethylamine (0.16 mL, 1.75 mmol) at room temperature. When the reaction mixture had turned into a homogeneous clear solution, it was stirred for an additional 15 min before the addition of isobutyryl chloride (0.13 g, 1.28 mmol) at 0 °C under N<sub>2</sub>. The reaction was stirred overnight and quenched by NaHCO<sub>3</sub> (sat.), extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was concentrated under vacuum to yield <i>N</i>-isobutyryl-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester that was used in the next step without further purification. To a solution of galiellalactone (<b>1</b>) (20 mg, 0.103 mmol) in methanol (2 mL) was added the <i>N</i>-isobutyryl-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester (0.046 g, 0.224 mmol), followed by triethylamine (1 μL, 0.010 mmol). The reaction was stirred at room temperature overnight, and the excess of solvent was removed under vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (6:4) as eluent, to yield compound <b>15</b> (27 mg, 66%) after two steps. δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 6.52 (1 H, d, <i>J</i> 8.1), 4.85 (1 H, dd, <i>J</i> 8.1, 5.9), 4.59 (1 H, t, <i>J</i> 3.2), 3.79 (3 H, s), 3.47 (1 H, m), 3.09 (1 H, dd, <i>J</i> 14.3, 5.9), 3.03 (1 H, dd, <i>J</i> 14.3, 5.9), 2.99 (1 H, dd, <i>J</i> 9.2, 2.1), 2.47 (1 H, m), 2.19 (1 H, m), 2.09 (1 H, ddd, <i>J</i> 14.4, 12.3, 6.9), 2.01 (2 H, m), 1.84 (1 H, ddd, <i>J</i> 14.2, 6.9, 3.2), 1.57 (1 H, m), 1.39 (1 H, m), 1.18 (3 H, d, <i>J</i> 3.9), 1.16 (3 H, d, <i>J</i> 3.9), 1.11 (3 H, d, <i>J</i> 6.7), 0.71 (1 H, dt, <i>J</i> 14.2, 12.3). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 177.7, 175.6, 171.3, 89.4, 84.5, 52.8, 52.6, 52.4, 47.5, 45.9, 36.6, 35.4, 34.2, 34.2, 31.5, 29.2, 21.1, 19.4, 19.3. HRMS calcd for C<sub>19</sub>H<sub>30</sub>NO<sub>6</sub>S [M + H], 400.1794; found, 400.1780.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3β-(<i>N</i>-(2-Fluorobenzoyl)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (<b>16</b>)</h3><div class="NLM_p last">To a solution of <span class="smallcaps smallerCapital">l</span>-cysteine methyl ester hydrochloride (0.3 g, 1.75 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added triethylamine (0.27 mL, 1.92 mmol) at room temperature. The reaction mixture was stirred for 15 min before the addition of 2-fluorobenzoyl chloride (0.23 g, 1.92 mmol) at 0 °C under N<sub>2</sub>. The reaction was stirred overnight and quenched by NaHCO<sub>3</sub> (sat.), extracted with EtOAc (3 × 10 mL) and the organic phase was concentrated under vacuum to yield <i>N</i>-(2-fluorobenzoyl)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester that was used in the next step without further purification. To a solution of galiellalactone (<b>1</b>) (20 mg, 0.103 mmol) in methanol (2 mL) was added the <i>N</i>-(2-fluorobenzoyl)-<span class="smallcaps smallerCapital">l</span>-cysteine methyl ester (0.063 g, 0.257 mmol), followed by triethylamine (1 μL, 0.010 mmol). The reaction was stirred at room temperature overnight, and the excess of solvent was removed under vacuum. The crude product was purified by SiO<sub>2</sub> chromatography using heptane/EtOAc (3:7) as eluent, to yield compound <b>16</b> (31 mg, 65%). δ <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) 8.04 (1 H, td, <i>J</i> 7.9, 1.5), 7.64 (1 H, dd, <i>J</i> 12.7, 7.5), 7.51 (1 H, m), 7.27 (1 H, ddd, <i>J</i> 8.6, 7.9, 1.5), 7.15 (1 H, ddd, <i>J</i> 12.7, 8.6, 1.5), 5.09 (1 H, dtd, <i>J</i> 7.5, 5.8, 2.1), 4.57 (1 H, dd, <i>J</i> 3.1, 2.5), 3.84 (3 H, s), 3.45 (1 H, m), 3.21 (2 H, qd, <i>J</i> 14.2, 5.8), 3.03 (1 H, dd, <i>J</i> 8.9, 1.9), 2.19 (1 H, ddd, <i>J</i> 12.4, 7.4, 4.4), 2.09 (1 H, m), 2.02 (2 H, ddd, <i>J</i> 8.1, 6.1, 3.2), 1.81 (1 H, ddd, <i>J</i> 14.2, 6.7, 3.3), 1.58 (1 H, m), 1.41 (1 H, m), 1.11 (3 H, d, <i>J</i> 6.7), 0.72 (1 H, dt, <i>J</i> 14.2, 12.4). δ <sup>13</sup>C (126 MHz, CDCl<sub>3</sub>) 175.2, 170.9, 163.6, 160.8, 133.9, 131.8, 124.8, 120.2, 116.3, 89.3, 84.5, 53.1, 53.0, 52.6, 47.1, 46.1, 36.4, 34.2, 33.8, 31.5, 29.2, 21.1. HRMS calcd for C<sub>22</sub>H<sub>27</sub>NO<sub>6</sub>FS [M + H], 452.1543; found, 452.1520.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3β-(Glutathione)-2aβ,3-dihydrogaliellalactone (<b>17</b>)</h3><div class="NLM_p last">To a solution of galiellalactone (<b>1</b>) (11 mg, 0.054 mmol) in methanol-<i>d</i><sub>4</sub> and D<sub>2</sub>O (1:1, 0.5 mL) were added glutathione (17 mg, 0.059 mmol) and triethylamine (1 μL, 0.005 mmol). The reaction was followed by NMR and was complete after 24 h, and the excess of solvent was removed in vacuum. The crude product was purified on Sephadex LH-20 with MeOH/H<sub>2</sub>O 1:9 as eluent and then flash chromatography with CHCl<sub>3</sub>/MeOH (1:1) containing 3% acetic acid to yield compound <b>17</b> (19 mg, 70%). δ <sup>1</sup>H (500 MHz, CD<sub>3</sub>OD/D<sub>2</sub>O 10%) 4.64 (1 H, dd, <i>J</i> 8.5, 5.6), 4.60 (1 H, m), 3.92 (2 H, s), 3.83 (1 H, t, <i>J</i> 7.6), 3.42 (1 H, m), 3.15/2.98 (2H, m), 2.87 (1 H, m), 2.55 (2 H, m), 2.39 (1 H, s), 2.19 (1 H, m), 2.15 (2 H, m), 2.11 (1 H, m), 1.99 (2 H, m), 1.92 (1 H, m), 1.65 (1 H, m), 1.27 (1 H, m), 1.22 (3 H, d, <i>J</i> 6.8), 0.62 (1 H, m). δ <sup>13</sup>C (126 MHz, CD<sub>3</sub>OD/D<sub>2</sub>O 10%) 175.2, 174.0, 173.2, 173.7, 173.2, 91.2, 85.5, 55.2, 55.2, 54.9, 48.6, 46.9, 42.5, 38.3, 35.2, 34.5, 32.8, 32.8, 30.2, 27.6, 21.6. HRMS calcd for C<sub>21</sub>H<sub>31</sub>DN<sub>3</sub>O<sub>9</sub>S [M + H], 503.1922; found, 503.1926.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Cell Culture</h3><div class="NLM_p last">The human prostate cancer cell lines DU145, PC3, and LNCaP from the American Type Culture Collection (ATCC) and long-term interleukin-6 (IL-6) stimulated LNCaP cells (LNCaP-IL6+ cells)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> were used. DU145, LNCaP, and LNCaP-IL6+ cells were cultured in RPMI-1640 medium, and PC3 cells were cultured in in HAM’s F-12 medium, both supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin solution. LNCaP-IL6+ cells were maintained in the above medium supplemented with IL-6 (5 ng/mL; Sigma-Aldrich, St. Louis, MO). Cells were incubated at 37 °C in a humidified atmosphere of 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Cells were used at low passages and not cultured for more than three months. The cells were routinely tested for and found free of mycoplasma. The molecular characterization of the cell lines was performed by LGC Standards (Cologne, Germany), and the results were then evaluated by comparison with the ATCC database. Our batches of DU145, LNCaP, and PC3 cells revealed a 100% match in comparison with ATCC standard for these cells.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> WST-1 Proliferation Assay</h3><div class="NLM_p last">DU145 and LNCaP-IL6+ cells were seeded at a density of 2000 cells/well and LNCaP and PC3 cells at a density of 5 000 cells/well in 96-well microplates and allowed to adhere for 24 h. The cells were incubated with the compounds for 72 h followed by cell proliferation measurement. At the end of the incubation time WST-1 reagent (Roche Applied Science) was added to each well and the absorbance was measured at a wavelength of 450 nm and 630 nm as a reference using ELISA reader. The result was calculated as percent of untreated cells after subtracting the background absorbance.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Western Blot Analysis</h3><div class="NLM_p last">For preparation of lysates, cells were washed and scraped in ice-cold PBS and centrifuged at 1400 rpm at 4 °C. The cells were lysed in mild cell lysis buffer containing 100 mM Tris HCl, 150 mM NaCl, 0.1% Nonidet P-40, 1 mM EDTA, Complete Mini EDTA-free protease inhibitor (Roche Applied Science), incubated for 30 min on ice, and centrifuged at 10 000 rpm for 30 min at 4 °C. The supernatant was collected, and protein content was determined using Bradford protein assay. Samples were separated on 7.5% precastgel (Mini-PROTEAN TGX; Bio-Rad). The gels were blotted onto PVDF membranes and blocked with 5% milk. Membranes were incubated with primary antibody diluted in 5% milk 1 h at room temperature antibodies raised against STAT3 and pSTAT3 Tyr-705 (Cell Signaling Technology). After incubation with secondary anti-rabbit antibody conjugated with horseradish peroxidase (GE Healthcare), the membrane was treated with enhanced chemiluminescent reagent (Santa Cruz Biotechnology) followed by exposure to X-ray film or visualized using a ChemiDoc XRS system (Bio-Rad).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Chemical Stability</h3><div class="NLM_p">The chemical stability of the compounds was determined in 96-well plate format. Compounds were dissolved in DMSO, with the exception of <b>3</b> which proved insoluble in this solvent and was dissolved in MeOH instead. These stock solutions were diluted (<i>n</i> = 2) in the required matrix (0.1 M PBS, pH 7.4) to a concentration of 10 μM (2% DMSO or methanol final) and mixed on an orbital shaker, with samples taken for analysis at a nominal 5, 15, 30, and 60 min. DMSO, containing an analytical internal standard, was added to the aliquots, vortex-mixed, and analyzed immediately by LC–MS/MS. Equivalent <i>T</i> = 0 samples were also included, with sample preparation staggered to allow sequential injections of timed aliquots and the <i>T</i> = 0 samples. The amount of compound remaining (expressed as %) was determined from the MS response in each sample relative to that in the <i>T</i> = 0 samples (normalized for internal standard). Samples were also monitored for the presence of parent compound, <b>1</b>. The stability at pH 1.2 was performed as described above for stability assessment in PBS but using a solution of 0.5 mM hydrochloric acid containing 2 mg/mL sodium chloride and adjusted to pH 1.2. As with testing in PBS, the amount of compound remaining (expressed as %) was determined from the MS response in each sample relative to that in the <i>T</i> = 0 samples (normalized for internal standard). Samples were also monitored for the presence of parent compound, <b>1</b>.</div><div class="NLM_p last">For analysis of plasma stability, test and control compounds (simvastatin, eucatropine) were prepared in DMSO and incubated with the corresponding plasma at 37 °C using an initial concentration of 5 μM in 1% DMSO (<i>n</i> = 2). Aliquots were removed at 0, 5, 15, 30, and 60 min for termination of reactions, and compound extraction was done with acetonitrile containing an analytical internal standard. Samples were centrifuged and the supernatant fractions analyzed for test compound and potential intermediates by mass spectrometry (LC–MS/MS). The amount of compound remaining (expressed as %) was determined from the MS response in each sample relative to that in the <i>T</i> = 0 samples (normalized for internal standard). The ln plots of the % remaining were used to determine the half-life for compound disappearance using the relationship <i>t</i><sub>1/2</sub> (min) = −0.693/λ where λ is the slope of the ln % remaining vs time curve.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Caco-2 Study</h3><div class="NLM_p last">The Caco-2 study was performed by AdmeScope (Finland). CacoReady monolayers in 24-well Transwell plates were used as provided by Readycell S.L. The apical side (donor) initial volume was 275 μL and the basolateral side (receiver) initial volume 775 μL. The buffer used was Hanks’ balanced salt solution (BioWest L0612-500) buffered with 10 mM Hepes, pH 7.4. Briefly the studies were started by placing the Transwell insert plate containing the apical solutions to a well plate containing the basolateral solutions. Test item concentrations used were 20 μM <b>1</b> and 5 μM <b>6</b>. Both compartments were sampled at 0, 60, and 120 min. Samples were analyzed by UPLC–MS/MS (Waters Acquity UPLC + Waters XEVO-TQ-S triple quadrupole MS with a Waters Acquity HSST3 C18 (2.1 mm × 50 mm, 1.8 μm) column.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> In Vitro Metabolism</h3><div class="NLM_p last">The in vitro metabolism study was performed by AdmeScope (Finland). Pooled cryopreserved mouse hepatocytes from Celsis IVT were used. The incubation volume was 300 μL in 48-well plate. Cell viability was determined using Trypan blue method, 1.0 million. The initial test item concentration was 10 μM (stock solution in DMSO). The incubations were done at pH 7.4, in Celsis InVitro HI medium and at 37 °C. Sampling was done at 0 and 120 min. Termination of incubations was performed by adding an equal volume of acetonitrile. Samples were analyzed by UPLC/Q-TOF-MS (Waters Acquity UPLC + Waters XEVO G2 Q-TOF-MS with a Waters Acquity HSST3 C18 (2.1 mm × 50 mm, 1.8 μm) column).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Pharmacokinetic Study</h3><div class="NLM_p">The in-life pharmacokinetic study was performed by BioFocus DPI Limited (U.K.). Doses were prepared at a drug concentration of 0.5, 2, and 5 mg/mL in 5% DMSO in 50 mM citrate buffer (citric acid/sodium citrate), pH 4.0. Oral doses were administered in a volume of 20 mL/kg to a group of 24 mice, and blood samples were taken under terminal barbiturate anesthesia, at eight time-points out to 8 h postdose (<i>n</i> = 3 mice per time-point). No adverse effects of dosing were observed. Blood samples were transferred to tubes containing EDTA as anticoagulant, and as soon as practicable after collection, samples were centrifuged to yield plasma which was immediately frozen awaiting analysis. All samples were frozen, prior to analysis using LC–-MS/MS.</div><div class="NLM_p">Plasma proteins were precipitated and compounds extracted by the addition of three volumes of acetonitrile containing analytical internal standard (reserpine). Samples were centrifuged for 30 min at 3452<i>g</i> in a Sorvall bench centrifuge and the supernatant fractions removed for MS analysis. Quantification of <b>1</b> was by extrapolation from calibration lines prepared in control mouse plasma and analyzed concurrently with experimental samples, and quality control (QC) samples were prepared in control mouse plasma. Due to the instability of <b>1</b> in mouse plasma, calibration lines were constructed in water for qualitative MS comparison with any <b>1</b> signal seen in plasma samples.</div><div class="NLM_p last">Pharmacokinetic parameters of <b>1</b> were determined using the mean data from the <i>n</i> = 3 mice at each time-point. Noncompartmental analysis was performed using the software package PK Solutions 2.0 from Summit Research Services. AUC values were calculated by the trapezoidal method.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> In Vivo Efficacy of Prodrug <b>6</b> Using Prostate Cancer Xenograft Model</h3><div class="NLM_p last">Twenty NMRI nude male mice were inoculated subcutaneously with 1.5 million DU145 cells in the flank. After 4 weeks the mice were divided in two groups with 10 mice in each. The mice were orally dosed using a feeding needle with either <b>6</b> (40 mg/kg) or vehicle (50 mM citrate buffer, pH 4.0, and 2% DMSO) daily five times per week for 4 weeks. The tumors were measured twice per week using a caliper. Tumor volume (mm<sup>3</sup>) = width (mm) × length × height × 0.52. After 4 weeks the mice were sacrificed by CO asphyxiation and the tumors were immediately dissected. Half of each tumor was snap frozen for mRNA extraction. The other half was fixed in formaldehyde for immunohistochemical analysis. The mice were kept on a 12 h light–dark cycle with access to food and water ad libitum. Experimental procedures were carried out according to the guidelines set by the Malmo-Lund Ethical Committee for Use and Care of Laboratory Animals.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Toxicity Study</h3><div class="NLM_p last">The study to assess maximum tolerated dose (MTD) was performed by Fidelta (Zagreb, Croatia) in an AAALAC I-approved facility. The standard study plan relating to this study was reviewed by the Ethical Committee (CARE, Zagreb) as required by International Laws/Regulations and Croatian Law on Animal Welfare and Animal Welfare Officer. Test item <b>6</b> was administered to the animals as a single oral dose. <b>6</b> was given as a solution (50 mM citrate buffer, pH 4.0, 5% DMSO) by oral gavage, using a cannula of appropriate size (metal feeding tube). Male CD1 mice (Charles River) were used, aged 7 weeks at the time of administration with body weights of 27.0–38.5 g. Mice were housed under ambient conditions and 12 h light–dark cycle with access to food and water ad libitum. Animals were weighed on day of randomization, on day 1, just before treatment, on day 4 and on day 8, at the end of study.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> QPCR Analysis</h3><div class="NLM_p last">The expression of the STAT3 related target genes MCL1 and BCL2 was investigated with quantitative real-time PCR (QPCR). Total RNA was isolated from DU145 xenograft tissue using RNeasy Plus Mini kit (Qiagen Sciences). Complementary DNA (cDNA) was synthesized using RevertAid reverse transcriptase (Thermo Fisher Scientific). An amount of 2 μg of total RNA was obtained for the cDNA synthesis. QPCR was carried out using 6–20 ng of cDNA, 250 nM forward and reverse primer in Maxima SYBR Green/ROX qPCR master mix (Thermo Fisher Scientific) in a 25 μL reaction. The cycling conditions were the following: 10 min at 95 °C to activate the enzyme, then 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Relative expression levels were quantified by the comparative Ct method and normalized to the expression of two internal control genes (HMBS and SDHA). Primers sequences were the following: HMBS, 5′-GGCAATGCGGCTGCAA-3′ and 5′-GGGTACCCACGCGAATCAC-3′; SDHA, 5′-TGGGAACAAGAGGGCATCTG-3′ and 5′-CCACCACTGCATCAAATTCATG-3′; MCL1, 5′-GGACATCAAAAACGAAGACG-3′ and 5′-GCAGCTTTCTTGGTTTATGG-3′; BCL2, 5′-GGGATGCCTTTGTGGAACTG-3′ and 5′-CAGCCAGGAGAAATCAAACAGA-3′. All primers were synthesized by Invitrogen and checked for specificity before use.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Immunohistochemical Analysis of Xenografts</h3><div class="NLM_p last">Tissue sections from the DU145 xenograft tumors were analyzed using immunohistochemistry (IHC) to evaluate the presence of actively proliferating cells with Ki67 staining and for apototic cells with cleaved caspase-3 staining. IHC staining was conducted using the EnVision Flex kit and Autostainer Plus (Dako, Glostrup, Denmark), according to the manufacturer’s instructions. The following antibodies were used: anti-Ki67 (RM-9106, clone SP6, Thermo Scientific, Sweden), anti-cleaved caspase-3 (no. 9661, Cell Signaling Technology) and anti-pSTAT3 (no. 9131, Cell Signaling Technology). For each stained slide, 10× magnification pictures were taken using the Aperio ScanScope XT slide scanner (Aperio Technologies, Vista, CA, USA) system for bright field microscopy. The number of cleaved caspase-3 positive cells per section was calculated as mean cleaved caspase-3 positive cells per view from five views. The amount of Ki67 positive cells was calculated as the ratio between the number of Ki67-positive cells and the number of total cells.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Statistical Analyses</h3><div class="NLM_p last">Statistical analyses were performed using GraphPad Prism software, and statistical significance was determined using ANOVA or Student’s <i>t</i> test. Statistical significance was considered when <i>p</i> ≤ 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01814">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01814" class="ext-link">10.1021/acs.jmedchem.5b01814</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and associated IC<sub>50</sub> values (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01814/suppl_file/jm5b01814_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01814/suppl_file/jm5b01814_si_001.csv">jm5b01814_si_001.csv (1.46 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01814" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin H Johansson</span> - <span class="hlFld-Affiliation affiliation">Glactone
Pharma Development AB, SE-252
20 Helsingborg, Sweden</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#87eae6f5f3eee9a9ede8efe6e9f4f4e8e9c7e0ebe6e4f3e8e9e2a9e4e8ea"><span class="__cf_email__" data-cfemail="35585447415c5b1b5f5a5d545b46465a5b7552595456415a5b501b565a58">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zilma Escobar</span> - <span class="hlFld-Affiliation affiliation">Center
for Analysis and Synthesis, Lund University, SE-221 00 Lund, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Bjartell</span> - <span class="hlFld-Affiliation affiliation">Division
of Urological Cancers, Department of Translational Medicine, Lund University, SE-205 02 Malmo, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giacomo Canesin</span> - <span class="hlFld-Affiliation affiliation">Division
of Urological Cancers, Department of Translational Medicine, Lund University, SE-205 02 Malmo, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Evans-Axelsson</span> - <span class="hlFld-Affiliation affiliation">Division
of Urological Cancers, Department of Translational Medicine, Lund University, SE-205 02 Malmo, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Olov Sterner</span> - <span class="hlFld-Affiliation affiliation">Center
for Analysis and Synthesis, Lund University, SE-221 00 Lund, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecka Hellsten</span> - <span class="hlFld-Affiliation affiliation">Division
of Urological Cancers, Department of Translational Medicine, Lund University, SE-205 02 Malmo, Sweden</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): A.B., O.S., R.H., and M.H.J. are shareholders and founders of Glactone Pharma AB. M.H.J. is a paid consultant of Glactone Pharma.<br /></br><sup>∥</sup>R.H. and M.H.J. are co-senior-authors.<br /></br></div></li></ul></div><div class="ack" id="ACK-d48e3658-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62567" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62567" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">At the Department on Translational Medicine, Lund University, we thank Anna Stiehm for QPCR analysis, Elise Nilsson for performing immunohistochemistry, and Nicholas Don-Doncow for Western blot analysis. This work was supported by the Swedish Cancer Society, the Swedish Research Council, the Cancer Foundation at Skåne University Hospital Malmö, Biocare Sweden, the Faculty of Science at Lund University, and Glactone Pharma AB.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i54" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i54"> Abbreviations Used</h2><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability coefficient</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bishop, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaper, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoubeidi, A.</span><span> </span><span class="NLM_article-title">The multifaceted roles of STAT3 signaling in the progression of prostate cancer</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span><span class="refDoi"> DOI: 10.3390/cancers6020829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.3390%2Fcancers6020829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=829-859&author=J.+L.+Bishopauthor=D.+Thaperauthor=A.+Zoubeidi&title=The+multifaceted+roles+of+STAT3+signaling+in+the+progression+of+prostate+cancer&doi=10.3390%2Fcancers6020829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fcancers6020829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6020829%26sid%3Dliteratum%253Aachs%26aulast%3DBishop%26aufirst%3DJ.%2BL.%26aulast%3DThaper%26aufirst%3DD.%26aulast%3DZoubeidi%26aufirst%3DA.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520STAT3%2520signaling%2520in%2520the%2520progression%2520of%2520prostate%2520cancer%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D829%26epage%3D859%26doi%3D10.3390%2Fcancers6020829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Peyser, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandis, J. R.</span><span> </span><span class="NLM_article-title">Critical analysis of the potential for targeting STAT3 in human malignancy</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span><span class="refDoi"> DOI: 10.2147/OTT.S47903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.2147%2FOTT.S47903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=23935373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yns7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=999-1010&author=N.+D.+Peyserauthor=J.+R.+Grandis&title=Critical+analysis+of+the+potential+for+targeting+STAT3+in+human+malignancy&doi=10.2147%2FOTT.S47903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Critical analysis of the potential for targeting STAT3 in human malignancy</span></div><div class="casAuthors">Peyser, Noah D.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">999-1010</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The signal transducer and activator of transcription (STAT) family of proteins was originally discovered in the context of normal cell biol. where they function to transduce intracellular and extracellular signals to the nucleus, ultimately leading to transcription of specific target genes and downstream phenotypic effects.  It was quickly appreciated that the STATs, esp. STAT3, play a fundamental role in human malignancy.  In contrast to normal biol. in which transient STAT3 signaling is strictly regulated by a tightly coordinated network of activators and deactivators, STAT3 is constitutively activated in human malignancies.  Constitutive STAT3 signaling has been assocd. with many cancerous phenotypes across nearly all human cancers, including the upregulation of cell growth, proliferation, survival and motility, among others.  Studies involving candidate preclin. STAT3 inhibitors have further demonstrated that the reversal of these phenotypes results from pharmacol. or genetic inhibition of STAT3, suggesting that STAT3 may be a promising target for clin. interventions.  Indeed, a Phase 0 clin. trial involving a STAT3 decoy oligonucleotide demonstrated that STAT3 is a druggable target in human tumors.  Because of the ubiquity of overactive STAT3 in cancer, its role in promoting a wide variety of cancerous phenotypes and the strong clin. and preclin. studies performed to date, STAT3 represents a promising target for the development of inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9fUDHex_-_LVg90H21EOLACvtfcHk0lhl3Gv1-vFCqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yns7vL&md5=d2754344f2a58ec47838c4150d2db06f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FOTT.S47903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S47903%26sid%3Dliteratum%253Aachs%26aulast%3DPeyser%26aufirst%3DN.%2BD.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DCritical%2520analysis%2520of%2520the%2520potential%2520for%2520targeting%2520STAT3%2520in%2520human%2520malignancy%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D999%26epage%3D1010%26doi%3D10.2147%2FOTT.S47903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Rebe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegran, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiringhelli, F.</span><span> </span><span class="NLM_article-title">STAT3 activation: A key factor in tumor immunoescape</span> <span class="citation_source-journal">JAKSTAT</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e23010</span><span class="refDoi"> DOI: 10.4161/jkst.23010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4161%2Fjkst.23010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e23010&author=C.+Rebeauthor=F.+Vegranauthor=H.+Bergerauthor=F.+Ghiringhelli&title=STAT3+activation%3A+A+key+factor+in+tumor+immunoescape&doi=10.4161%2Fjkst.23010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4161%2Fjkst.23010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.23010%26sid%3Dliteratum%253Aachs%26aulast%3DRebe%26aufirst%3DC.%26aulast%3DVegran%26aufirst%3DF.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DGhiringhelli%26aufirst%3DF.%26atitle%3DSTAT3%2520activation%253A%2520A%2520key%2520factor%2520in%2520tumor%2520immunoescape%26jtitle%3DJAKSTAT%26date%3D2013%26volume%3D2%26spage%3De23010%26doi%3D10.4161%2Fjkst.23010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zhang, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span> </span><span class="NLM_article-title">STAT3 in cancer-friend or foe?</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1440</span><span class="refDoi"> DOI: 10.3390/cancers6031408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.3390%2Fcancers6031408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1408-1440&author=H.+F.+Zhangauthor=R.+Lai&title=STAT3+in+cancer-friend+or+foe%3F&doi=10.3390%2Fcancers6031408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fcancers6031408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6031408%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BF.%26aulast%3DLai%26aufirst%3DR.%26atitle%3DSTAT3%2520in%2520cancer-friend%2520or%2520foe%253F%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D1408%26epage%3D1440%26doi%3D10.3390%2Fcancers6031408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pilati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucman-Rossi, J.</span><span> </span><span class="NLM_article-title">Mutations leading to constitutive active gp130/JAK1/STAT3 pathway</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.cytogfr.2015.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26188635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=499-506&author=C.+Pilatiauthor=J.+Zucman-Rossi&title=Mutations+leading+to+constitutive+active+gp130%2FJAK1%2FSTAT3+pathway&doi=10.1016%2Fj.cytogfr.2015.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations leading to constitutive active gp130/JAK1/STAT3 pathway</span></div><div class="casAuthors">Pilati, Camilla; Zucman-Rossi, Jessica</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Constitutive activation of STAT (Signal Transducer and Activator of Transcription) transcription factors is a common feature identified in numerous tumors.  Inflammatory hepatocellular adenomas (IHCA) are benign liver tumors characterized by an inflammatory phenotype and an overexpression of STAT3 target genes.  Recurrent somatic mutations in major actors belonging to the IL6/JAK/STAT3 pathway have been identified in these tumors.  (1) 60% Of IHCA show IL-6 signal transducer (IL6ST; gp130) mutations; (2) 10% harbor mutations of the Fyn-related kinase FRK; (3) 5% harbor mutations in STAT3; (4) 5% harbor somatic mutations in the GNAS complex locus; and (5) 1% of IHCA harbor mutations in the Janus kinase 1 (JAK1).  All these IHCA-assocd. mutations promote the constitutive activation of STAT3.  In this review, we discuss the role of these mutated genes in IHCA and other tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr32M45DrEm3rVg90H21EOLACvtfcHk0libtPGL5KD_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktbrF&md5=9e41e270f0fe93b8ff0bcc4fcf183a16</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DPilati%26aufirst%3DC.%26aulast%3DZucman-Rossi%26aufirst%3DJ.%26atitle%3DMutations%2520leading%2520to%2520constitutive%2520active%2520gp130%252FJAK1%252FSTAT3%2520pathway%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2015%26volume%3D26%26spage%3D499%26epage%3D506%26doi%3D10.1016%2Fj.cytogfr.2015.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jerez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemente, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makishima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskela, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przychodzen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afable, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Segui, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guinta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsi, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGraw, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarski, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekeres, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">List, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, J. P.</span><span> </span><span class="NLM_article-title">STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">3048</span><span class="NLM_x">–</span> <span class="NLM_lpage">3057</span><span class="refDoi"> DOI: 10.1182/blood-2012-06-435297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1182%2Fblood-2012-06-435297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=3048-3057&author=A.+Jerezauthor=M.+J.+Clementeauthor=H.+Makishimaauthor=H.+Koskelaauthor=F.+Leblancauthor=K.+Peng+Ngauthor=T.+Olsonauthor=B.+Przychodzenauthor=M.+Afableauthor=I.+Gomez-Seguiauthor=K.+Guintaauthor=L.+Durkinauthor=E.+D.+Hsiauthor=K.+McGrawauthor=D.+Zhangauthor=M.+W.+Wlodarskiauthor=K.+Porkkaauthor=M.+A.+Sekeresauthor=A.+Listauthor=S.+Mustjokiauthor=T.+P.+Loughranauthor=J.+P.+Maciejewski&title=STAT3+mutations+unify+the+pathogenesis+of+chronic+lymphoproliferative+disorders+of+NK+cells+and+T-cell+large+granular+lymphocyte+leukemia&doi=10.1182%2Fblood-2012-06-435297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-06-435297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-06-435297%26sid%3Dliteratum%253Aachs%26aulast%3DJerez%26aufirst%3DA.%26aulast%3DClemente%26aufirst%3DM.%2BJ.%26aulast%3DMakishima%26aufirst%3DH.%26aulast%3DKoskela%26aufirst%3DH.%26aulast%3DLeblanc%26aufirst%3DF.%26aulast%3DPeng%2BNg%26aufirst%3DK.%26aulast%3DOlson%26aufirst%3DT.%26aulast%3DPrzychodzen%26aufirst%3DB.%26aulast%3DAfable%26aufirst%3DM.%26aulast%3DGomez-Segui%26aufirst%3DI.%26aulast%3DGuinta%26aufirst%3DK.%26aulast%3DDurkin%26aufirst%3DL.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DMcGraw%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWlodarski%26aufirst%3DM.%2BW.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DList%26aufirst%3DA.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DMaciejewski%26aufirst%3DJ.%2BP.%26atitle%3DSTAT3%2520mutations%2520unify%2520the%2520pathogenesis%2520of%2520chronic%2520lymphoproliferative%2520disorders%2520of%2520NK%2520cells%2520and%2520T-cell%2520large%2520granular%2520lymphocyte%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D3048%26epage%3D3057%26doi%3D10.1182%2Fblood-2012-06-435297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Milner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray-Pedersen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemela, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topcagic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberson, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbsky, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas-Hernandez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karam, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahmod, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makedonas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorte, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perminow, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElwee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santibanez-Koref, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slowik, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinwiddie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciaccio, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Septer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsmore, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cant, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. A.</span><span> </span><span class="NLM_article-title">Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span><span class="refDoi"> DOI: 10.1182/blood-2014-09-602763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1182%2Fblood-2014-09-602763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=591-599&author=J.+D.+Milnerauthor=T.+P.+Vogelauthor=L.+Forbesauthor=C.+A.+Maauthor=A.+Stray-Pedersenauthor=J.+E.+Niemelaauthor=J.+J.+Lyonsauthor=K.+R.+Engelhardtauthor=Y.+Zhangauthor=N.+Topcagicauthor=E.+D.+Robersonauthor=H.+Matthewsauthor=J.+W.+Verbskyauthor=T.+Dasuauthor=A.+Vargas-Hernandezauthor=N.+Vargheseauthor=K.+L.+McClainauthor=L.+B.+Karamauthor=K.+Nahmodauthor=G.+Makedonasauthor=E.+M.+Maceauthor=H.+S.+Sorteauthor=G.+Perminowauthor=V.+K.+Raoauthor=M.+P.+O%E2%80%99Connellauthor=S.+Priceauthor=H.+C.+Suauthor=M.+Butrickauthor=J.+McElweeauthor=J.+D.+Hughesauthor=J.+Willetauthor=D.+Swanauthor=Y.+Xuauthor=M.+Santibanez-Korefauthor=V.+Slowikauthor=D.+L.+Dinwiddieauthor=C.+E.+Ciaccioauthor=C.+J.+Saundersauthor=S.+Septerauthor=S.+F.+Kingsmoreauthor=A.+J.+Whiteauthor=A.+J.+Cantauthor=S.+Hambletonauthor=M.+A.+Cooper&title=Early-onset+lymphoproliferation+and+autoimmunity+caused+by+germline+STAT3+gain-of-function+mutations&doi=10.1182%2Fblood-2014-09-602763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-09-602763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-09-602763%26sid%3Dliteratum%253Aachs%26aulast%3DMilner%26aufirst%3DJ.%2BD.%26aulast%3DVogel%26aufirst%3DT.%2BP.%26aulast%3DForbes%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DC.%2BA.%26aulast%3DStray-Pedersen%26aufirst%3DA.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DLyons%26aufirst%3DJ.%2BJ.%26aulast%3DEngelhardt%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTopcagic%26aufirst%3DN.%26aulast%3DRoberson%26aufirst%3DE.%2BD.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DVerbsky%26aufirst%3DJ.%2BW.%26aulast%3DDasu%26aufirst%3DT.%26aulast%3DVargas-Hernandez%26aufirst%3DA.%26aulast%3DVarghese%26aufirst%3DN.%26aulast%3DMcClain%26aufirst%3DK.%2BL.%26aulast%3DKaram%26aufirst%3DL.%2BB.%26aulast%3DNahmod%26aufirst%3DK.%26aulast%3DMakedonas%26aufirst%3DG.%26aulast%3DMace%26aufirst%3DE.%2BM.%26aulast%3DSorte%26aufirst%3DH.%2BS.%26aulast%3DPerminow%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.%2BC.%26aulast%3DButrick%26aufirst%3DM.%26aulast%3DMcElwee%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DWillet%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DSantibanez-Koref%26aufirst%3DM.%26aulast%3DSlowik%26aufirst%3DV.%26aulast%3DDinwiddie%26aufirst%3DD.%2BL.%26aulast%3DCiaccio%26aufirst%3DC.%2BE.%26aulast%3DSaunders%26aufirst%3DC.%2BJ.%26aulast%3DSepter%26aufirst%3DS.%26aulast%3DKingsmore%26aufirst%3DS.%2BF.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DHambleton%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DEarly-onset%2520lymphoproliferation%2520and%2520autoimmunity%2520caused%2520by%2520germline%2520STAT3%2520gain-of-function%2520mutations%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D591%26epage%3D599%26doi%3D10.1182%2Fblood-2014-09-602763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Siveen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B. K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishayee, A.</span><span> </span><span class="NLM_article-title">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1845</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bbcan.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24388873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1845&publication_year=2014&pages=136-154&author=K.+S.+Siveenauthor=S.+Sikkaauthor=R.+Suranaauthor=X.+Daiauthor=J.+Zhangauthor=A.+P.+Kumarauthor=B.+K.+H.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Targeting+the+STAT3+signaling+pathway+in+cancer%3A+Role+of+synthetic+and+natural+inhibitors&doi=10.1016%2Fj.bbcan.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span></div><div class="casAuthors">Siveen, Kodappully Sivaraman; Sikka, Sakshi; Surana, Rohit; Dai, Xiaoyun; Zhang, Jingwen; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1845</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-154</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to the nucleus.  Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human tumors, including hematol. malignancies (leukemias, lymphomas, and multiple myeloma) as well as diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers).  There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.  Suppression of STAT3 activation results in the induction of apoptosis in tumor cells, and accordingly its pharmacol. modulation by tyrosine kinase inhibitors, antisense oligonucleotides, decoy nucleotides, dominant neg. proteins, RNA interference and chemopreventive agents have been employed to suppress the proliferation of various human cancer cells in culture and tumorigenicity in vivo.  However, the identification and development of novel drugs that can target deregulated STAT3 activation effectively remains an important scientific and clin. challenge.  This review presents the evidence for crit. roles of STAT3 in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT3 signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeL6KQ0obpY7Vg90H21EOLACvtfcHk0li_sja7PAaCXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D&md5=c2514f54684fb89a2f5ac489425f42d5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DSurana%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%2BH.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520STAT3%2520signaling%2520pathway%2520in%2520cancer%253A%2520Role%2520of%2520synthetic%2520and%2520natural%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1845%26spage%3D136%26epage%3D154%26doi%3D10.1016%2Fj.bbcan.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Debnath, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6645</span><span class="NLM_x">–</span> <span class="NLM_lpage">6668</span><span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0li4uHO6SMez_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkson, J.</span><span> </span><span class="NLM_article-title">Targeting STAT3 in cancer: how successful are we?</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1517/13543780802565791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1517%2F13543780802565791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=19053881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGhtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=45-56&author=P.+Yueauthor=J.+Turkson&title=Targeting+STAT3+in+cancer%3A+how+successful+are+we%3F&doi=10.1517%2F13543780802565791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 in cancer: how successful are we?</span></div><div class="casAuthors">Yue, Peibin; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the signal transducer and activator of transcription (STAT)3 occurs in many human tumors.  Moreover, studies utilizing genetic and pharmacol. approaches to modulate constitutive STAT3 activity have provided compelling evidence for the crit. role of aberrant STAT3 activity in malignant transformation and tumor progression, and thereby validated STAT3 as a novel cancer drug target.  This review is intended to be a full coverage of the efforts to develop direct STAT3 inhibitors and will provide a discussion on the inhibitory modalities developed to date.  Review of the literature focused on the modalities and mechanisms that directly target and inhibit the STAT protein or its functions.  While a variety of STAT3 inhibitors have been identified that induce antitumor cell effects in vitro and in vivo, the landscape remains murky.  With a few exceptions, most of the STAT3 inhibitors reported to date have not undergone an in vivo efficacy, pharmacol. or toxicity testing.  Also, there is no evidence, per the published literature of an impending clin. development for the few agents that were reported to exhibit in vivo efficacy.  Overall, there is the need for a reassessment of the ongoing strategies to target STAT3 intended not only for refinement, but also for incorporating some new technologies to strengthen our efforts and ensure the success, sooner, rather than later, of identifying suitable anti-STAT3 agents for development into clin. useful anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGo96b-3KjRLVg90H21EOLACvtfcHk0lgT2ALKLPKiaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGhtbvO&md5=e0f4fe796305b7e28ff3020f57b5dc8e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543780802565791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780802565791%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DP.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DTargeting%2520STAT3%2520in%2520cancer%253A%2520how%2520successful%2520are%2520we%253F%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D45%26epage%3D56%26doi%3D10.1517%2F13543780802565791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namanja, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paladino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunning, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkson, J.</span><span> </span><span class="NLM_article-title">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">9623</span><span class="NLM_x">–</span> <span class="NLM_lpage">9628</span><span class="refDoi"> DOI: 10.1073/pnas.1121606109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1073%2Fpnas.1121606109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=22623533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9623-9628&author=X.+Zhangauthor=P.+Yueauthor=B.+D.+Pageauthor=T.+Liauthor=W.+Zhaoauthor=A.+T.+Namanjaauthor=D.+Paladinoauthor=J.+Zhaoauthor=Y.+Chenauthor=P.+T.+Gunningauthor=J.+Turkson&title=Orally+bioavailable+small-molecule+inhibitor+of+transcription+factor+Stat3+regresses+human+breast+and+lung+cancer+xenografts&doi=10.1073%2Fpnas.1121606109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Page, Brent D. G.; Li, Tianshu; Zhao, Wei; Namanja, Andrew T.; Paladino, David; Zhao, Jihe; Chen, Yuan; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9623-9628, S9623/1-S9623/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homol. 2 domain.  BP-1-102 binds Stat3 with an affinity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells.  BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Kruppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion.  Treatment of breast cancer cells with BP-1-102 further blocks Stat3-NF-κB cross-talk, the release of granulocyte colony-stimulating factor, sol. intercellular adhesion mol. 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression.  I.v. or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrljEafjbznr7Vg90H21EOLACvtfcHk0ljzX6Mqj6rUfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D&md5=4da78174a7c00eacc1f1a1ce553c5aa7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121606109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121606109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DOrally%2520bioavailable%2520small-molecule%2520inhibitor%2520of%2520transcription%2520factor%2520Stat3%2520regresses%2520human%2520breast%2520and%2520lung%2520cancer%2520xenografts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D9623%26epage%3D9628%26doi%3D10.1073%2Fpnas.1121606109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Weidler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rether, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erkel, G.</span><span> </span><span class="NLM_article-title">Inhibition of interleukin-6 signaling by galiellalactone</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">484</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/S0014-5793(00)02115-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2FS0014-5793%2800%2902115-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=11056211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns12nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2000&pages=1-6&author=M.+Weidlerauthor=J.+Retherauthor=T.+Ankeauthor=G.+Erkel&title=Inhibition+of+interleukin-6+signaling+by+galiellalactone&doi=10.1016%2FS0014-5793%2800%2902115-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of interleukin-6 signaling by galiellalactone</span></div><div class="casAuthors">Weidler, M.; Rether, J.; Anke, T.; Erkel, G.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">484</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A search for inhibitors of the IL-6-mediated signal transduction in HepG2 cells using secreted alk. phosphatase (SEAP) as reporter gene resulted in the isolation of galiellalactone from fermns. of the ascomycete strain A111-95.  Galiellalactone inhibits the IL-6-induced SEAP expression with IC50 values of 250-500 nM by blocking the binding of the activated Stat3 dimers to their DNA binding sites without inhibiting the tyrosine and serine phosphorylation of the Stat3 transcription factor.  Due to its selective activity, galiellalactone may serve as a lead compd. for the development of new therapeutic agents for diseases originating from the inappropriate expression of IL-6 and as mol. tool to dissect the JAK/STAT pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoacHmhNL-lNbVg90H21EOLACvtfcHk0lhVNIC3wmc3Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns12nt70%253D&md5=cc62a693822f8dc612df16819b8cc7ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2800%2902115-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252800%252902115-3%26sid%3Dliteratum%253Aachs%26aulast%3DWeidler%26aufirst%3DM.%26aulast%3DRether%26aufirst%3DJ.%26aulast%3DAnke%26aufirst%3DT.%26aulast%3DErkel%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520interleukin-6%2520signaling%2520by%2520galiellalactone%26jtitle%3DFEBS%2520Lett.%26date%3D2000%26volume%3D484%26spage%3D1%26epage%3D6%26doi%3D10.1016%2FS0014-5793%2800%2902115-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Don-Doncow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escobar, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjellstrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellsten, R.</span><span> </span><span class="NLM_article-title">Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">15969</span><span class="NLM_x">–</span> <span class="NLM_lpage">15978</span><span class="refDoi"> DOI: 10.1074/jbc.M114.564252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1074%2Fjbc.M114.564252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24755219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=15969-15978&author=N.+Don-Doncowauthor=Z.+Escobarauthor=M.+Johanssonauthor=S.+Kjellstromauthor=V.+Garciaauthor=E.+Munozauthor=O.+Sternerauthor=A.+Bjartellauthor=R.+Hellsten&title=Galiellalactone+is+a+direct+inhibitor+of+the+transcription+factor+STAT3+in+prostate+cancer+cells&doi=10.1074%2Fjbc.M114.564252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone25 Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells</span></div><div class="casAuthors">Don-Doncow, Nicholas; Escobar, Zilma; Johansson, Martin; Kjellstroem, Sven; Garcia, Victor; Munoz, Eduardo; Sterner, Olov; Bjartell, Anders; Hellsten, Rebecka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">15969-15978</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in several malignancies including castration-resistant prostate cancer and has been identified as a promising therapeutic target.  The fungal metabolite galiellalactone, a STAT3 signaling inhibitor, inhibits the growth, both in vitro and in vivo, of prostate cancer cells expressing active STAT3 and induces apoptosis of prostate cancer stem cell-like cells expressing phosphorylated STAT3 (pSTAT3).  However, the mol. mechanism of this STAT3-inhibiting effect by galiellalactone has not been clarified.  A biotinylated analog of galiellalactone (GL-biot) was synthesized to be used for identification of galiellalactone target proteins.  By adding streptavidin-Sepharose beads to GL-biot-treated DU145 cell lyzates, STAT3 was isolated and identified as a target protein.  Confocal microscopy revealed GL-biot in both the cytoplasm and the nucleus of DU145 cells treated with GL-biot, appearing to co-localize with STAT3 in the nucleus.  Galiellalactone inhibited STAT3 binding to DNA in DU145 cell lyzates without affecting phosphorylation status of STAT3.  Mass spectrometry anal. of recombinant STAT3 protein pretreated with galiellalactone revealed three modified cysteines (Cys-367, Cys-468, and Cys-542).  Here we demonstrate with chem. and mol. pharmacol. methods that galiellalactone is a cysteine reactive inhibitor that covalently binds to one or more cysteines in STAT3 and that this leads to inhibition of STAT3 binding to DNA and thus blocks STAT3 signaling without affecting phosphorylation.  This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3avlluHh2P7Vg90H21EOLACvtfcHk0ljFCzEhmwBUCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D&md5=44961890281d144bd6f9283999c34aa1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.564252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.564252%26sid%3Dliteratum%253Aachs%26aulast%3DDon-Doncow%26aufirst%3DN.%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DKjellstrom%26aufirst%3DS.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMunoz%26aufirst%3DE.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DHellsten%26aufirst%3DR.%26atitle%3DGaliellalactone%2520is%2520a%2520direct%2520inhibitor%2520of%2520the%2520transcription%2520factor%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D15969%26epage%3D15978%26doi%3D10.1074%2Fjbc.M114.564252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corzano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rashid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senthil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedvat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushijin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushijin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidehi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugiu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. C.</span><span> </span><span class="NLM_article-title">Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1021/cb100253e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100253e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=432-443&author=R.+Buettnerauthor=R.+Corzanoauthor=R.+Rashidauthor=J.+Linauthor=M.+Senthilauthor=M.+Hedvatauthor=A.+Schroederauthor=A.+Maoauthor=A.+Herrmannauthor=J.+Yimauthor=H.+Liauthor=Y.+C.+Yuanauthor=K.+Yakushijinauthor=F.+Yakushijinauthor=N.+Vaidehiauthor=R.+Mooreauthor=G.+Gugiuauthor=T.+D.+Leeauthor=R.+Yipauthor=Y.+Chenauthor=R.+Joveauthor=D.+Horneauthor=J.+C.+Williams&title=Alkylation+of+cysteine+468+in+Stat3+defines+a+novel+site+for+therapeutic+development&doi=10.1021%2Fcb100253e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development</span></div><div class="casAuthors">Buettner, Ralf; Corzano, Renzo; Rashid, Rumana; Lin, Jian-Ping; Senthil, Maheswari; Hedvat, Michael; Schroeder, Anne; Mao, Allen; Herrmann, Andreas; Yim, John; Li, Hong-Zhi; Yuan, Yate-Ching; Yakushijin, Ken-Ichi; Yakushijin, Fumiko; Vaidehi, Nagarajan; Moore, Roger; Gugiu, Gabriel; Lee, Terry D.; Yip, Richard; Chen, Yuan; Jove, Richard; Horne, David; Williams, John C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">432-443</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stat3 is a latent transcription factor that promotes cell survival and proliferation and is often constitutively active in multiple cancers.  Inhibition of Stat3 signaling pathways suppresses cell survival signals and leads to apoptosis in cancer cells, suggesting direct inhibition of Stat3 function is a viable therapeutic approach.  Herein, we identify a small mol., C48, as a selective Stat3-family member inhibitor.  To det. its mechanism of action, we used site-directed mutagenesis and multiple biochem. techniques to show that C48 alkylates Cys468 in Stat3, a residue at the DNA-binding interface.  We further demonstrate that C48 blocks accumulation of activated Stat3 in the nucleus in tumor cell lines that overexpress active Stat3, leading to impressive inhibition of tumor growth in mouse models.  Collectively, these findings suggest Cys468 in Stat3 represents a novel site for therapeutic intervention and demonstrates the promise of alkylation as a potentially effective chem. approach for Stat3-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp63z_APNdkQLVg90H21EOLACvtfcHk0ljFCzEhmwBUCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D&md5=256b3b0921a625e19fe232488e1996db</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcb100253e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100253e%26sid%3Dliteratum%253Aachs%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DCorzano%26aufirst%3DR.%26aulast%3DRashid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSenthil%26aufirst%3DM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYim%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DY.%2BC.%26aulast%3DYakushijin%26aufirst%3DK.%26aulast%3DYakushijin%26aufirst%3DF.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGugiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DYip%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DHorne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BC.%26atitle%3DAlkylation%2520of%2520cysteine%2520468%2520in%2520Stat3%2520defines%2520a%2520novel%2520site%2520for%2520therapeutic%2520development%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D432%26epage%3D443%26doi%3D10.1021%2Fcb100253e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0lgu85NealK8xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bauer, R. A.</span><span> </span><span class="NLM_article-title">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+inhibitors+in+drug+discovery%3A+from+accidental+discoveries+to+avoided+liabilities+and+designed+therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0lgu85NealK8xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520inhibitors%2520in%2520drug%2520discovery%253A%2520from%2520accidental%2520discoveries%2520to%2520avoided%2520liabilities%2520and%2520designed%2520therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhJoxkyU-G3Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lhJoxkyU-G3Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.bmcl.2013.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhJoxkyU-G3Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Johansson, M. H.</span><span> </span><span class="NLM_article-title">Reversible Michael additions: covalent inhibitors and prodrugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span><span class="refDoi"> DOI: 10.2174/13895575112091330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.2174%2F13895575112091330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=22625413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1330-1344&author=M.+H.+Johansson&title=Reversible+Michael+additions%3A+covalent+inhibitors+and+prodrugs&doi=10.2174%2F13895575112091330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael additions: covalent inhibitors and prodrugs</span></div><div class="casAuthors">Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1330-1344</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent inhibition is an efficient mol. mechanism for inhibiting enzymes or modulating the function of proteins and is found in the action of many drugs and biol. active natural products.  However, it is has been less appreciated that the formation of covalent bonds can be reversible or irreversible.  This review focuses on biol. active compds. that are Michael acceptors and how the reversible nature of the Michael addn. reaction influences biol. activity and how this can be exploited in designing prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X1yh9k4q-7Vg90H21EOLACvtfcHk0lhSfyPLmR8CXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ&md5=f90694162e39fe57915e888bbadbd2bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F13895575112091330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13895575112091330%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DReversible%2520Michael%2520additions%253A%2520covalent%2520inhibitors%2520and%2520prodrugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1330%26epage%3D1344%26doi%3D10.2174%2F13895575112091330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Neelakantan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooks, P. A.</span><span> </span><span class="NLM_article-title">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4346</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bmcl.2009.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=19505822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4346-4349&author=S.+Neelakantanauthor=S.+Nasimauthor=M.+L.+Guzmanauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Aminoparthenolides+as+novel+anti-leukemic+agents%3A+Discovery+of+the+NF-kappaB+inhibitor%2C+DMAPT+%28LC-1%29&doi=10.1016%2Fj.bmcl.2009.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)</span></div><div class="casAuthors">Neelakantan, Sundar; Nasim, Shama; Guzman, Monica L.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4346-4349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of aminoparthenolide analogs were synthesized and evaluated for their anti-leukemic activity.  Eight compds. exhibited good anti-leukemic activity with LD50's in the low μM range (1.5-3.0 μM).  Compds. I, II and III were the most potent compds. in the series, causing greater than 90% cell death at 10 μM concn. against primary AML cells in culture, with LD50 values of 1.7, 1.8 and 1.6 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFsAppmWkqbVg90H21EOLACvtfcHk0lhSfyPLmR8CXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D&md5=aff3db6b1997e882d2474e120a1419fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DS.%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DAminoparthenolides%2520as%2520novel%2520anti-leukemic%2520agents%253A%2520Discovery%2520of%2520the%2520NF-kappaB%2520inhibitor%252C%2520DMAPT%2520%2528LC-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4346%26epage%3D4349%26doi%3D10.1016%2Fj.bmcl.2009.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span> </span><span class="NLM_article-title">Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8757</span><span class="NLM_x">–</span> <span class="NLM_lpage">8769</span><span class="refDoi"> DOI: 10.1021/jm301064b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301064b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8757-8769&author=Q.+Zhangauthor=Y.+Luauthor=Y.+Dingauthor=J.+Zhaiauthor=Q.+Jiauthor=W.+Maauthor=M.+Yangauthor=H.+Fanauthor=J.+Longauthor=Z.+Tongauthor=Y.+Shiauthor=Y.+Jiaauthor=B.+Hanauthor=W.+Zhangauthor=C.+Qiuauthor=X.+Maauthor=Q.+Liauthor=Q.+Shiauthor=H.+Zhangauthor=D.+Liauthor=J.+Zhangauthor=J.+Linauthor=L.+Y.+Liauthor=Y.+Gaoauthor=Y.+Chen&title=Guaianolide+sesquiterpene+lactones%2C+a+source+to+discover+agents+that+selectively+inhibit+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1021%2Fjm301064b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Guaianolide Sesquiterpene Lactones, a Source To Discover Agents That Selectively Inhibit Acute Myelogenous Leukemia Stem and Progenitor Cells</span></div><div class="casAuthors">Zhang, Quan; Lu, Yaxin; Ding, Yahui; Zhai, Jiadai; Ji, Qing; Ma, Weiwei; Yang, Ming; Fan, Hongxia; Long, Jing; Tong, Zhongsheng; Shi, Yehui; Jia, Yongsheng; Han, Bin; Zhang, Wenpeng; Qiu, Chuanjiang; Ma, Xiaoyan; Li, Qiuying; Shi, Qianqian; Zhang, Haoliang; Li, Dongmei; Zhang, Jing; Lin, Jianping; Li, Lu-Yuan; Gao, Yingdai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8757-8769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mols. that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features.  Here, we report a series of guaianolide sesquiterpene lactones (GSLs) and their derivs. that can selectively eradicate acute myelogenous leukemia (AML) stem or progenitor cells.  Natural GSL compds. arglabin, an anticancer clin. drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.  Targeting of AML stem cells is further confirmed by a sharp redn. of colony-forming units of primary AML cells upon MCL treatment.  Moreover, the dimethylamino Michael adduct of MCL, I, slowly releases MCL in plasma and in vivo and demonstrates remarkable therapeutic efficacy in the nonobese diabetic/severe combined immunodeficiency AML models.  These findings indicate that GSL is an ample source for chem. agents against AML stem or progenitor cells and that GSL is potentially highly useful to explore anti-CSC approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_V3OAFoCjrVg90H21EOLACvtfcHk0lhSfyPLmR8CXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN&md5=064c942ed395fc35e71155c45206a5bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm301064b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301064b%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DGuaianolide%2520sesquiterpene%2520lactones%252C%2520a%2520source%2520to%2520discover%2520agents%2520that%2520selectively%2520inhibit%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8757%26epage%3D8769%26doi%3D10.1021%2Fjm301064b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Woods, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieberich, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavanja, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, D. A.</span><span> </span><span class="NLM_article-title">Amino-derivatives of the sesquiterpene lactone class of natural products as prodrugs</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span><span class="refDoi"> DOI: 10.1039/C2MD20172K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1039%2FC2MD20172K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=27-33&author=J.+R.+Woodsauthor=H.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Amino-derivatives+of+the+sesquiterpene+lactone+class+of+natural+products+as+prodrugs&doi=10.1039%2FC2MD20172K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Amino-derivatives of the sesquiterpene lactone class of natural products as prodrugs</span></div><div class="casAuthors">Woods, James R.; Mo, Huaping; Bieberich, Andrew A.; Alavanja, Tanja; Colby, David A.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The sesquiterpene lactone class of natural products displays a diverse array of biol. activities due to the presence of the α-methylene-γ-lactone motif.  However, clin. translation of this class has been hampered by poor aq. soly. and non-selective binding as a Michael acceptor at undesired targets.  A prodrug approach has been developed to overcome these problems in which an amine is added into the α-methylene-γ-lactone to mask this group from nucleophiles and increase soly.  The medicinal chem. of amino-derivs. of the sesquiterpene lactones is described, beginning with synthetic development, moving into pharmacol. applications, and finishing with clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCqzj8kSJ8GbVg90H21EOLACvtfcHk0ljhh0KAwKgv3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr%252FP&md5=967984b301dda68ba4f5a093fedc1fc7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2FC2MD20172K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20172K%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DAmino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%2520class%2520of%2520natural%2520products%2520as%2520prodrugs%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D27%26epage%3D33%26doi%3D10.1039%2FC2MD20172K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Canesin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans-Axelsson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellsten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzyzanowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span> </span><span class="NLM_article-title">The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1016/j.eururo.2015.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.eururo.2015.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26144873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=400-404&author=G.+Canesinauthor=S.+Evans-Axelssonauthor=R.+Hellstenauthor=O.+Sternerauthor=A.+Krzyzanowskaauthor=T.+Anderssonauthor=A.+Bjartell&title=The+STAT3+inhibitor+galiellalactone+effectively+reduces+tumor+growth+and+metastatic+spread+in+an+orthotopic+xenograft+mouse+model+of+prostate+cancer&doi=10.1016%2Fj.eururo.2015.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer</span></div><div class="casAuthors">Canesin, Giacomo; Evans-Axelsson, Susan; Hellsten, Rebecka; Sterner, Olov; Krzyzanowska, Agnieszka; Andersson, Tommy; Bjartell, Anders</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">400-404</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is known to be involved in the progression of prostate cancer (PCa) and is a key factor in drug resistance and tumor immunoescape.  As a result, it represents a promising target for PCa therapy.  We studied the effects of the STAT3 inhibitor galiellalactone (GL) on tumor growth and metastatic spread in vitro and in vivo.  The effect of GL on cell viability, apoptosis, and invasion was studied in vitro using androgen-independent DU145 and DU145-Luc cell lines.  For in vivo studies, mice were injected orthotopically with DU145-Luc cells and treated with daily i.p. injections of GL for 6 wk.  GL significantly reduced the growth of the primary tumor and the metastatic spread of PCa cells to regional and distal lymph nodes in vivo.  Treatment with GL also resulted in decreased cell proliferation and increased apoptosis compared with controls.  In vitro, GL reduces the viability and invasive abilities of DU145-Luc cells and induces apoptosis.  Our results showed that tumor growth and early metastatic dissemination of PCa can be significantly reduced by GL, indicating its potential use as a therapeutic compd. in advanced metastatic PCa.In this study, we tested the STAT3 inhibitor galiellalactone (GL) in an animal model of PCa.  We found that mice treated with GL had smaller primary tumors and decreased lymph node metastases compared with mice treated with vehicle.  GL has potential for treating advanced metastatic PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2ixXAGCp4LVg90H21EOLACvtfcHk0ljhh0KAwKgv3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7%252FP&md5=7f0a9db87973b0a20797dec8527fe530</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2015.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2015.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DCanesin%26aufirst%3DG.%26aulast%3DEvans-Axelsson%26aufirst%3DS.%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DKrzyzanowska%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%26aulast%3DBjartell%26aufirst%3DA.%26atitle%3DThe%2520STAT3%2520inhibitor%2520galiellalactone%2520effectively%2520reduces%2520tumor%2520growth%2520and%2520metastatic%2520spread%2520in%2520an%2520orthotopic%2520xenograft%2520mouse%2520model%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%26date%3D2016%26volume%3D69%26spage%3D400%26epage%3D404%26doi%3D10.1016%2Fj.eururo.2015.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hellsten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizeyi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span> </span><span class="NLM_article-title">Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/pros.20699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1002%2Fpros.20699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=18163422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=269-280&author=R.+Hellstenauthor=M.+Johanssonauthor=A.+Dahlmanauthor=N.+Dizeyiauthor=O.+Sternerauthor=A.+Bjartell&title=Galiellalactone+is+a+novel+therapeutic+candidate+against+hormone-refractory+prostate+cancer+expressing+activated+Stat3&doi=10.1002%2Fpros.20699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3</span></div><div class="casAuthors">Hellsten, Rebecka; Johansson, Martin; Dahlman, Anna; Dizeyi, Nishtman; Sterner, Olov; Bjartell, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-280</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Background: Signal transducer and activator of transcription 3 (Stat3) is constitutively active (phosphorylated) in several forms of cancer, including prostate cancer (PCa).  Stat3 signaling may be an interesting target for cancer therapy since inhibition of this pathway mediates growth inhibition and apoptosis of these cells.  In this study we investigated the in vitro and in vivo effects of the fungal metabolite galiellalactone, a direct inhibitor of Stat3, on PCa cells.  Methods: The human PCa cell lines DU145, PC-3, and LNCaP were used.  Nude mice with s.c. PCa cell xenografts were subjected to daily i.p. injections of galiellalactone for 3 wk.  The effect of galiellalactone on the induction of apoptosis of cultured PCa cells was investigated by Western blot anal., immunocytochem., and annexin V staining.  Effects of galiellalactone on Stat3 signaling were investigated by a luciferase reporter gene assay.  Expression of Stat3 assocd. proteins and mRNA was investigated by Western blot and real-time quant. PCR anal.  Results: Galiellalactone induced apoptosis of p-Stat3 pos. PCa cells (androgen-insensitive DU145 and PC-3) but not in cells lacking p-Stat3 (androgen-sensitive LNCaP).  Galiellalactone inhibited Stat3-mediated luciferase activity (IC50 ∼ 5 μM) and reduced the expression of Bcl-2, Bcl-xL, c-myc, and cyclin D1.  Furthermore, galiellalactone significantly suppressed DU145 xenograft growth in vivo (42% growth redn.; P < 0.002) and reduced the relative mRNA expression of Bcl-xL and Mcl-1.  Conclusions: Galiellalactone induced growth inhibition and apoptosis in androgen-insensitive PCa cells expressing p-Stat3.  We suggest that galiellalactone is a potential anti-tumor lead against hormone-refractory PCa with constitutively active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolRH_73FC3QbVg90H21EOLACvtfcHk0ljhh0KAwKgv3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFemuro%253D&md5=97a60d32632d431ea0b2b10d66721202</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fpros.20699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20699%26sid%3Dliteratum%253Aachs%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DA.%26aulast%3DDizeyi%26aufirst%3DN.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26atitle%3DGaliellalactone%2520is%2520a%2520novel%2520therapeutic%2520candidate%2520against%2520hormone-refractory%2520prostate%2520cancer%2520expressing%2520activated%2520Stat3%26jtitle%3DProstate%26date%3D2008%26volume%3D68%26spage%3D269%26epage%3D280%26doi%3D10.1002%2Fpros.20699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">von Nussbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benet-Buchholz, J.</span><span> </span><span class="NLM_article-title">The high-intrinsic Diels–Alder reactivity of (−)-galiellalactone; generating four quaternary carbon centers under mild conditions</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">2783</span><span class="NLM_x">–</span> <span class="NLM_lpage">2790</span><span class="refDoi"> DOI: 10.1002/ejoc.200400137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1002%2Fejoc.200400137" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2004&publication_year=2004&pages=2783-2790&author=F.+von+Nussbaumauthor=R.+Hankeauthor=T.+Fahrigauthor=J.+Benet-Buchholz&title=The+high-intrinsic+Diels%E2%80%93Alder+reactivity+of+%28%E2%88%92%29-galiellalactone%3B+generating+four+quaternary+carbon+centers+under+mild+conditions&doi=10.1002%2Fejoc.200400137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400137%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DHanke%26aufirst%3DR.%26aulast%3DFahrig%26aufirst%3DT.%26aulast%3DBenet-Buchholz%26aufirst%3DJ.%26atitle%3DThe%2520high-intrinsic%2520Diels%25E2%2580%2593Alder%2520reactivity%2520of%2520%2528%25E2%2588%2592%2529-galiellalactone%253B%2520generating%2520four%2520quaternary%2520carbon%2520centers%2520under%2520mild%2520conditions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2004%26volume%3D2004%26spage%3D2783%26epage%3D2790%26doi%3D10.1002%2Fejoc.200400137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Schmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahl, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merfort, I.</span><span> </span><span class="NLM_article-title">Helenanolide type sesquiterpene lactones. Part 5: the role of glutathione addition under physiological conditions</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2849</span><span class="NLM_x">–</span> <span class="NLM_lpage">2855</span><span class="refDoi"> DOI: 10.1016/S0968-0896(99)00234-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2FS0968-0896%2899%2900234-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10658589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=2849-2855&author=T.+J.+Schmidtauthor=G.+Lyssauthor=H.+L.+Pahlauthor=I.+Merfort&title=Helenanolide+type+sesquiterpene+lactones.+Part+5%3A+the+role+of+glutathione+addition+under+physiological+conditions&doi=10.1016%2FS0968-0896%2899%2900234-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions</span></div><div class="casAuthors">Schmidt, Thomas J.; Lyss, Guido; Pahl, Heike L.; Merfort, Irmgard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2849-2855</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Sesquiterpene lactones (STLs) are known to exert most of their numerous biol. activities through inhibition of enzymes and other functional proteins by forming covalent bonds with free cysteine residues in these macromols.  The question arises how these drugs can alkylate such vital target structures instead of being quickly deactivated by reaction with the cysteine group of glutathione (GSH) which is present in high concns. in all cells.  The authors have measured in this study the pH dependent kinetics of GSH addn. to the cyclopentenone and α-methylene-γ-lactone group of helenanolide type sesquiterpene lactones using UV-spectrophotometry.  The reaction with GSH at physiol. pH proceeds very quickly but is reversible so that a fraction of STL mols. will always be available for reaction with protein targets.  In agreement with these chem. data, helenalin-mono- and -bis-glutathionyl adducts were demonstrated to inhibit the nuclear transcription factor NF-κB at concns. similar to the free sesquiterpene lactone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqkVtGdFq5Y7Vg90H21EOLACvtfcHk0ljRgeywrv9c6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCgtA%253D%253D&md5=773a60cca35a2e3238602eb7885cd9d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900234-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900234-5%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DLyss%26aufirst%3DG.%26aulast%3DPahl%26aufirst%3DH.%2BL.%26aulast%3DMerfort%26aufirst%3DI.%26atitle%3DHelenanolide%2520type%2520sesquiterpene%2520lactones.%2520Part%25205%253A%2520the%2520role%2520of%2520glutathione%2520addition%2520under%2520physiological%2520conditions%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D2849%26epage%3D2855%26doi%3D10.1016%2FS0968-0896%2899%2900234-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greaney, M. F.</span><span> </span><span class="NLM_article-title">Reversible Michael addition of thiols as a new tool for dynamic combinatorial chemistry</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">886</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1039/b414300k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1039%2Fb414300k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=15700070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=886-888&author=B.+Shiauthor=M.+F.+Greaney&title=Reversible+Michael+addition+of+thiols+as+a+new+tool+for+dynamic+combinatorial+chemistry&doi=10.1039%2Fb414300k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael addition of thiols as a new tool for dynamic combinatorial chemistry</span></div><div class="casAuthors">Shi, Baolu; Greaney, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">886-888</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The Michael addn. of thiols to enones is reported as a new method for dynamic combinatorial library synthesis.  Thus, Michael addn. of glutathione with ethacrynic acid derivs. I [X = OH, piperidino, NHCH2CF3, etc.] led to sulfides II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox8kO8xzUPebVg90H21EOLACvtfcHk0lhA3TVJ1U58Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KqsrY%253D&md5=71992a58655ad0a8b880f31c7abf81d7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fb414300k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb414300k%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DB.%26aulast%3DGreaney%26aufirst%3DM.%2BF.%26atitle%3DReversible%2520Michael%2520addition%2520of%2520thiols%2520as%2520a%2520new%2520tool%2520for%2520dynamic%2520combinatorial%2520chemistry%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2005%26spage%3D886%26epage%3D888%26doi%3D10.1039%2Fb414300k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniwaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munakata, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kageyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatake, K.</span><span> </span><span class="NLM_article-title">Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1111/cas.12683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1111%2Fcas.12683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25912076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVClur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=896-901&author=M.+Oguraauthor=T.+Uchidaauthor=Y.+Teruiauthor=F.+Hayakawaauthor=Y.+Kobayashiauthor=M.+Taniwakiauthor=Y.+Takamatsuauthor=T.+Naoeauthor=K.+Tobinaiauthor=W.+Munakataauthor=T.+Yamauchiauthor=A.+Kageyamaauthor=M.+Yuasaauthor=M.+Motoyamaauthor=T.+Tsunodaauthor=K.+Hatake&title=Phase+I+study+of+OPB-51602%2C+an+oral+inhibitor+of+signal+transducer+and+activator+of+transcription+3%2C+in+patients+with+relapsed%2Frefractory+hematological+malignancies&doi=10.1111%2Fcas.12683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies</span></div><div class="casAuthors">Ogura, Michinori; Uchida, Toshiki; Terui, Yasuhito; Hayakawa, Fumihiko; Kobayashi, Yukio; Taniwaki, Masafumi; Takamatsu, Yasushi; Naoe, Tomoki; Tobinai, Kensei; Munakata, Wataru; Yamauchi, Takeshi; Kageyama, Akiko; Yuasa, Miyuki; Motoyama, Masaaki; Tsunoda, Takeshi; Hatake, Kiyohiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-901</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We carried out a multicenter dose-escalation phase I study of oral OPB-51602, a signal transducer and activator of transcription 3 phosphorylation inhibitor, in patients with relapsed or refractory hematol. malignancies to evaluate the safety, max. tolerated dose (MTD), pharmacokinetics, and preliminary antitumor activity.  Twenty patients were treated with OPB-51602 at doses of 1, 2, 3, 4, and 6 mg in the "3 + 3" dose escalation design.  The most common treatment-related adverse events included nausea (55%), peripheral sensory neuropathy (45%), and diarrhea (40%).  The most frequently obsd. grade 3 or 4 drug-related adverse events were neutropenia (20%), leukopenia (15%), lymphopenia (10%), and thrombocytopenia (10%).  The MTD was 6 mg, with dose-limiting toxicities of grade 3 lactic acidosis and increased blood lactic acid levels obsd. in one of three patients and grade 1-2 peripheral neuropathy in three of three patients.  The recommended dose was detd. to be 4 mg.  OPB-51602 was rapidly absorbed, and exposure tended to increase in a dose-dependent manner.  Accumulation of OPB-51602 was seen with 4 wk of multiple treatments.  No clear therapeutic response was obsd.  Durable stable disease was obsd. in two patients with acute myeloid leukemia and one with myeloma.  In conclusion, the MTD of OPB-51602 was 6 mg.  OPB-51602 was safe and well tolerated in a dose range of 1-4 mg.  However, long-term administration at higher doses was difficult with the daily dosing schedule, and no response was seen.  Therefore, further clin. development of OPB-51602 for hematol. malignancies with a daily dosing schedule was terminated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP1VSTl7NbYrVg90H21EOLACvtfcHk0lhA3TVJ1U58Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVClur8%253D&md5=5173296bfc67ade88f7abcc84159ed4b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fcas.12683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12683%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DT.%26aulast%3DTerui%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTaniwaki%26aufirst%3DM.%26aulast%3DTakamatsu%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DMunakata%26aufirst%3DW.%26aulast%3DYamauchi%26aufirst%3DT.%26aulast%3DKageyama%26aufirst%3DA.%26aulast%3DYuasa%26aufirst%3DM.%26aulast%3DMotoyama%26aufirst%3DM.%26aulast%3DTsunoda%26aufirst%3DT.%26aulast%3DHatake%26aufirst%3DK.%26atitle%3DPhase%2520I%2520study%2520of%2520OPB-51602%252C%2520an%2520oral%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%252C%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520hematological%2520malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2015%26volume%3D106%26spage%3D896%26epage%3D901%26doi%3D10.1111%2Fcas.12683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span> </span><span class="NLM_article-title">Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.4143/crt.2014.249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4143%2Fcrt.2014.249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25715763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=607-615&author=D.+Y.+Ohauthor=S.+H.+Leeauthor=S.+W.+Hanauthor=M.+J.+Kimauthor=T.+M.+Kimauthor=T.+Y.+Kimauthor=D.+S.+Heoauthor=M.+Yuasaauthor=Y.+Yanagiharaauthor=Y.+J.+Bang&title=Phase+I+study+of+OPB-31121%2C+an+oral+STAT3+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.4143%2Fcrt.2014.249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Oh Do-Youn; Lee Se-Hoon; Han Sae-Won; Kim Mi-Jung; Kim Tae-Min; Kim Tae-You; Heo Dae Seog; Bang Yung-Jue; Oh Do-Youn; Lee Se-Hoon; Han Sae-Won; Kim Mi-Jung; Kim Tae-Min; Kim Tae-You; Heo Dae Seog; Bang Yung-Jue; Yuasa Miyuki; Yanagihara Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity.  This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.  MATERIALS AND METHODS:  Patients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest.  A standard 3+3 design was used for dose-escalation.  Safety and response were evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.  RESULTS:  Twenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200 mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8).  Seven patients discontinued treatment during cycle 1 for various reasons other than study drug-related adverse events.  Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs were observed: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3 diarrhea) at 800 mg.  The MTD was determined as 800 mg/day.  Common adverse events were gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea (72%).  Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121.  Eight patients had stable disease and 10 patients had disease progression.  Two patients (1 colon cancer, 1 rectal cancer) showed tumor shrinkage.  One gastric cancer patient continued treatment up to cycle 13 before disease progression.  CONCLUSION:  This study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor.  OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has a preliminary antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO4HjIonre9iM8MEzWGjS9fW6udTcc2eb33ZYptEz8erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslKgug%253D%253D&md5=499f3d1b07c7760b88d12e1be071d398</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.249%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DYuasa%26aufirst%3DM.%26aulast%3DYanagihara%26aufirst%3DY.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520OPB-31121%252C%2520an%2520oral%2520STAT3%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2015%26volume%3D47%26spage%3D607%26epage%3D615%26doi%3D10.4143%2Fcrt.2014.249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Hobisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramoner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godoy-Tundidor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klocker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culig, Z.</span><span> </span><span class="NLM_article-title">Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">–</span> <span class="NLM_lpage">2948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=11555613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFSitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2941-2948&author=A.+Hobischauthor=R.+Ramonerauthor=D.+Fuchsauthor=S.+Godoy-Tundidorauthor=G.+Bartschauthor=H.+Klockerauthor=Z.+Culig&title=Prostate+cancer+cells+%28LNCaP%29+generated+after+long-term+interleukin+6+%28IL-6%29+treatment+express+IL-6+and+acquire+an+IL-6+partially+resistant+phenotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype</span></div><div class="casAuthors">Hobisch, Alfred; Ramoner, Reinhold; Fuchs, Dietmar; Godoy-Tundidor, Sonia; Bartsch, Georg; Klocker, Helmut; Culig, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2941-2948</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The levels of interleukin-6 (IL-6) are frequently elevated in sera from patients with advanced prostate carcinoma.  Our main objective was to investigate changes in responsiveness to IL-6 and/or androgen that occur in LNCaP cells after long-term treatment with IL-6.  This in vitro model could be of clin. relevance because of its similarity with late-stage prostate carcinoma.  LNCaP human prostate cancer cells were treated with IL-6 at a concn. of 5 ng/mL.  After 20 passages, the new subline LNCaP-IL-6+ has been established.  Passages 20-40 are referred to as low passages (LP) and passages 41-73 as high passages (HP).  LNCaP cells passaged at the same time in the absence of IL-6 were used as controls (LNCaP-IL-6-).  Cells were counted after treatment with either IL-6 or the synthetic androgen methyltrienolone (R1881), and cell cycle anal. was performed.  Binding of IL-6 or R1881 was assessed by radioligand binding assays.  Reporter gene activity was measured by chloramphenicol acetyltransferase assay.  Prostate-specific antigen in LNCaP-IL-6+ supernatants was measured by an enzyme immunoassay.  Expression of IL-6 mRNA and protein was assessed by reverse transcription-PCR and ELISA, resp.  The basal proliferation rate in HP LNCaP-IL-6+ cells was higher than that in LNCaP-IL-6- cells.  IL-6 inhibited proliferation of LNCaP-IL-6- cells but not that of either LP or HP of LNCaP-IL-6+ cells.  This inability to elicit a growth-inhibitory response was assocd. with lack of effect on cell cycle distribution in the LNCaP-IL-6+ subline.  In parallel, IL-6 binding decreased gradually during long-term IL-6 treatment and, in HP, reached only 33% of the levels measured in controls.  Binding of radiolabeled androgen increased 2-fold in HP LNCaP-IL-6+ cells.  Reporter gene assays revealed that R1881, at nanomolar concns., was a more potent androgen receptor activator in LNCaP-IL-6+ than in LNCaP-IL-6- cells.  However, androgen- and IL-6-induced prostate-specific antigen secretion decreased in long-term IL-6-treated cells.  IL-6 cDNA fragments were detected by reverse transcription-PCR in HP LNCaP-IL-6+ cells but not in controls or LP.  IL-6 protein was first detected in passage 36 of LNCaP-IL-6+ cells, and it increased in HP.  Long-term treatment of LNCaP human prostate cancer cells with IL-6 leads to abolishment of inhibitory growth response.  In contrast to control cells, the LNCaP-IL-6+ subline expresses IL-6 mRNA and protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpueitsJLg547Vg90H21EOLACvtfcHk0li8hNfsios14g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFSitbc%253D&md5=3a8aab7eee5b86661eb8681c472f03e0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHobisch%26aufirst%3DA.%26aulast%3DRamoner%26aufirst%3DR.%26aulast%3DFuchs%26aufirst%3DD.%26aulast%3DGodoy-Tundidor%26aufirst%3DS.%26aulast%3DBartsch%26aufirst%3DG.%26aulast%3DKlocker%26aufirst%3DH.%26aulast%3DCulig%26aufirst%3DZ.%26atitle%3DProstate%2520cancer%2520cells%2520%2528LNCaP%2529%2520generated%2520after%2520long-term%2520interleukin%25206%2520%2528IL-6%2529%2520treatment%2520express%2520IL-6%2520and%2520acquire%2520an%2520IL-6%2520partially%2520resistant%2520phenotype%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2941%26epage%3D2948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jinyun Dong, Xiang-Dong Cheng, Wei-Dong Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Jiang-Jiang Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8884-8915. <a href="https://doi.org/10.1021/acs.jmedchem.1c00629" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00629%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BUpdate%252Bon%252BDevelopment%252Bof%252BSmall-Molecule%252BSTAT3%252BInhibitors%252Bfor%252BCancer%252BTherapy%25253A%252BFrom%252BPhosphorylation%252BInhibition%252Bto%252BProtein%252BDegradation%26aulast%3DDong%26aufirst%3DJinyun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06042021%26date%3D25062021%26volume%3D64%26issue%3D13%26spage%3D8884%26epage%3D8915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zilma Escobar, Jakob Nilsson, Ritha Gidlöf, Martin Johansson, <span class="NLM_string-name hlFld-ContribAuthor">Olov Sterner</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoretentive Nucleophilic Substitution at the Tetrasubstituted Carbon of Galiellalactone. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (12)
                                     , 7704-7710. <a href="https://doi.org/10.1021/acs.joc.0c00152" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00152%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoretentive%252BNucleophilic%252BSubstitution%252Bat%252Bthe%252BTetrasubstituted%252BCarbon%252Bof%252BGaliellalactone%26aulast%3DEscobar%26aufirst%3DZilma%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20012020%26date%3D02062020%26date%3D18052020%26volume%3D85%26issue%3D12%26spage%3D7704%26epage%3D7710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shaoyong Lu, Xinheng He, Duan Ni, <span class="NLM_string-name hlFld-ContribAuthor">Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6405-6421. <a href="https://doi.org/10.1021/acs.jmedchem.8b01749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAllosteric%252BModulator%252BDiscovery%25253A%252BFrom%252BSerendipity%252Bto%252BStructure-Based%252BDesign%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D11112018%26date%3D07032019%26date%3D28022019%26volume%3D62%26issue%3D14%26spage%3D6405%26epage%3D6421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giacomo  Canesin</span>, <span class="hlFld-ContribAuthor ">Valentina  Maggio</span>, <span class="hlFld-ContribAuthor ">Macarena  Palominos</span>, <span class="hlFld-ContribAuthor ">Anna  Stiehm</span>, <span class="hlFld-ContribAuthor ">Hector R.  Contreras</span>, <span class="hlFld-ContribAuthor ">Enrique A.  Castellón</span>, <span class="hlFld-ContribAuthor ">Juan  Morote</span>, <span class="hlFld-ContribAuthor ">Rosanna  Paciucci</span>, <span class="hlFld-ContribAuthor ">Norman J.  Maitland</span>, <span class="hlFld-ContribAuthor ">Anders  Bjartell</span>, <span class="hlFld-ContribAuthor ">Rebecka  Hellsten</span>. </span><span class="cited-content_cbyCitation_article-title">STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-70948-5" title="DOI URL">https://doi.org/10.1038/s41598-020-70948-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-70948-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-70948-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DSTAT3%252Binhibition%252Bwith%252Bgaliellalactone%252Beffectively%252Btargets%252Bthe%252Bprostate%252Bcancer%252Bstem-like%252Bcell%252Bpopulation%26aulast%3DCanesin%26aufirst%3DGiacomo%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sailan  Zou</span>, <span class="hlFld-ContribAuthor ">Qiyu  Tong</span>, <span class="hlFld-ContribAuthor ">Bowen  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Tian</span>, <span class="hlFld-ContribAuthor ">Xianghui  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting STAT3 in Cancer Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-020-01258-7" title="DOI URL">https://doi.org/10.1186/s12943-020-01258-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-020-01258-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-020-01258-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DTargeting%252BSTAT3%252Bin%252BCancer%252BImmunotherapy%26aulast%3DZou%26aufirst%3DSailan%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aliaa M.  Mohassab</span>, <span class="hlFld-ContribAuthor ">Heba A.  Hassan</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Mohamed  Abdel-Aziz</span>. </span><span class="cited-content_cbyCitation_article-title">STAT3 transcription factor as target for anti-cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reports</span><span> <strong>2020,</strong> <em>72 </em>
                                    (5)
                                     , 1101-1124. <a href="https://doi.org/10.1007/s43440-020-00156-5" title="DOI URL">https://doi.org/10.1007/s43440-020-00156-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s43440-020-00156-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs43440-020-00156-5%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reports%26atitle%3DSTAT3%252Btranscription%252Bfactor%252Bas%252Btarget%252Bfor%252Banti-cancer%252Btherapy%26aulast%3DMohassab%26aufirst%3DAliaa%2BM.%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D5%26spage%3D1101%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping-Lian  Yang</span>, <span class="hlFld-ContribAuthor ">Lu-Xin  Liu</span>, <span class="hlFld-ContribAuthor ">En-Min  Li</span>, <span class="hlFld-ContribAuthor ">Li-Yan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (9)
                                     , 2459. <a href="https://doi.org/10.3390/cancers12092459" title="DOI URL">https://doi.org/10.3390/cancers12092459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12092459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12092459%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSTAT3%25252C%252Bthe%252BChallenge%252Bfor%252BChemotherapeutic%252Band%252BRadiotherapeutic%252BEfficacy%26aulast%3DYang%26aufirst%3DPing-Lian%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D9%26spage%3D2459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Zohreh  Babaloo</span>, <span class="hlFld-ContribAuthor ">Arezoo  Hosseini</span>, <span class="hlFld-ContribAuthor ">Meghdad  Abdollahpour-alitappeh</span>, <span class="hlFld-ContribAuthor ">Vida  Hashemi</span>, <span class="hlFld-ContribAuthor ">Faroogh  Marofi</span>, <span class="hlFld-ContribAuthor ">Kazem  Nejati</span>, <span class="hlFld-ContribAuthor ">Behzad  Baradaran</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting STAT3 in cancer and autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>878 </em>, 173107. <a href="https://doi.org/10.1016/j.ejphar.2020.173107" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173107%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DTargeting%252BSTAT3%252Bin%252Bcancer%252Band%252Bautoimmune%252Bdiseases%26aulast%3DGharibi%26aufirst%3DTohid%26date%3D2020%26volume%3D878%26spage%3D173107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lorna  Conway</span>, <span class="hlFld-ContribAuthor ">Anna  Riccio</span>, <span class="hlFld-ContribAuthor ">M. Gabriella  Santoro</span>, <span class="hlFld-ContribAuthor ">Paul  Evans</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of the 4-aza cyclopentenone analogue of Δ12,14-15-deoxy-PGJ2 and S-cysteine adducts. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (25)
                                     , 151969. <a href="https://doi.org/10.1016/j.tetlet.2020.151969" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.151969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.151969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.151969%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Bthe%252B4-aza%252Bcyclopentenone%252Banalogue%252Bof%252B%2525CE%25259412%25252C14-15-deoxy-PGJ2%252Band%252BS-cysteine%252Badducts%26aulast%3DConway%26aufirst%3DLorna%26date%3D2020%26volume%3D61%26issue%3D25%26spage%3D151969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi Yong  Neo</span>, <span class="hlFld-ContribAuthor ">Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Julien  Record</span>, <span class="hlFld-ContribAuthor ">Ran  Ma</span>, <span class="hlFld-ContribAuthor ">Xinsong  Chen</span>, <span class="hlFld-ContribAuthor ">Ziqing  Chen</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Tobin</span>, <span class="hlFld-ContribAuthor ">Emily  Blake</span>, <span class="hlFld-ContribAuthor ">Christina  Seitz</span>, <span class="hlFld-ContribAuthor ">Ron  Thomas</span>, <span class="hlFld-ContribAuthor ">Arnika Kathleen  Wagner</span>, <span class="hlFld-ContribAuthor ">John  Andersson</span>, <span class="hlFld-ContribAuthor ">Jana  de Boniface</span>, <span class="hlFld-ContribAuthor ">Jonas  Bergh</span>, <span class="hlFld-ContribAuthor ">Shannon  Murray</span>, <span class="hlFld-ContribAuthor ">Evren  Alici</span>, <span class="hlFld-ContribAuthor ">Richard  Childs</span>, <span class="hlFld-ContribAuthor ">Martin  Johansson</span>, <span class="hlFld-ContribAuthor ">Lisa S.  Westerberg</span>, <span class="hlFld-ContribAuthor ">Felix  Haglund</span>, <span class="hlFld-ContribAuthor ">Johan  Hartman</span>, <span class="hlFld-ContribAuthor ">Andreas  Lundqvist</span>. </span><span class="cited-content_cbyCitation_article-title">CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Investigation</span><span> <strong>2020,</strong> <em>130 </em>
                                    (3)
                                     , 1185-1198. <a href="https://doi.org/10.1172/JCI128895" title="DOI URL">https://doi.org/10.1172/JCI128895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/JCI128895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2FJCI128895%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Investigation%26atitle%3DCD73%252Bimmune%252Bcheckpoint%252Bdefines%252Bregulatory%252BNK%252Bcells%252Bwithin%252Bthe%252Btumor%252Bmicroenvironment%26aulast%3DNeo%26aufirst%3DShi%2BYong%26date%3D2020%26date%3D2020%26volume%3D130%26issue%3D3%26spage%3D1185%26epage%3D1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuki  Uchihara</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Ohe</span>, <span class="hlFld-ContribAuthor ">Tadahiko  Mashino</span>, <span class="hlFld-ContribAuthor ">Takayuki  Kidokoro</span>, <span class="hlFld-ContribAuthor ">Kenji  Tago</span>, <span class="hlFld-ContribAuthor ">Hiroomi  Tamura</span>, <span class="hlFld-ContribAuthor ">Megumi  Funakoshi-Tago</span>. </span><span class="cited-content_cbyCitation_article-title">N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reports</span><span> <strong>2019,</strong> <em>71 </em>
                                    (6)
                                     , 1067-1078. <a href="https://doi.org/10.1016/j.pharep.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.pharep.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharep.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharep.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reports%26atitle%3DN-Acetyl%252Bcysteine%252Bprevents%252Bactivities%252Bof%252BSTAT3%252Binhibitors%25252C%252BStattic%252Band%252BBP-1-102%252Bindependently%252Bof%252Bits%252Bantioxidant%252Bproperties%26aulast%3DUchihara%26aufirst%3DYuki%26date%3D2019%26volume%3D71%26issue%3D6%26spage%3D1067%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arianna  Gelain</span>, <span class="hlFld-ContribAuthor ">Matteo  Mori</span>, <span class="hlFld-ContribAuthor ">Fiorella  Meneghetti</span>, <span class="hlFld-ContribAuthor ">Stefania  Villa</span>. </span><span class="cited-content_cbyCitation_article-title">Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (27)
                                     , 5165-5206. <a href="https://doi.org/10.2174/0929867325666180719122729" title="DOI URL">https://doi.org/10.2174/0929867325666180719122729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180719122729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180719122729%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DSignal%252BTransducer%252Band%252BActivator%252Bof%252BTranscription%252BProtein%252B3%252B%252528STAT3%252529%25253A%252BAn%252BUpdate%252Bon%252Bits%252BDirect%252BInhibitors%252Bas%252BPromising%252BAnticancer%252BAgents%26aulast%3DGelain%26aufirst%3DArianna%26date%3D2019%26volume%3D26%26issue%3D27%26spage%3D5165%26epage%3D5206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rashmin  khanam</span>, <span class="hlFld-ContribAuthor ">Iram I.  Hejazi</span>, <span class="hlFld-ContribAuthor ">Syed  Shahabuddin</span>, <span class="hlFld-ContribAuthor ">Abdul R.  Bhat</span>, <span class="hlFld-ContribAuthor ">Fareeda  Athar</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Analysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (2)
                                     , 133-141. <a href="https://doi.org/10.1016/j.jpha.2018.12.002" title="DOI URL">https://doi.org/10.1016/j.jpha.2018.12.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpha.2018.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpha.2018.12.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Analysis%26atitle%3DPharmacokinetic%252Bevaluation%25252C%252Bmolecular%252Bdocking%252Band%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Bof%252B1%25252C%252B3%25252C%252B4-oxadiazole%252Bderivatives%252Bas%252Bpotent%252Bantioxidants%252Band%252BSTAT3%252Binhibitors%26aulast%3Dkhanam%26aufirst%3DRashmin%26date%3D2019%26volume%3D9%26issue%3D2%26spage%3D133%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yandong  Lu</span>, <span class="hlFld-ContribAuthor ">Shan  Zhao</span>, <span class="hlFld-ContribAuthor ">Shijie  Zhou</span>, <span class="hlFld-ContribAuthor ">Si-Cong  Chen</span>, <span class="hlFld-ContribAuthor ">Tuoping  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective syntheses and application of 4-
              epi
              -galiellalactone and the corresponding activity-based probe: from strained bicycles to strained tricycles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (7)
                                     , 1886-1892. <a href="https://doi.org/10.1039/C8OB01915K" title="DOI URL">https://doi.org/10.1039/C8OB01915K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01915K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01915K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DEnantioselective%252Bsyntheses%252Band%252Bapplication%252Bof%252B4-%252Bepi%252B-galiellalactone%252Band%252Bthe%252Bcorresponding%252Bactivity-based%252Bprobe%25253A%252Bfrom%252Bstrained%252Bbicycles%252Bto%252Bstrained%252Btricycles%26aulast%3DLu%26aufirst%3DYandong%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D7%26spage%3D1886%26epage%3D1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Handle</span>, <span class="hlFld-ContribAuthor ">Martin  Puhr</span>, <span class="hlFld-ContribAuthor ">Georg  Schaefer</span>, <span class="hlFld-ContribAuthor ">Nicla  Lorito</span>, <span class="hlFld-ContribAuthor ">Julia  Hoefer</span>, <span class="hlFld-ContribAuthor ">Martina  Gruber</span>, <span class="hlFld-ContribAuthor ">Fabian  Guggenberger</span>, <span class="hlFld-ContribAuthor ">Frédéric R.  Santer</span>, <span class="hlFld-ContribAuthor ">Rute B.  Marques</span>, <span class="hlFld-ContribAuthor ">Wytske M.  van Weerden</span>, <span class="hlFld-ContribAuthor ">Frank  Claessens</span>, <span class="hlFld-ContribAuthor ">Holger H.H.  Erb</span>, <span class="hlFld-ContribAuthor ">Zoran  Culig</span>. </span><span class="cited-content_cbyCitation_article-title">The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (12)
                                     , 2722-2731. <a href="https://doi.org/10.1158/1535-7163.MCT-18-0508" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-18-0508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-18-0508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-18-0508%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DThe%252BSTAT3%252BInhibitor%252BGaliellalactone%252BReduces%252BIL6-Mediated%252BAR%252BActivity%252Bin%252BBenign%252Band%252BMalignant%252BProstate%252BModels%26aulast%3DHandle%26aufirst%3DFlorian%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D12%26spage%3D2722%26epage%3D2731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jenny D.  Beebe</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Jian-Ting  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>191 </em>, 74-91. <a href="https://doi.org/10.1016/j.pharmthera.2018.06.006" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2018.06.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2018.06.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTwo%252Bdecades%252Bof%252Bresearch%252Bin%252Bdiscovery%252Bof%252Banticancer%252Bdrugs%252Btargeting%252BSTAT3%25252C%252Bhow%252Bclose%252Bare%252Bwe%25253F%26aulast%3DBeebe%26aufirst%3DJenny%2BD.%26date%3D2018%26volume%3D191%26spage%3D74%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mélanie  Lambert</span>, <span class="hlFld-ContribAuthor ">Samy  Jambon</span>, <span class="hlFld-ContribAuthor ">Sabine  Depauw</span>, <span class="hlFld-ContribAuthor ">Marie-Hélène  David-Cordonnier</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Transcription Factors for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (6)
                                     , 1479. <a href="https://doi.org/10.3390/molecules23061479" title="DOI URL">https://doi.org/10.3390/molecules23061479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23061479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23061479%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTargeting%252BTranscription%252BFactors%252Bfor%252BCancer%252BTreatment%26aulast%3DLambert%26aufirst%3DM%25C3%25A9lanie%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D6%26spage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenda  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Ma</span>, <span class="hlFld-ContribAuthor ">Shanshan  Li</span>, <span class="hlFld-ContribAuthor ">Yanwei  Yang</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Guo</span>, <span class="hlFld-ContribAuthor ">Wenying  Yu</span>, <span class="hlFld-ContribAuthor ">Lingyi  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 538-550. <a href="https://doi.org/10.1016/j.ejmech.2016.09.068" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.09.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.09.068%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAntagonizing%252BSTAT3%252Bactivation%252Bwith%252Bbenzo%25255Bb%25255Dthiophene%252B1%25252C%252B1-dioxide%252Bbased%252Bsmall%252Bmolecules%26aulast%3DZhang%26aufirst%3DWenda%26date%3D2017%26volume%3D125%26spage%3D538%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reaction of <b>1</b> with Cysteine in PBS and MeOH</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: RCH<sub>2</sub>SH, triethylamine, MeOH, room temperature, overnight.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Galiellalactone adducts <b>2</b>–<b>17</b> prepared according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro efficacy of <b>1</b> and thiol adducts. (A) Effect of <b>1</b> on viability and proliferation of prostate cancer cells incubated with 3 μM <b>1</b> for 72 h. The proliferation was measured using the WST-1 proliferation assay and calculated as percent of untreated control (<i>n</i> = 6). (B) Western blot analysis of the expression of STAT3 and pSTAT3 in prostate cancer cell lines. (C) DU145 prostate cancer cells expressing active STAT3 were treated with compounds at various concentrations for 72 h (<i>n</i> = 3). The proliferation was measured using the WST-1 proliferation assay and calculated as percent of untreated control and presented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Pharmacokinetic analysis of <b>1</b> and <b>6</b> following a single oral dose (10 mg/kg po) in mice (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Oral treatment with <b>6</b> inhibits prostate cancer xenograft growth. Mice with subcutaneous DU145 xenografts were treated orally with <b>6</b> (40 mg/kg) or vehicle (2% DMSO in citric buffer) for 4 weeks, daily 5 times per week. (A) Mice treated with <b>6</b> had significantly smaller tumors compared to vehicle treated mice at day 26 and day 29 ((∗) <i>p</i> < 0.05 and (∗∗) <i>p</i> < 0.01; <i>n</i> = 10). (B) There was no significant difference in body weights between vehicle and <b>6</b> treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>6</b> inhibits proliferation and induces apoptosis of tumor cells in vivo. (A) Proliferation measured as Ki67 ratio was significantly decreased by <b>6</b> treatment in DU145 xenografts (<i>p</i> = 0.0061; <i>n</i> = 9). (B) The amount of cleaved caspase-3 expressing cells, indicating apoptotic cells, was significantly increased by <b>6</b> treatment in xenograft tumors (<i>p</i> = 0.0005; <i>n</i> = 9). (C) The mRNA expression of the antiapoptotic genes MCL1 and BCL2 in <b>6</b> treated tumor xenografts (<i>p</i> = 0.015 and <i>p</i> = 0.18, respectively; <i>n</i> = 8). (D) pSTAT3 expression in DU145 xenografts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/medium/jm-2015-018144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed conversion of prodrug <b>6</b> to active parent <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.5b01814/20160520/images/large/jm-2015-018144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01814&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bishop, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaper, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoubeidi, A.</span><span> </span><span class="NLM_article-title">The multifaceted roles of STAT3 signaling in the progression of prostate cancer</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span><span class="refDoi"> DOI: 10.3390/cancers6020829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.3390%2Fcancers6020829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=829-859&author=J.+L.+Bishopauthor=D.+Thaperauthor=A.+Zoubeidi&title=The+multifaceted+roles+of+STAT3+signaling+in+the+progression+of+prostate+cancer&doi=10.3390%2Fcancers6020829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fcancers6020829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6020829%26sid%3Dliteratum%253Aachs%26aulast%3DBishop%26aufirst%3DJ.%2BL.%26aulast%3DThaper%26aufirst%3DD.%26aulast%3DZoubeidi%26aufirst%3DA.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520STAT3%2520signaling%2520in%2520the%2520progression%2520of%2520prostate%2520cancer%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D829%26epage%3D859%26doi%3D10.3390%2Fcancers6020829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Peyser, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandis, J. R.</span><span> </span><span class="NLM_article-title">Critical analysis of the potential for targeting STAT3 in human malignancy</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span><span class="refDoi"> DOI: 10.2147/OTT.S47903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.2147%2FOTT.S47903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=23935373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yns7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=999-1010&author=N.+D.+Peyserauthor=J.+R.+Grandis&title=Critical+analysis+of+the+potential+for+targeting+STAT3+in+human+malignancy&doi=10.2147%2FOTT.S47903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Critical analysis of the potential for targeting STAT3 in human malignancy</span></div><div class="casAuthors">Peyser, Noah D.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">999-1010</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The signal transducer and activator of transcription (STAT) family of proteins was originally discovered in the context of normal cell biol. where they function to transduce intracellular and extracellular signals to the nucleus, ultimately leading to transcription of specific target genes and downstream phenotypic effects.  It was quickly appreciated that the STATs, esp. STAT3, play a fundamental role in human malignancy.  In contrast to normal biol. in which transient STAT3 signaling is strictly regulated by a tightly coordinated network of activators and deactivators, STAT3 is constitutively activated in human malignancies.  Constitutive STAT3 signaling has been assocd. with many cancerous phenotypes across nearly all human cancers, including the upregulation of cell growth, proliferation, survival and motility, among others.  Studies involving candidate preclin. STAT3 inhibitors have further demonstrated that the reversal of these phenotypes results from pharmacol. or genetic inhibition of STAT3, suggesting that STAT3 may be a promising target for clin. interventions.  Indeed, a Phase 0 clin. trial involving a STAT3 decoy oligonucleotide demonstrated that STAT3 is a druggable target in human tumors.  Because of the ubiquity of overactive STAT3 in cancer, its role in promoting a wide variety of cancerous phenotypes and the strong clin. and preclin. studies performed to date, STAT3 represents a promising target for the development of inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9fUDHex_-_LVg90H21EOLACvtfcHk0ljsxrLowTYwTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yns7vL&md5=d2754344f2a58ec47838c4150d2db06f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FOTT.S47903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S47903%26sid%3Dliteratum%253Aachs%26aulast%3DPeyser%26aufirst%3DN.%2BD.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DCritical%2520analysis%2520of%2520the%2520potential%2520for%2520targeting%2520STAT3%2520in%2520human%2520malignancy%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D999%26epage%3D1010%26doi%3D10.2147%2FOTT.S47903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Rebe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegran, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiringhelli, F.</span><span> </span><span class="NLM_article-title">STAT3 activation: A key factor in tumor immunoescape</span> <span class="citation_source-journal">JAKSTAT</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e23010</span><span class="refDoi"> DOI: 10.4161/jkst.23010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4161%2Fjkst.23010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e23010&author=C.+Rebeauthor=F.+Vegranauthor=H.+Bergerauthor=F.+Ghiringhelli&title=STAT3+activation%3A+A+key+factor+in+tumor+immunoescape&doi=10.4161%2Fjkst.23010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4161%2Fjkst.23010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.23010%26sid%3Dliteratum%253Aachs%26aulast%3DRebe%26aufirst%3DC.%26aulast%3DVegran%26aufirst%3DF.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DGhiringhelli%26aufirst%3DF.%26atitle%3DSTAT3%2520activation%253A%2520A%2520key%2520factor%2520in%2520tumor%2520immunoescape%26jtitle%3DJAKSTAT%26date%3D2013%26volume%3D2%26spage%3De23010%26doi%3D10.4161%2Fjkst.23010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zhang, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span> </span><span class="NLM_article-title">STAT3 in cancer-friend or foe?</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1440</span><span class="refDoi"> DOI: 10.3390/cancers6031408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.3390%2Fcancers6031408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1408-1440&author=H.+F.+Zhangauthor=R.+Lai&title=STAT3+in+cancer-friend+or+foe%3F&doi=10.3390%2Fcancers6031408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fcancers6031408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6031408%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BF.%26aulast%3DLai%26aufirst%3DR.%26atitle%3DSTAT3%2520in%2520cancer-friend%2520or%2520foe%253F%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D1408%26epage%3D1440%26doi%3D10.3390%2Fcancers6031408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pilati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucman-Rossi, J.</span><span> </span><span class="NLM_article-title">Mutations leading to constitutive active gp130/JAK1/STAT3 pathway</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.cytogfr.2015.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26188635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=499-506&author=C.+Pilatiauthor=J.+Zucman-Rossi&title=Mutations+leading+to+constitutive+active+gp130%2FJAK1%2FSTAT3+pathway&doi=10.1016%2Fj.cytogfr.2015.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations leading to constitutive active gp130/JAK1/STAT3 pathway</span></div><div class="casAuthors">Pilati, Camilla; Zucman-Rossi, Jessica</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Constitutive activation of STAT (Signal Transducer and Activator of Transcription) transcription factors is a common feature identified in numerous tumors.  Inflammatory hepatocellular adenomas (IHCA) are benign liver tumors characterized by an inflammatory phenotype and an overexpression of STAT3 target genes.  Recurrent somatic mutations in major actors belonging to the IL6/JAK/STAT3 pathway have been identified in these tumors.  (1) 60% Of IHCA show IL-6 signal transducer (IL6ST; gp130) mutations; (2) 10% harbor mutations of the Fyn-related kinase FRK; (3) 5% harbor mutations in STAT3; (4) 5% harbor somatic mutations in the GNAS complex locus; and (5) 1% of IHCA harbor mutations in the Janus kinase 1 (JAK1).  All these IHCA-assocd. mutations promote the constitutive activation of STAT3.  In this review, we discuss the role of these mutated genes in IHCA and other tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr32M45DrEm3rVg90H21EOLACvtfcHk0lhTewYIlSQqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktbrF&md5=9e41e270f0fe93b8ff0bcc4fcf183a16</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DPilati%26aufirst%3DC.%26aulast%3DZucman-Rossi%26aufirst%3DJ.%26atitle%3DMutations%2520leading%2520to%2520constitutive%2520active%2520gp130%252FJAK1%252FSTAT3%2520pathway%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2015%26volume%3D26%26spage%3D499%26epage%3D506%26doi%3D10.1016%2Fj.cytogfr.2015.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jerez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemente, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makishima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskela, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przychodzen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afable, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Segui, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guinta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsi, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGraw, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarski, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekeres, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">List, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, J. P.</span><span> </span><span class="NLM_article-title">STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">3048</span><span class="NLM_x">–</span> <span class="NLM_lpage">3057</span><span class="refDoi"> DOI: 10.1182/blood-2012-06-435297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1182%2Fblood-2012-06-435297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=3048-3057&author=A.+Jerezauthor=M.+J.+Clementeauthor=H.+Makishimaauthor=H.+Koskelaauthor=F.+Leblancauthor=K.+Peng+Ngauthor=T.+Olsonauthor=B.+Przychodzenauthor=M.+Afableauthor=I.+Gomez-Seguiauthor=K.+Guintaauthor=L.+Durkinauthor=E.+D.+Hsiauthor=K.+McGrawauthor=D.+Zhangauthor=M.+W.+Wlodarskiauthor=K.+Porkkaauthor=M.+A.+Sekeresauthor=A.+Listauthor=S.+Mustjokiauthor=T.+P.+Loughranauthor=J.+P.+Maciejewski&title=STAT3+mutations+unify+the+pathogenesis+of+chronic+lymphoproliferative+disorders+of+NK+cells+and+T-cell+large+granular+lymphocyte+leukemia&doi=10.1182%2Fblood-2012-06-435297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-06-435297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-06-435297%26sid%3Dliteratum%253Aachs%26aulast%3DJerez%26aufirst%3DA.%26aulast%3DClemente%26aufirst%3DM.%2BJ.%26aulast%3DMakishima%26aufirst%3DH.%26aulast%3DKoskela%26aufirst%3DH.%26aulast%3DLeblanc%26aufirst%3DF.%26aulast%3DPeng%2BNg%26aufirst%3DK.%26aulast%3DOlson%26aufirst%3DT.%26aulast%3DPrzychodzen%26aufirst%3DB.%26aulast%3DAfable%26aufirst%3DM.%26aulast%3DGomez-Segui%26aufirst%3DI.%26aulast%3DGuinta%26aufirst%3DK.%26aulast%3DDurkin%26aufirst%3DL.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DMcGraw%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWlodarski%26aufirst%3DM.%2BW.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DList%26aufirst%3DA.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DMaciejewski%26aufirst%3DJ.%2BP.%26atitle%3DSTAT3%2520mutations%2520unify%2520the%2520pathogenesis%2520of%2520chronic%2520lymphoproliferative%2520disorders%2520of%2520NK%2520cells%2520and%2520T-cell%2520large%2520granular%2520lymphocyte%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D3048%26epage%3D3057%26doi%3D10.1182%2Fblood-2012-06-435297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Milner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray-Pedersen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemela, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topcagic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberson, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbsky, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas-Hernandez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karam, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahmod, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makedonas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorte, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perminow, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElwee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santibanez-Koref, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slowik, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinwiddie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciaccio, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Septer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsmore, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cant, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. A.</span><span> </span><span class="NLM_article-title">Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span><span class="refDoi"> DOI: 10.1182/blood-2014-09-602763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1182%2Fblood-2014-09-602763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=591-599&author=J.+D.+Milnerauthor=T.+P.+Vogelauthor=L.+Forbesauthor=C.+A.+Maauthor=A.+Stray-Pedersenauthor=J.+E.+Niemelaauthor=J.+J.+Lyonsauthor=K.+R.+Engelhardtauthor=Y.+Zhangauthor=N.+Topcagicauthor=E.+D.+Robersonauthor=H.+Matthewsauthor=J.+W.+Verbskyauthor=T.+Dasuauthor=A.+Vargas-Hernandezauthor=N.+Vargheseauthor=K.+L.+McClainauthor=L.+B.+Karamauthor=K.+Nahmodauthor=G.+Makedonasauthor=E.+M.+Maceauthor=H.+S.+Sorteauthor=G.+Perminowauthor=V.+K.+Raoauthor=M.+P.+O%E2%80%99Connellauthor=S.+Priceauthor=H.+C.+Suauthor=M.+Butrickauthor=J.+McElweeauthor=J.+D.+Hughesauthor=J.+Willetauthor=D.+Swanauthor=Y.+Xuauthor=M.+Santibanez-Korefauthor=V.+Slowikauthor=D.+L.+Dinwiddieauthor=C.+E.+Ciaccioauthor=C.+J.+Saundersauthor=S.+Septerauthor=S.+F.+Kingsmoreauthor=A.+J.+Whiteauthor=A.+J.+Cantauthor=S.+Hambletonauthor=M.+A.+Cooper&title=Early-onset+lymphoproliferation+and+autoimmunity+caused+by+germline+STAT3+gain-of-function+mutations&doi=10.1182%2Fblood-2014-09-602763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-09-602763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-09-602763%26sid%3Dliteratum%253Aachs%26aulast%3DMilner%26aufirst%3DJ.%2BD.%26aulast%3DVogel%26aufirst%3DT.%2BP.%26aulast%3DForbes%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DC.%2BA.%26aulast%3DStray-Pedersen%26aufirst%3DA.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DLyons%26aufirst%3DJ.%2BJ.%26aulast%3DEngelhardt%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTopcagic%26aufirst%3DN.%26aulast%3DRoberson%26aufirst%3DE.%2BD.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DVerbsky%26aufirst%3DJ.%2BW.%26aulast%3DDasu%26aufirst%3DT.%26aulast%3DVargas-Hernandez%26aufirst%3DA.%26aulast%3DVarghese%26aufirst%3DN.%26aulast%3DMcClain%26aufirst%3DK.%2BL.%26aulast%3DKaram%26aufirst%3DL.%2BB.%26aulast%3DNahmod%26aufirst%3DK.%26aulast%3DMakedonas%26aufirst%3DG.%26aulast%3DMace%26aufirst%3DE.%2BM.%26aulast%3DSorte%26aufirst%3DH.%2BS.%26aulast%3DPerminow%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.%2BC.%26aulast%3DButrick%26aufirst%3DM.%26aulast%3DMcElwee%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DWillet%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DSantibanez-Koref%26aufirst%3DM.%26aulast%3DSlowik%26aufirst%3DV.%26aulast%3DDinwiddie%26aufirst%3DD.%2BL.%26aulast%3DCiaccio%26aufirst%3DC.%2BE.%26aulast%3DSaunders%26aufirst%3DC.%2BJ.%26aulast%3DSepter%26aufirst%3DS.%26aulast%3DKingsmore%26aufirst%3DS.%2BF.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DHambleton%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DEarly-onset%2520lymphoproliferation%2520and%2520autoimmunity%2520caused%2520by%2520germline%2520STAT3%2520gain-of-function%2520mutations%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D591%26epage%3D599%26doi%3D10.1182%2Fblood-2014-09-602763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Siveen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B. K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishayee, A.</span><span> </span><span class="NLM_article-title">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1845</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bbcan.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24388873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1845&publication_year=2014&pages=136-154&author=K.+S.+Siveenauthor=S.+Sikkaauthor=R.+Suranaauthor=X.+Daiauthor=J.+Zhangauthor=A.+P.+Kumarauthor=B.+K.+H.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Targeting+the+STAT3+signaling+pathway+in+cancer%3A+Role+of+synthetic+and+natural+inhibitors&doi=10.1016%2Fj.bbcan.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span></div><div class="casAuthors">Siveen, Kodappully Sivaraman; Sikka, Sakshi; Surana, Rohit; Dai, Xiaoyun; Zhang, Jingwen; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1845</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-154</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to the nucleus.  Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human tumors, including hematol. malignancies (leukemias, lymphomas, and multiple myeloma) as well as diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers).  There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.  Suppression of STAT3 activation results in the induction of apoptosis in tumor cells, and accordingly its pharmacol. modulation by tyrosine kinase inhibitors, antisense oligonucleotides, decoy nucleotides, dominant neg. proteins, RNA interference and chemopreventive agents have been employed to suppress the proliferation of various human cancer cells in culture and tumorigenicity in vivo.  However, the identification and development of novel drugs that can target deregulated STAT3 activation effectively remains an important scientific and clin. challenge.  This review presents the evidence for crit. roles of STAT3 in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT3 signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeL6KQ0obpY7Vg90H21EOLACvtfcHk0ljjQi1mPu11tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D&md5=c2514f54684fb89a2f5ac489425f42d5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DSurana%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%2BH.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520STAT3%2520signaling%2520pathway%2520in%2520cancer%253A%2520Role%2520of%2520synthetic%2520and%2520natural%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1845%26spage%3D136%26epage%3D154%26doi%3D10.1016%2Fj.bbcan.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Debnath, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6645</span><span class="NLM_x">–</span> <span class="NLM_lpage">6668</span><span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0lj6HlM4QjbL-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkson, J.</span><span> </span><span class="NLM_article-title">Targeting STAT3 in cancer: how successful are we?</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1517/13543780802565791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1517%2F13543780802565791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=19053881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGhtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=45-56&author=P.+Yueauthor=J.+Turkson&title=Targeting+STAT3+in+cancer%3A+how+successful+are+we%3F&doi=10.1517%2F13543780802565791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 in cancer: how successful are we?</span></div><div class="casAuthors">Yue, Peibin; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the signal transducer and activator of transcription (STAT)3 occurs in many human tumors.  Moreover, studies utilizing genetic and pharmacol. approaches to modulate constitutive STAT3 activity have provided compelling evidence for the crit. role of aberrant STAT3 activity in malignant transformation and tumor progression, and thereby validated STAT3 as a novel cancer drug target.  This review is intended to be a full coverage of the efforts to develop direct STAT3 inhibitors and will provide a discussion on the inhibitory modalities developed to date.  Review of the literature focused on the modalities and mechanisms that directly target and inhibit the STAT protein or its functions.  While a variety of STAT3 inhibitors have been identified that induce antitumor cell effects in vitro and in vivo, the landscape remains murky.  With a few exceptions, most of the STAT3 inhibitors reported to date have not undergone an in vivo efficacy, pharmacol. or toxicity testing.  Also, there is no evidence, per the published literature of an impending clin. development for the few agents that were reported to exhibit in vivo efficacy.  Overall, there is the need for a reassessment of the ongoing strategies to target STAT3 intended not only for refinement, but also for incorporating some new technologies to strengthen our efforts and ensure the success, sooner, rather than later, of identifying suitable anti-STAT3 agents for development into clin. useful anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGo96b-3KjRLVg90H21EOLACvtfcHk0lgnSbAD5prh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGhtbvO&md5=e0f4fe796305b7e28ff3020f57b5dc8e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F13543780802565791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780802565791%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DP.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DTargeting%2520STAT3%2520in%2520cancer%253A%2520how%2520successful%2520are%2520we%253F%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D45%26epage%3D56%26doi%3D10.1517%2F13543780802565791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namanja, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paladino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunning, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkson, J.</span><span> </span><span class="NLM_article-title">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">9623</span><span class="NLM_x">–</span> <span class="NLM_lpage">9628</span><span class="refDoi"> DOI: 10.1073/pnas.1121606109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1073%2Fpnas.1121606109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=22623533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9623-9628&author=X.+Zhangauthor=P.+Yueauthor=B.+D.+Pageauthor=T.+Liauthor=W.+Zhaoauthor=A.+T.+Namanjaauthor=D.+Paladinoauthor=J.+Zhaoauthor=Y.+Chenauthor=P.+T.+Gunningauthor=J.+Turkson&title=Orally+bioavailable+small-molecule+inhibitor+of+transcription+factor+Stat3+regresses+human+breast+and+lung+cancer+xenografts&doi=10.1073%2Fpnas.1121606109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Page, Brent D. G.; Li, Tianshu; Zhao, Wei; Namanja, Andrew T.; Paladino, David; Zhao, Jihe; Chen, Yuan; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9623-9628, S9623/1-S9623/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homol. 2 domain.  BP-1-102 binds Stat3 with an affinity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells.  BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Kruppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion.  Treatment of breast cancer cells with BP-1-102 further blocks Stat3-NF-κB cross-talk, the release of granulocyte colony-stimulating factor, sol. intercellular adhesion mol. 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression.  I.v. or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrljEafjbznr7Vg90H21EOLACvtfcHk0ljIbmCJtZ52Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D&md5=4da78174a7c00eacc1f1a1ce553c5aa7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121606109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121606109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DOrally%2520bioavailable%2520small-molecule%2520inhibitor%2520of%2520transcription%2520factor%2520Stat3%2520regresses%2520human%2520breast%2520and%2520lung%2520cancer%2520xenografts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D9623%26epage%3D9628%26doi%3D10.1073%2Fpnas.1121606109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Weidler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rether, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erkel, G.</span><span> </span><span class="NLM_article-title">Inhibition of interleukin-6 signaling by galiellalactone</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">484</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/S0014-5793(00)02115-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2FS0014-5793%2800%2902115-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=11056211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns12nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2000&pages=1-6&author=M.+Weidlerauthor=J.+Retherauthor=T.+Ankeauthor=G.+Erkel&title=Inhibition+of+interleukin-6+signaling+by+galiellalactone&doi=10.1016%2FS0014-5793%2800%2902115-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of interleukin-6 signaling by galiellalactone</span></div><div class="casAuthors">Weidler, M.; Rether, J.; Anke, T.; Erkel, G.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">484</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A search for inhibitors of the IL-6-mediated signal transduction in HepG2 cells using secreted alk. phosphatase (SEAP) as reporter gene resulted in the isolation of galiellalactone from fermns. of the ascomycete strain A111-95.  Galiellalactone inhibits the IL-6-induced SEAP expression with IC50 values of 250-500 nM by blocking the binding of the activated Stat3 dimers to their DNA binding sites without inhibiting the tyrosine and serine phosphorylation of the Stat3 transcription factor.  Due to its selective activity, galiellalactone may serve as a lead compd. for the development of new therapeutic agents for diseases originating from the inappropriate expression of IL-6 and as mol. tool to dissect the JAK/STAT pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoacHmhNL-lNbVg90H21EOLACvtfcHk0ljIbmCJtZ52Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns12nt70%253D&md5=cc62a693822f8dc612df16819b8cc7ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2800%2902115-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252800%252902115-3%26sid%3Dliteratum%253Aachs%26aulast%3DWeidler%26aufirst%3DM.%26aulast%3DRether%26aufirst%3DJ.%26aulast%3DAnke%26aufirst%3DT.%26aulast%3DErkel%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520interleukin-6%2520signaling%2520by%2520galiellalactone%26jtitle%3DFEBS%2520Lett.%26date%3D2000%26volume%3D484%26spage%3D1%26epage%3D6%26doi%3D10.1016%2FS0014-5793%2800%2902115-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Don-Doncow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escobar, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjellstrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellsten, R.</span><span> </span><span class="NLM_article-title">Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">15969</span><span class="NLM_x">–</span> <span class="NLM_lpage">15978</span><span class="refDoi"> DOI: 10.1074/jbc.M114.564252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1074%2Fjbc.M114.564252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24755219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=15969-15978&author=N.+Don-Doncowauthor=Z.+Escobarauthor=M.+Johanssonauthor=S.+Kjellstromauthor=V.+Garciaauthor=E.+Munozauthor=O.+Sternerauthor=A.+Bjartellauthor=R.+Hellsten&title=Galiellalactone+is+a+direct+inhibitor+of+the+transcription+factor+STAT3+in+prostate+cancer+cells&doi=10.1074%2Fjbc.M114.564252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone25 Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells</span></div><div class="casAuthors">Don-Doncow, Nicholas; Escobar, Zilma; Johansson, Martin; Kjellstroem, Sven; Garcia, Victor; Munoz, Eduardo; Sterner, Olov; Bjartell, Anders; Hellsten, Rebecka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">15969-15978</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in several malignancies including castration-resistant prostate cancer and has been identified as a promising therapeutic target.  The fungal metabolite galiellalactone, a STAT3 signaling inhibitor, inhibits the growth, both in vitro and in vivo, of prostate cancer cells expressing active STAT3 and induces apoptosis of prostate cancer stem cell-like cells expressing phosphorylated STAT3 (pSTAT3).  However, the mol. mechanism of this STAT3-inhibiting effect by galiellalactone has not been clarified.  A biotinylated analog of galiellalactone (GL-biot) was synthesized to be used for identification of galiellalactone target proteins.  By adding streptavidin-Sepharose beads to GL-biot-treated DU145 cell lyzates, STAT3 was isolated and identified as a target protein.  Confocal microscopy revealed GL-biot in both the cytoplasm and the nucleus of DU145 cells treated with GL-biot, appearing to co-localize with STAT3 in the nucleus.  Galiellalactone inhibited STAT3 binding to DNA in DU145 cell lyzates without affecting phosphorylation status of STAT3.  Mass spectrometry anal. of recombinant STAT3 protein pretreated with galiellalactone revealed three modified cysteines (Cys-367, Cys-468, and Cys-542).  Here we demonstrate with chem. and mol. pharmacol. methods that galiellalactone is a cysteine reactive inhibitor that covalently binds to one or more cysteines in STAT3 and that this leads to inhibition of STAT3 binding to DNA and thus blocks STAT3 signaling without affecting phosphorylation.  This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3avlluHh2P7Vg90H21EOLACvtfcHk0lgtI21Jspd2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D&md5=44961890281d144bd6f9283999c34aa1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.564252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.564252%26sid%3Dliteratum%253Aachs%26aulast%3DDon-Doncow%26aufirst%3DN.%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DKjellstrom%26aufirst%3DS.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMunoz%26aufirst%3DE.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DHellsten%26aufirst%3DR.%26atitle%3DGaliellalactone%2520is%2520a%2520direct%2520inhibitor%2520of%2520the%2520transcription%2520factor%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D15969%26epage%3D15978%26doi%3D10.1074%2Fjbc.M114.564252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corzano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rashid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senthil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedvat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushijin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushijin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidehi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugiu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. C.</span><span> </span><span class="NLM_article-title">Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1021/cb100253e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100253e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=432-443&author=R.+Buettnerauthor=R.+Corzanoauthor=R.+Rashidauthor=J.+Linauthor=M.+Senthilauthor=M.+Hedvatauthor=A.+Schroederauthor=A.+Maoauthor=A.+Herrmannauthor=J.+Yimauthor=H.+Liauthor=Y.+C.+Yuanauthor=K.+Yakushijinauthor=F.+Yakushijinauthor=N.+Vaidehiauthor=R.+Mooreauthor=G.+Gugiuauthor=T.+D.+Leeauthor=R.+Yipauthor=Y.+Chenauthor=R.+Joveauthor=D.+Horneauthor=J.+C.+Williams&title=Alkylation+of+cysteine+468+in+Stat3+defines+a+novel+site+for+therapeutic+development&doi=10.1021%2Fcb100253e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development</span></div><div class="casAuthors">Buettner, Ralf; Corzano, Renzo; Rashid, Rumana; Lin, Jian-Ping; Senthil, Maheswari; Hedvat, Michael; Schroeder, Anne; Mao, Allen; Herrmann, Andreas; Yim, John; Li, Hong-Zhi; Yuan, Yate-Ching; Yakushijin, Ken-Ichi; Yakushijin, Fumiko; Vaidehi, Nagarajan; Moore, Roger; Gugiu, Gabriel; Lee, Terry D.; Yip, Richard; Chen, Yuan; Jove, Richard; Horne, David; Williams, John C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">432-443</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stat3 is a latent transcription factor that promotes cell survival and proliferation and is often constitutively active in multiple cancers.  Inhibition of Stat3 signaling pathways suppresses cell survival signals and leads to apoptosis in cancer cells, suggesting direct inhibition of Stat3 function is a viable therapeutic approach.  Herein, we identify a small mol., C48, as a selective Stat3-family member inhibitor.  To det. its mechanism of action, we used site-directed mutagenesis and multiple biochem. techniques to show that C48 alkylates Cys468 in Stat3, a residue at the DNA-binding interface.  We further demonstrate that C48 blocks accumulation of activated Stat3 in the nucleus in tumor cell lines that overexpress active Stat3, leading to impressive inhibition of tumor growth in mouse models.  Collectively, these findings suggest Cys468 in Stat3 represents a novel site for therapeutic intervention and demonstrates the promise of alkylation as a potentially effective chem. approach for Stat3-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp63z_APNdkQLVg90H21EOLACvtfcHk0liMSJXip1T4NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D&md5=256b3b0921a625e19fe232488e1996db</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcb100253e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100253e%26sid%3Dliteratum%253Aachs%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DCorzano%26aufirst%3DR.%26aulast%3DRashid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSenthil%26aufirst%3DM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYim%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DY.%2BC.%26aulast%3DYakushijin%26aufirst%3DK.%26aulast%3DYakushijin%26aufirst%3DF.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGugiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DYip%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DHorne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BC.%26atitle%3DAlkylation%2520of%2520cysteine%2520468%2520in%2520Stat3%2520defines%2520a%2520novel%2520site%2520for%2520therapeutic%2520development%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D432%26epage%3D443%26doi%3D10.1021%2Fcb100253e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0lhM6MaTcYP1LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bauer, R. A.</span><span> </span><span class="NLM_article-title">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+inhibitors+in+drug+discovery%3A+from+accidental+discoveries+to+avoided+liabilities+and+designed+therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0lj0xhxq2Zi9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520inhibitors%2520in%2520drug%2520discovery%253A%2520from%2520accidental%2520discoveries%2520to%2520avoided%2520liabilities%2520and%2520designed%2520therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhwMKw-VWX17A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lhwMKw-VWX17A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.bmcl.2013.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0libB6xOq1EdeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Johansson, M. H.</span><span> </span><span class="NLM_article-title">Reversible Michael additions: covalent inhibitors and prodrugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span><span class="refDoi"> DOI: 10.2174/13895575112091330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.2174%2F13895575112091330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=22625413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1330-1344&author=M.+H.+Johansson&title=Reversible+Michael+additions%3A+covalent+inhibitors+and+prodrugs&doi=10.2174%2F13895575112091330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael additions: covalent inhibitors and prodrugs</span></div><div class="casAuthors">Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1330-1344</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent inhibition is an efficient mol. mechanism for inhibiting enzymes or modulating the function of proteins and is found in the action of many drugs and biol. active natural products.  However, it is has been less appreciated that the formation of covalent bonds can be reversible or irreversible.  This review focuses on biol. active compds. that are Michael acceptors and how the reversible nature of the Michael addn. reaction influences biol. activity and how this can be exploited in designing prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X1yh9k4q-7Vg90H21EOLACvtfcHk0libB6xOq1EdeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ&md5=f90694162e39fe57915e888bbadbd2bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F13895575112091330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13895575112091330%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DReversible%2520Michael%2520additions%253A%2520covalent%2520inhibitors%2520and%2520prodrugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1330%26epage%3D1344%26doi%3D10.2174%2F13895575112091330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Neelakantan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooks, P. A.</span><span> </span><span class="NLM_article-title">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4346</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.bmcl.2009.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=19505822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4346-4349&author=S.+Neelakantanauthor=S.+Nasimauthor=M.+L.+Guzmanauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Aminoparthenolides+as+novel+anti-leukemic+agents%3A+Discovery+of+the+NF-kappaB+inhibitor%2C+DMAPT+%28LC-1%29&doi=10.1016%2Fj.bmcl.2009.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)</span></div><div class="casAuthors">Neelakantan, Sundar; Nasim, Shama; Guzman, Monica L.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4346-4349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of aminoparthenolide analogs were synthesized and evaluated for their anti-leukemic activity.  Eight compds. exhibited good anti-leukemic activity with LD50's in the low μM range (1.5-3.0 μM).  Compds. I, II and III were the most potent compds. in the series, causing greater than 90% cell death at 10 μM concn. against primary AML cells in culture, with LD50 values of 1.7, 1.8 and 1.6 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFsAppmWkqbVg90H21EOLACvtfcHk0libB6xOq1EdeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D&md5=aff3db6b1997e882d2474e120a1419fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DS.%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DAminoparthenolides%2520as%2520novel%2520anti-leukemic%2520agents%253A%2520Discovery%2520of%2520the%2520NF-kappaB%2520inhibitor%252C%2520DMAPT%2520%2528LC-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4346%26epage%3D4349%26doi%3D10.1016%2Fj.bmcl.2009.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span> </span><span class="NLM_article-title">Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8757</span><span class="NLM_x">–</span> <span class="NLM_lpage">8769</span><span class="refDoi"> DOI: 10.1021/jm301064b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301064b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8757-8769&author=Q.+Zhangauthor=Y.+Luauthor=Y.+Dingauthor=J.+Zhaiauthor=Q.+Jiauthor=W.+Maauthor=M.+Yangauthor=H.+Fanauthor=J.+Longauthor=Z.+Tongauthor=Y.+Shiauthor=Y.+Jiaauthor=B.+Hanauthor=W.+Zhangauthor=C.+Qiuauthor=X.+Maauthor=Q.+Liauthor=Q.+Shiauthor=H.+Zhangauthor=D.+Liauthor=J.+Zhangauthor=J.+Linauthor=L.+Y.+Liauthor=Y.+Gaoauthor=Y.+Chen&title=Guaianolide+sesquiterpene+lactones%2C+a+source+to+discover+agents+that+selectively+inhibit+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1021%2Fjm301064b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Guaianolide Sesquiterpene Lactones, a Source To Discover Agents That Selectively Inhibit Acute Myelogenous Leukemia Stem and Progenitor Cells</span></div><div class="casAuthors">Zhang, Quan; Lu, Yaxin; Ding, Yahui; Zhai, Jiadai; Ji, Qing; Ma, Weiwei; Yang, Ming; Fan, Hongxia; Long, Jing; Tong, Zhongsheng; Shi, Yehui; Jia, Yongsheng; Han, Bin; Zhang, Wenpeng; Qiu, Chuanjiang; Ma, Xiaoyan; Li, Qiuying; Shi, Qianqian; Zhang, Haoliang; Li, Dongmei; Zhang, Jing; Lin, Jianping; Li, Lu-Yuan; Gao, Yingdai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8757-8769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mols. that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features.  Here, we report a series of guaianolide sesquiterpene lactones (GSLs) and their derivs. that can selectively eradicate acute myelogenous leukemia (AML) stem or progenitor cells.  Natural GSL compds. arglabin, an anticancer clin. drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.  Targeting of AML stem cells is further confirmed by a sharp redn. of colony-forming units of primary AML cells upon MCL treatment.  Moreover, the dimethylamino Michael adduct of MCL, I, slowly releases MCL in plasma and in vivo and demonstrates remarkable therapeutic efficacy in the nonobese diabetic/severe combined immunodeficiency AML models.  These findings indicate that GSL is an ample source for chem. agents against AML stem or progenitor cells and that GSL is potentially highly useful to explore anti-CSC approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_V3OAFoCjrVg90H21EOLACvtfcHk0lgxLFhRFobnIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN&md5=064c942ed395fc35e71155c45206a5bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm301064b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301064b%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DGuaianolide%2520sesquiterpene%2520lactones%252C%2520a%2520source%2520to%2520discover%2520agents%2520that%2520selectively%2520inhibit%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8757%26epage%3D8769%26doi%3D10.1021%2Fjm301064b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Woods, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieberich, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavanja, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, D. A.</span><span> </span><span class="NLM_article-title">Amino-derivatives of the sesquiterpene lactone class of natural products as prodrugs</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span><span class="refDoi"> DOI: 10.1039/C2MD20172K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1039%2FC2MD20172K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=27-33&author=J.+R.+Woodsauthor=H.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Amino-derivatives+of+the+sesquiterpene+lactone+class+of+natural+products+as+prodrugs&doi=10.1039%2FC2MD20172K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Amino-derivatives of the sesquiterpene lactone class of natural products as prodrugs</span></div><div class="casAuthors">Woods, James R.; Mo, Huaping; Bieberich, Andrew A.; Alavanja, Tanja; Colby, David A.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The sesquiterpene lactone class of natural products displays a diverse array of biol. activities due to the presence of the α-methylene-γ-lactone motif.  However, clin. translation of this class has been hampered by poor aq. soly. and non-selective binding as a Michael acceptor at undesired targets.  A prodrug approach has been developed to overcome these problems in which an amine is added into the α-methylene-γ-lactone to mask this group from nucleophiles and increase soly.  The medicinal chem. of amino-derivs. of the sesquiterpene lactones is described, beginning with synthetic development, moving into pharmacol. applications, and finishing with clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCqzj8kSJ8GbVg90H21EOLACvtfcHk0lgxLFhRFobnIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr%252FP&md5=967984b301dda68ba4f5a093fedc1fc7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2FC2MD20172K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20172K%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DAmino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%2520class%2520of%2520natural%2520products%2520as%2520prodrugs%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D27%26epage%3D33%26doi%3D10.1039%2FC2MD20172K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Canesin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans-Axelsson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellsten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzyzanowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span> </span><span class="NLM_article-title">The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1016/j.eururo.2015.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2Fj.eururo.2015.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=26144873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=400-404&author=G.+Canesinauthor=S.+Evans-Axelssonauthor=R.+Hellstenauthor=O.+Sternerauthor=A.+Krzyzanowskaauthor=T.+Anderssonauthor=A.+Bjartell&title=The+STAT3+inhibitor+galiellalactone+effectively+reduces+tumor+growth+and+metastatic+spread+in+an+orthotopic+xenograft+mouse+model+of+prostate+cancer&doi=10.1016%2Fj.eururo.2015.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer</span></div><div class="casAuthors">Canesin, Giacomo; Evans-Axelsson, Susan; Hellsten, Rebecka; Sterner, Olov; Krzyzanowska, Agnieszka; Andersson, Tommy; Bjartell, Anders</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">400-404</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is known to be involved in the progression of prostate cancer (PCa) and is a key factor in drug resistance and tumor immunoescape.  As a result, it represents a promising target for PCa therapy.  We studied the effects of the STAT3 inhibitor galiellalactone (GL) on tumor growth and metastatic spread in vitro and in vivo.  The effect of GL on cell viability, apoptosis, and invasion was studied in vitro using androgen-independent DU145 and DU145-Luc cell lines.  For in vivo studies, mice were injected orthotopically with DU145-Luc cells and treated with daily i.p. injections of GL for 6 wk.  GL significantly reduced the growth of the primary tumor and the metastatic spread of PCa cells to regional and distal lymph nodes in vivo.  Treatment with GL also resulted in decreased cell proliferation and increased apoptosis compared with controls.  In vitro, GL reduces the viability and invasive abilities of DU145-Luc cells and induces apoptosis.  Our results showed that tumor growth and early metastatic dissemination of PCa can be significantly reduced by GL, indicating its potential use as a therapeutic compd. in advanced metastatic PCa.In this study, we tested the STAT3 inhibitor galiellalactone (GL) in an animal model of PCa.  We found that mice treated with GL had smaller primary tumors and decreased lymph node metastases compared with mice treated with vehicle.  GL has potential for treating advanced metastatic PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2ixXAGCp4LVg90H21EOLACvtfcHk0lgxLFhRFobnIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7%252FP&md5=7f0a9db87973b0a20797dec8527fe530</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2015.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2015.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DCanesin%26aufirst%3DG.%26aulast%3DEvans-Axelsson%26aufirst%3DS.%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DKrzyzanowska%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%26aulast%3DBjartell%26aufirst%3DA.%26atitle%3DThe%2520STAT3%2520inhibitor%2520galiellalactone%2520effectively%2520reduces%2520tumor%2520growth%2520and%2520metastatic%2520spread%2520in%2520an%2520orthotopic%2520xenograft%2520mouse%2520model%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%26date%3D2016%26volume%3D69%26spage%3D400%26epage%3D404%26doi%3D10.1016%2Fj.eururo.2015.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hellsten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizeyi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjartell, A.</span><span> </span><span class="NLM_article-title">Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/pros.20699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1002%2Fpros.20699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=18163422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=269-280&author=R.+Hellstenauthor=M.+Johanssonauthor=A.+Dahlmanauthor=N.+Dizeyiauthor=O.+Sternerauthor=A.+Bjartell&title=Galiellalactone+is+a+novel+therapeutic+candidate+against+hormone-refractory+prostate+cancer+expressing+activated+Stat3&doi=10.1002%2Fpros.20699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3</span></div><div class="casAuthors">Hellsten, Rebecka; Johansson, Martin; Dahlman, Anna; Dizeyi, Nishtman; Sterner, Olov; Bjartell, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-280</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Background: Signal transducer and activator of transcription 3 (Stat3) is constitutively active (phosphorylated) in several forms of cancer, including prostate cancer (PCa).  Stat3 signaling may be an interesting target for cancer therapy since inhibition of this pathway mediates growth inhibition and apoptosis of these cells.  In this study we investigated the in vitro and in vivo effects of the fungal metabolite galiellalactone, a direct inhibitor of Stat3, on PCa cells.  Methods: The human PCa cell lines DU145, PC-3, and LNCaP were used.  Nude mice with s.c. PCa cell xenografts were subjected to daily i.p. injections of galiellalactone for 3 wk.  The effect of galiellalactone on the induction of apoptosis of cultured PCa cells was investigated by Western blot anal., immunocytochem., and annexin V staining.  Effects of galiellalactone on Stat3 signaling were investigated by a luciferase reporter gene assay.  Expression of Stat3 assocd. proteins and mRNA was investigated by Western blot and real-time quant. PCR anal.  Results: Galiellalactone induced apoptosis of p-Stat3 pos. PCa cells (androgen-insensitive DU145 and PC-3) but not in cells lacking p-Stat3 (androgen-sensitive LNCaP).  Galiellalactone inhibited Stat3-mediated luciferase activity (IC50 ∼ 5 μM) and reduced the expression of Bcl-2, Bcl-xL, c-myc, and cyclin D1.  Furthermore, galiellalactone significantly suppressed DU145 xenograft growth in vivo (42% growth redn.; P < 0.002) and reduced the relative mRNA expression of Bcl-xL and Mcl-1.  Conclusions: Galiellalactone induced growth inhibition and apoptosis in androgen-insensitive PCa cells expressing p-Stat3.  We suggest that galiellalactone is a potential anti-tumor lead against hormone-refractory PCa with constitutively active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolRH_73FC3QbVg90H21EOLACvtfcHk0lhhpcD5yhnABA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFemuro%253D&md5=97a60d32632d431ea0b2b10d66721202</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fpros.20699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20699%26sid%3Dliteratum%253Aachs%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DA.%26aulast%3DDizeyi%26aufirst%3DN.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26atitle%3DGaliellalactone%2520is%2520a%2520novel%2520therapeutic%2520candidate%2520against%2520hormone-refractory%2520prostate%2520cancer%2520expressing%2520activated%2520Stat3%26jtitle%3DProstate%26date%3D2008%26volume%3D68%26spage%3D269%26epage%3D280%26doi%3D10.1002%2Fpros.20699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">von Nussbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benet-Buchholz, J.</span><span> </span><span class="NLM_article-title">The high-intrinsic Diels–Alder reactivity of (−)-galiellalactone; generating four quaternary carbon centers under mild conditions</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">2783</span><span class="NLM_x">–</span> <span class="NLM_lpage">2790</span><span class="refDoi"> DOI: 10.1002/ejoc.200400137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1002%2Fejoc.200400137" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2004&publication_year=2004&pages=2783-2790&author=F.+von+Nussbaumauthor=R.+Hankeauthor=T.+Fahrigauthor=J.+Benet-Buchholz&title=The+high-intrinsic+Diels%E2%80%93Alder+reactivity+of+%28%E2%88%92%29-galiellalactone%3B+generating+four+quaternary+carbon+centers+under+mild+conditions&doi=10.1002%2Fejoc.200400137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400137%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DHanke%26aufirst%3DR.%26aulast%3DFahrig%26aufirst%3DT.%26aulast%3DBenet-Buchholz%26aufirst%3DJ.%26atitle%3DThe%2520high-intrinsic%2520Diels%25E2%2580%2593Alder%2520reactivity%2520of%2520%2528%25E2%2588%2592%2529-galiellalactone%253B%2520generating%2520four%2520quaternary%2520carbon%2520centers%2520under%2520mild%2520conditions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2004%26volume%3D2004%26spage%3D2783%26epage%3D2790%26doi%3D10.1002%2Fejoc.200400137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Schmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahl, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merfort, I.</span><span> </span><span class="NLM_article-title">Helenanolide type sesquiterpene lactones. Part 5: the role of glutathione addition under physiological conditions</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2849</span><span class="NLM_x">–</span> <span class="NLM_lpage">2855</span><span class="refDoi"> DOI: 10.1016/S0968-0896(99)00234-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1016%2FS0968-0896%2899%2900234-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10658589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=2849-2855&author=T.+J.+Schmidtauthor=G.+Lyssauthor=H.+L.+Pahlauthor=I.+Merfort&title=Helenanolide+type+sesquiterpene+lactones.+Part+5%3A+the+role+of+glutathione+addition+under+physiological+conditions&doi=10.1016%2FS0968-0896%2899%2900234-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions</span></div><div class="casAuthors">Schmidt, Thomas J.; Lyss, Guido; Pahl, Heike L.; Merfort, Irmgard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2849-2855</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Sesquiterpene lactones (STLs) are known to exert most of their numerous biol. activities through inhibition of enzymes and other functional proteins by forming covalent bonds with free cysteine residues in these macromols.  The question arises how these drugs can alkylate such vital target structures instead of being quickly deactivated by reaction with the cysteine group of glutathione (GSH) which is present in high concns. in all cells.  The authors have measured in this study the pH dependent kinetics of GSH addn. to the cyclopentenone and α-methylene-γ-lactone group of helenanolide type sesquiterpene lactones using UV-spectrophotometry.  The reaction with GSH at physiol. pH proceeds very quickly but is reversible so that a fraction of STL mols. will always be available for reaction with protein targets.  In agreement with these chem. data, helenalin-mono- and -bis-glutathionyl adducts were demonstrated to inhibit the nuclear transcription factor NF-κB at concns. similar to the free sesquiterpene lactone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqkVtGdFq5Y7Vg90H21EOLACvtfcHk0lhhpcD5yhnABA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCgtA%253D%253D&md5=773a60cca35a2e3238602eb7885cd9d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900234-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900234-5%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DLyss%26aufirst%3DG.%26aulast%3DPahl%26aufirst%3DH.%2BL.%26aulast%3DMerfort%26aufirst%3DI.%26atitle%3DHelenanolide%2520type%2520sesquiterpene%2520lactones.%2520Part%25205%253A%2520the%2520role%2520of%2520glutathione%2520addition%2520under%2520physiological%2520conditions%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D2849%26epage%3D2855%26doi%3D10.1016%2FS0968-0896%2899%2900234-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greaney, M. F.</span><span> </span><span class="NLM_article-title">Reversible Michael addition of thiols as a new tool for dynamic combinatorial chemistry</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">886</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1039/b414300k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1039%2Fb414300k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=15700070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=886-888&author=B.+Shiauthor=M.+F.+Greaney&title=Reversible+Michael+addition+of+thiols+as+a+new+tool+for+dynamic+combinatorial+chemistry&doi=10.1039%2Fb414300k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael addition of thiols as a new tool for dynamic combinatorial chemistry</span></div><div class="casAuthors">Shi, Baolu; Greaney, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">886-888</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The Michael addn. of thiols to enones is reported as a new method for dynamic combinatorial library synthesis.  Thus, Michael addn. of glutathione with ethacrynic acid derivs. I [X = OH, piperidino, NHCH2CF3, etc.] led to sulfides II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox8kO8xzUPebVg90H21EOLACvtfcHk0lhhpcD5yhnABA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KqsrY%253D&md5=71992a58655ad0a8b880f31c7abf81d7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fb414300k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb414300k%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DB.%26aulast%3DGreaney%26aufirst%3DM.%2BF.%26atitle%3DReversible%2520Michael%2520addition%2520of%2520thiols%2520as%2520a%2520new%2520tool%2520for%2520dynamic%2520combinatorial%2520chemistry%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2005%26spage%3D886%26epage%3D888%26doi%3D10.1039%2Fb414300k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniwaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munakata, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kageyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatake, K.</span><span> </span><span class="NLM_article-title">Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1111/cas.12683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.1111%2Fcas.12683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25912076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVClur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=896-901&author=M.+Oguraauthor=T.+Uchidaauthor=Y.+Teruiauthor=F.+Hayakawaauthor=Y.+Kobayashiauthor=M.+Taniwakiauthor=Y.+Takamatsuauthor=T.+Naoeauthor=K.+Tobinaiauthor=W.+Munakataauthor=T.+Yamauchiauthor=A.+Kageyamaauthor=M.+Yuasaauthor=M.+Motoyamaauthor=T.+Tsunodaauthor=K.+Hatake&title=Phase+I+study+of+OPB-51602%2C+an+oral+inhibitor+of+signal+transducer+and+activator+of+transcription+3%2C+in+patients+with+relapsed%2Frefractory+hematological+malignancies&doi=10.1111%2Fcas.12683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies</span></div><div class="casAuthors">Ogura, Michinori; Uchida, Toshiki; Terui, Yasuhito; Hayakawa, Fumihiko; Kobayashi, Yukio; Taniwaki, Masafumi; Takamatsu, Yasushi; Naoe, Tomoki; Tobinai, Kensei; Munakata, Wataru; Yamauchi, Takeshi; Kageyama, Akiko; Yuasa, Miyuki; Motoyama, Masaaki; Tsunoda, Takeshi; Hatake, Kiyohiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-901</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We carried out a multicenter dose-escalation phase I study of oral OPB-51602, a signal transducer and activator of transcription 3 phosphorylation inhibitor, in patients with relapsed or refractory hematol. malignancies to evaluate the safety, max. tolerated dose (MTD), pharmacokinetics, and preliminary antitumor activity.  Twenty patients were treated with OPB-51602 at doses of 1, 2, 3, 4, and 6 mg in the "3 + 3" dose escalation design.  The most common treatment-related adverse events included nausea (55%), peripheral sensory neuropathy (45%), and diarrhea (40%).  The most frequently obsd. grade 3 or 4 drug-related adverse events were neutropenia (20%), leukopenia (15%), lymphopenia (10%), and thrombocytopenia (10%).  The MTD was 6 mg, with dose-limiting toxicities of grade 3 lactic acidosis and increased blood lactic acid levels obsd. in one of three patients and grade 1-2 peripheral neuropathy in three of three patients.  The recommended dose was detd. to be 4 mg.  OPB-51602 was rapidly absorbed, and exposure tended to increase in a dose-dependent manner.  Accumulation of OPB-51602 was seen with 4 wk of multiple treatments.  No clear therapeutic response was obsd.  Durable stable disease was obsd. in two patients with acute myeloid leukemia and one with myeloma.  In conclusion, the MTD of OPB-51602 was 6 mg.  OPB-51602 was safe and well tolerated in a dose range of 1-4 mg.  However, long-term administration at higher doses was difficult with the daily dosing schedule, and no response was seen.  Therefore, further clin. development of OPB-51602 for hematol. malignancies with a daily dosing schedule was terminated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP1VSTl7NbYrVg90H21EOLACvtfcHk0lgURu_LdNOhoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVClur8%253D&md5=5173296bfc67ade88f7abcc84159ed4b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fcas.12683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12683%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DT.%26aulast%3DTerui%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTaniwaki%26aufirst%3DM.%26aulast%3DTakamatsu%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DMunakata%26aufirst%3DW.%26aulast%3DYamauchi%26aufirst%3DT.%26aulast%3DKageyama%26aufirst%3DA.%26aulast%3DYuasa%26aufirst%3DM.%26aulast%3DMotoyama%26aufirst%3DM.%26aulast%3DTsunoda%26aufirst%3DT.%26aulast%3DHatake%26aufirst%3DK.%26atitle%3DPhase%2520I%2520study%2520of%2520OPB-51602%252C%2520an%2520oral%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%252C%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520hematological%2520malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2015%26volume%3D106%26spage%3D896%26epage%3D901%26doi%3D10.1111%2Fcas.12683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span> </span><span class="NLM_article-title">Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.4143/crt.2014.249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=10.4143%2Fcrt.2014.249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=25715763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=607-615&author=D.+Y.+Ohauthor=S.+H.+Leeauthor=S.+W.+Hanauthor=M.+J.+Kimauthor=T.+M.+Kimauthor=T.+Y.+Kimauthor=D.+S.+Heoauthor=M.+Yuasaauthor=Y.+Yanagiharaauthor=Y.+J.+Bang&title=Phase+I+study+of+OPB-31121%2C+an+oral+STAT3+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.4143%2Fcrt.2014.249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Oh Do-Youn; Lee Se-Hoon; Han Sae-Won; Kim Mi-Jung; Kim Tae-Min; Kim Tae-You; Heo Dae Seog; Bang Yung-Jue; Oh Do-Youn; Lee Se-Hoon; Han Sae-Won; Kim Mi-Jung; Kim Tae-Min; Kim Tae-You; Heo Dae Seog; Bang Yung-Jue; Yuasa Miyuki; Yanagihara Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity.  This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.  MATERIALS AND METHODS:  Patients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest.  A standard 3+3 design was used for dose-escalation.  Safety and response were evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.  RESULTS:  Twenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200 mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8).  Seven patients discontinued treatment during cycle 1 for various reasons other than study drug-related adverse events.  Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs were observed: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3 diarrhea) at 800 mg.  The MTD was determined as 800 mg/day.  Common adverse events were gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea (72%).  Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121.  Eight patients had stable disease and 10 patients had disease progression.  Two patients (1 colon cancer, 1 rectal cancer) showed tumor shrinkage.  One gastric cancer patient continued treatment up to cycle 13 before disease progression.  CONCLUSION:  This study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor.  OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has a preliminary antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO4HjIonre9iM8MEzWGjS9fW6udTcc2eYfWhxVmSA2Mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslKgug%253D%253D&md5=499f3d1b07c7760b88d12e1be071d398</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.249%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DYuasa%26aufirst%3DM.%26aulast%3DYanagihara%26aufirst%3DY.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520OPB-31121%252C%2520an%2520oral%2520STAT3%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2015%26volume%3D47%26spage%3D607%26epage%3D615%26doi%3D10.4143%2Fcrt.2014.249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Hobisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramoner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godoy-Tundidor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klocker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culig, Z.</span><span> </span><span class="NLM_article-title">Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">–</span> <span class="NLM_lpage">2948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=11555613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFSitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2941-2948&author=A.+Hobischauthor=R.+Ramonerauthor=D.+Fuchsauthor=S.+Godoy-Tundidorauthor=G.+Bartschauthor=H.+Klockerauthor=Z.+Culig&title=Prostate+cancer+cells+%28LNCaP%29+generated+after+long-term+interleukin+6+%28IL-6%29+treatment+express+IL-6+and+acquire+an+IL-6+partially+resistant+phenotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype</span></div><div class="casAuthors">Hobisch, Alfred; Ramoner, Reinhold; Fuchs, Dietmar; Godoy-Tundidor, Sonia; Bartsch, Georg; Klocker, Helmut; Culig, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2941-2948</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The levels of interleukin-6 (IL-6) are frequently elevated in sera from patients with advanced prostate carcinoma.  Our main objective was to investigate changes in responsiveness to IL-6 and/or androgen that occur in LNCaP cells after long-term treatment with IL-6.  This in vitro model could be of clin. relevance because of its similarity with late-stage prostate carcinoma.  LNCaP human prostate cancer cells were treated with IL-6 at a concn. of 5 ng/mL.  After 20 passages, the new subline LNCaP-IL-6+ has been established.  Passages 20-40 are referred to as low passages (LP) and passages 41-73 as high passages (HP).  LNCaP cells passaged at the same time in the absence of IL-6 were used as controls (LNCaP-IL-6-).  Cells were counted after treatment with either IL-6 or the synthetic androgen methyltrienolone (R1881), and cell cycle anal. was performed.  Binding of IL-6 or R1881 was assessed by radioligand binding assays.  Reporter gene activity was measured by chloramphenicol acetyltransferase assay.  Prostate-specific antigen in LNCaP-IL-6+ supernatants was measured by an enzyme immunoassay.  Expression of IL-6 mRNA and protein was assessed by reverse transcription-PCR and ELISA, resp.  The basal proliferation rate in HP LNCaP-IL-6+ cells was higher than that in LNCaP-IL-6- cells.  IL-6 inhibited proliferation of LNCaP-IL-6- cells but not that of either LP or HP of LNCaP-IL-6+ cells.  This inability to elicit a growth-inhibitory response was assocd. with lack of effect on cell cycle distribution in the LNCaP-IL-6+ subline.  In parallel, IL-6 binding decreased gradually during long-term IL-6 treatment and, in HP, reached only 33% of the levels measured in controls.  Binding of radiolabeled androgen increased 2-fold in HP LNCaP-IL-6+ cells.  Reporter gene assays revealed that R1881, at nanomolar concns., was a more potent androgen receptor activator in LNCaP-IL-6+ than in LNCaP-IL-6- cells.  However, androgen- and IL-6-induced prostate-specific antigen secretion decreased in long-term IL-6-treated cells.  IL-6 cDNA fragments were detected by reverse transcription-PCR in HP LNCaP-IL-6+ cells but not in controls or LP.  IL-6 protein was first detected in passage 36 of LNCaP-IL-6+ cells, and it increased in HP.  Long-term treatment of LNCaP human prostate cancer cells with IL-6 leads to abolishment of inhibitory growth response.  In contrast to control cells, the LNCaP-IL-6+ subline expresses IL-6 mRNA and protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpueitsJLg547Vg90H21EOLACvtfcHk0ljLSih08dSR5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFSitbc%253D&md5=3a8aab7eee5b86661eb8681c472f03e0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHobisch%26aufirst%3DA.%26aulast%3DRamoner%26aufirst%3DR.%26aulast%3DFuchs%26aufirst%3DD.%26aulast%3DGodoy-Tundidor%26aufirst%3DS.%26aulast%3DBartsch%26aufirst%3DG.%26aulast%3DKlocker%26aufirst%3DH.%26aulast%3DCulig%26aufirst%3DZ.%26atitle%3DProstate%2520cancer%2520cells%2520%2528LNCaP%2529%2520generated%2520after%2520long-term%2520interleukin%25206%2520%2528IL-6%2529%2520treatment%2520express%2520IL-6%2520and%2520acquire%2520an%2520IL-6%2520partially%2520resistant%2520phenotype%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2941%26epage%3D2948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01814">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_72010"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01814">10.1021/acs.jmedchem.5b01814</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and associated IC<sub>50</sub> values (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01814/suppl_file/jm5b01814_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01814/suppl_file/jm5b01814_si_001.csv">jm5b01814_si_001.csv (1.46 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-10%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01814%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01814" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a5143df3b3d8e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
